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Abstract
The world’s attention to the burden and spread of hepatitis B has increased significantly
in the recent past. A number of interventions by way of treatment and immunisation have
been initiated to fight the pandemic, especially in high prevalence regions such as Africa
and Asia. Lack of good quality information about hepatitis B is a major hindrance to pol-
icy direction and comprehensive implementation of interventions in Sub-Saharan Africa
designated as an endemic region. Limited studies on hepatitis B, coupled with lack of
adequate health care systems and infrastructure, have led to ignorance or misconceptions
and stigmatisation about the disease and worsened the disease prevalence in Ghana a
Sub-Saharan African country. As a contribution, this study employed a SEIR determin-
istic compartmental model, which incorporates latent period and vertical transmission,
to examine the transmission and spread of hepatitis B in the context of the Sub-Saharan
Africa with incidence data obtained from Ghana.
The SEIR deterministic compartmental modelling divided the human population into
separate classes namely susceptible (S), exposed (E), infectious (I) and removed (R) or
recovered, and disease progression among population members in the various classes was
described using a system of nonlinear ordinary differential equations (ODEs). The model
has two equilibrium states namely, the disease-free equilibrium Q0 and the endemic equi-
librium Q∗. Stability analysis indicated that the model has an epidemiological threshold
parameter R0 which is defined as the expected proportion of secondary infections gen-
erated as a result of introducing a single infected individual into the population. When
R0 ≤ 1 the disease-free equilibrium state is globally asymptotically stable whilst the en-
demic equilibrium state is unstable and so the disease is brought under control. When
R0 > 1, the disease-free equilibrium is unstable whilst the endemic equilibrium state is
stable and so the disease persists in the population. Stability of the model was analysed
in terms of proportions instead of the absolute number of cases and so disease eradication
or persistence referred to the infected proportions vanishing or persisting respectively. A
iii
hybrid nonlinear least squares method, that combines a Genetic Algorithm (GA) and a
modified Levenberg-Marquadt (LM) algorithm, was applied to the hepatitis B incidence
data to estimate the parameters of the model for Ghana (global) and also for each of the
ten regions of Ghana. By numerical simulations, sensitivity analysis was performed to ex-
amine the effects of the model parameters on the threshold parameter R0 using MATLAB.
Furthermore, the model was modified to include a vaccination component to examine the
impact of an intervention on the transmission and spread of the disease. The vaccination
model also has an epidemiological threshold parameter Rv0 such that when the vaccination
rate k is greater than a threshold value k∗, then Rv0 < 1 and the disease decreases; and
when k is less than k∗, Rv0 > 1 and the disease increases. This indicated that when the
rate of vaccination k was increased beyond the threshold value k∗, the disease would be
kept under control.
The threshold parameter was calculated as R0 = 1.6854 for Ghana. This indicated that
the endemic proportion equilibrium is asymptotically stable and so hepatitis B persists in
the population of Ghana. The contact rate β, latency rate γ and vertical transmission rate
α were identified as driving the disease spread in the population. A critical proportion
of H = 0.4067 was calculated as the herd immunity threshold value of the population.
This means that about 41% of the population are needed to be immune in order to
adequately reduce the rates of transmission to keep the disease under control. Variability
in the regional threshold parameters R0 indicated significant disparities in the spread and
burden of hepatitis B across the ten regions of Ghana. The highest and the least values
of (R0 = 3.7212, H = 0.7312) and (R0 = 1.3669, H = 0.2684) were calculated for Upper
West and Volta regions respectively. The regional threshold parameters R0 also indicated
that the trend of transmission and spread of the disease increase from south to north
across the regions of Ghana. A simple regression analysis performed indicated that the
increasing trend from south to north is highly associated with poverty and health sector
differentials. Another factor that was considered in this study to have potentially impacted
the distribution and pattern of spread and burden of hepatitis B in Ghana is prevalence
differentials among regions and between Ghana and its neighbouring countries.
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Hepatitis B is known to be a global health concern. It is caused by the Hepatitis B virus
(HBV). Hepatitis B is characterised by a broad spectrum of clinical outcomes; ranging from
asymptomatic hepatitis to fulminant liver failure [1, 2]. Failure to clear the disease at the
acute stage leads to chronic carriage, with asymptomatic course, progressing to cirrhosis of
the liver or hepatocelular carcinoma. In fact, chronic hepatitis B has increasingly gained
recognition as the major cause of cirrhosis and liver cancer in recent times [3]. Rated second
to tobacco globally as a major cause of human malignancy, the disease is also known to
be a major cause of death of HIV/AIDS co-infected individuals [4, 5]. Hepatitis B is also
associated with extrahepatic diseases such as polyarteritis nodosa and glomerulonephritis
[6, 7, 8].
This global health burden has seen some efforts from health bodies, worldwide on all fronts,
to stem the ravaging effects of the disease. The World Health Organisation (WHO) through
its agency, the World Health Assembly (WHA) has rolled out a number of programmes
aimed at prevention and control of the disease. An outright cure has not been found.
However, antiviral drugs are available for treatment of chronic hepatitis B that are meant
to suppress viral replication and consequent liver damage. These drugs come at a cost
and most invariably pose some financial difficulty especially to developing countries. Apart
from these antiviral treatments, effective vaccines are also available for prevention through
immunisation programmes [9, 10, 11]. In fact, vaccination has been identified as the single
major measure of intervention for controlling hepatitis B [12].
1
Chapter 1. Background and introduction
The disease is transmitted mainly through contaminated blood and body fluids, which
puts people in developing countries at the greatest risk [11, 13]. Ghana in Sub-Saharan
Africa is noted to have high hepatitis B prevalence, which places an enormous burden
on the economy and health management system of the country. Poverty, unavailability of
standard health care systems, lack of relevant information and ignorance or misconceptions
about the disease have together contributed to the worsening disease prevalence among the
people in this part of the world. Surveys in Ghana report a lack of adequate information
on hepatitis B to support necessary political decisions [14, 15]. The Ghana Health Service
(GHS) admits to using inefficient data collection tools for the surveillance and management
of hepatitis B in the country [16]. Like many other weak economies, lack of resources has
also contributed to little or no response to some of the interventions suggested by WHO
which include general education about the disease, vaccination and antiviral treatments
[11, 13, 14, 15, 16, 17].
A number of studies have sought to provide a theoretical framework for understanding
the dynamics of the hepatitis B pandemic worldwide. Compartmental modelling as a
key tool has been used to explain the dynamics of hepatitis B pandemic in Africa and
elsewhere [9, 17, 18, 19]. Many of these studies placed emphasis on the horizontal route
of transmission of the disease [20, 21]. Some studies have also tried to review the impact
of the latent period in the dynamics of hepatitis B on the key parameters defining the
epidemiological threshold parameter usually referred to as the basic reproduction number
[1, 22, 23, 24].
There have been few instances in which compartmental models were used to study hepatitis
B in Ghana and with limited geographical scope [9, 17, 19]. These studies neglected the
latent period which some literature indicate as important in the study of hepatitis B
[25]. The studies also placed emphasis on the horizontal mode of transmission but other
studies have shown that vertical transmission is a major route through which hepatitis B
is acquired [7, 18]. Lack of knowledge and awareness about the disease and committed
action towards treatment, prevention and control of the disease is a complete setback to
policy development and implementation in fighting hepatitis B in Ghana. This study seeks
to use the SEIR compartmental model to address the enumerated gaps which have led to
the state of misinformation and misconceptions about hepatitis B in Ghana, and to inform
policy directives in the attempt to control the disease in the country [26, 27]. Particularly,
the modelling could provide information on the major parameters that determine the
dynamics of the disease, which include the mode of transmission and the rates of disease
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progression in the population. This information could determine the current state and
trend of the disease and whether or not it can be controlled with time.
1.2 Background to hepatitis B
Hepatitis B, originally known as Serum Hepatitis, is an infectious viral disease which
causes inflammation of the liver. Caused by the HBV, the disease is known to affect
all hominoidea including humans. It transmits through contact with infectious blood
and body fluids, such as semen and vaginal discharges. Studies have shown that Viral
DNA has been present in saliva, tears and urine of individuals with the chronic disease
[11, 13, 28, 29, 30].
The HBV will survive for a minimum of 7 days outside the body and can still cause
infection on entering the body of another person who is not protected by immunisation.
The virus incubates for a period of 75 days on average, ranging from 30 to 180 days or
even much longer depending on the age and the viral load of the infected individual. The
disease is an important occupational hazard to health practitioners. Other risk factors
include transfusion and dialysis, acupuncture, tattooing and all practices involving use of
contaminated needles [11, 29, 30, 31].
Hepatitis B is characterised by the presence of the Hepatitis B surface antigen (HBsAg)
and the immunoglobulin M (IgM), which is an antibody to the Hepatitis B core antigen
(HBcAg). The presence of Hepatitis B envelope antigen (HBeAg) is an indication that
the blood and body fluids of the infected individual are highly contagious [10, 11]. At
the acute stage, some individuals exhibit symptoms such as yellowing of skin and eyes
(jaundice), dark urine, extreme fatigue, nausea, vomiting and abdominal pains lasting for
several weeks. The disease may be entirely asymptomatic and may go unrecognised. The
disease may be first detected between 30 to 60 days after an individual has been infected
[13, 30, 32, 33, 34].
The disease may be cleared at the acute stage [35, 36], or may continue to develop into the
chronic stage where the individual will begin to experience cirrhosis of the liver or liver
cancer [5, 17, 37]. Hepatitis B is however preventable with the current availability of safe
and effective vaccines [35, 38, 39]. There is no found cure but there are available antiviral
treatments for chronic hepatitis that can help stop or minimise virus replication and thus
reduce the risk of liver damage [13, 30].
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1.3 The global hepatitis B burden
Hepatitis B threatens life and as a result constitutes a global health burden. Viral hep-
atitis substantially contributes to the burden of chronic diseases, which is associated with
morbidity and premature mortality worldwide. The epidemiology of hepatitis B is said to
be geographically diverse, essentially regarding population prevalence, age and mode of
contraction and the likelihood of progression to the chronic infection [3, 12]. The disease
has caused epidemics in Asia and Africa and it is endemic in China. WHO Global report
indicated that one out of every three of the world’s population has been infected with the
disease [10, 12]. Over 240 million people are estimated to have chronic hepatitis B with
more than 780, 000 dying each year as a result of the disease [10, 40].
Figure 1.1: Global prevalence of hepatitis B (CDC - 2012)
The prevalence of hepatitis B is highest in Sub-Saharan Africa and East Asia where most
people become infected with the disease during childhood and 5 − 10% of adults are
chronically infected. High rates of infection are also found in the Amazon and parts of
Eastern and Central Europe. Approximately 2 − 5% of the general population in the
Middle East and India and less than 1% of the population in Western Europe and North
America are chronically infected. The most common routes for the spread of hepatitis B
4
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in highly endemic regions are vertical (from mother-to-child) and horizontal (from person-
to-person), with the majority of infections acquired at early childhood [10, 35]. Figure 1.1
displays the global distribution of HBsAg prevalence of hepatitis B.
Africa with 12% of the world’s population carries 18% of the global burden of hepatitis B
[41]. Although hepatitis B is endemic in Africa and hyperendemic (disease is constantly
present at a high incidence and/or prevalence rate and affects all groups equally) in some
regions of Africa, not much attention has been given to its management and control.
In Africa, studies have indicated that hepatitis B has shown severe virologic expressions
in HIV-infected patients [42, 43, 44, 45, 46]. Hepatitis B is estimated at 15% among
HIV infected individuals in Africa as a whole, 8% in West Africa and 5 − 7% in Central
Africa [41]. Poor management of hepatitis B/hepatitis C virus (HBV/HCV) coinfection
has resulted in high risk levels of mortality of patients especially in Sub-Saharan Africa
[42, 43, 44, 45, 46, 47, 48, 49].
In spite of Hepatitis B being a significant global concern, there is a lack of quality data
on the burden of disease [50]. Obtaining hepatitis related incidence, prevalence, morbidity
and mortality is challenging. Thus the utility of case reporting data is limited by the fact
that it is primarily a reflection of testing availability and practises and of the willingness
of healthcare providers to report cases to the relevant health authorities [50]. Limitations
in surveillance programmes and the asymptomatic nature of the disease also result in un-
derestimation of the true number of cases of incidence [50, 51]. Data on the precise burden
of the disease is lacking in most countries even though available information indicates that
the disease related burden is considerable [50].
1.4 The state of hepatitis B in Ghana
Ghana, like many other Sub-Saharan African countries, is threatened by the hepatitis B
pandemic. Ghana is located in the West African sub-region, bounded on the south by the
gulf of Guinea, to the north by Burkina Faso, to the east by Togo and to the west by
Ivory Coast. The population of the country is currently estimated at 28.9 million with a
growth rate of about 2.4% per year [52]. The birth and death rates stand at 31.4 births
and 7.37 deaths per 1, 000 population per year respectively. Occupying a land area of
239, 460 square kilometres (92, 456 square miles) with an estimated population density of
107.6 persons/km2, the country is divided into 10 administrative regions and 216 districts,
metropolitans and municipals [52, 53, 54]. Figure 1.2 shows the administrative boundaries
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of the country [55].
Figure 1.2: Ghana administrative map [Library of Congress - Washington, D.C. : Central
Intelligence Agency, 2007]
Only limited epidemiological data pertaining to prevalence of common persistent viruses
has been reported in Ghana [56]. There is limited screening, unavailability and inacces-
sibility of vaccination due to large scale absence of standard health facilities especially
6
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in the rural areas [15]. There is a general lack of knowledge and many misconceptions
about hepatitis B among the people of Ghana. Many people resort to herbal medicine
which is relatively cheap instead of officially reporting to the available health facilities to
be treated and so to be captured into the national database [26, 27]. About one third
of Ghanaians living with viral hepatitis are unaware of their status and are not receiving
care and treatment for the condition [26, 27].
In 2011, the annual report of the Ghana Health Service (GHS) indicated that their current
data collection tools did not capture confirmed cases of the disease in the syndromic
diagnosis state [16]. A total of 22, 851 cases of hepatitis B diagnosis, of which 100 resulted
in fatalities, were reported for all the regions in Ghana; constituting an estimated national
incidence rate of 89.1 per 100, 000 population. The highest incidence of 1, 059.4 per 100, 000
population was recorded for the Upper East region. Other regional incidence clearly above
the average national rate recorded were 212.9 and 123.5 per 100, 000 population for the
Brong Ahafo and the Upper West regions respectively [16].
In 2013, WHO reported that Ghana was conspicuously absent from a survey they con-
ducted to determine the capacity of its member states pursuant to the WHA’s resolution
2010 [10]. This seeks, among other policy interventions, to develop a comprehensive ap-
proach to prevention and control of hepatitis B through awareness creation and urgent
action with respect to vaccination and antiviral treatments. Nonetheless, the implemen-
tation of these policies pose complexities and challenges for most economies and health
communities in developing countries including Ghana [57]. This has generated concern
and apprehension from the general public. As a result, civil society and nongovernmental
organisations (NGO) through the various media are making the effort to create awareness
in the populace regarding the hazards of the disease and the need for action to fight it
[26, 27, 58].
The GHS in its 2014 annual report indicated that there were 108 deaths out of 51, 052
suspected acute viral hepatitis cases, representing a Case Fatality Ratio (CFR) of 0.2%, re-
ported from 9 out 10 regions (Northern region did not report), with 7, 581 cases confirmed
positive representing an incidence rate of about 14.8% (approximately 1 in 7 people re-
porting) [59]. Studies have indicated that prevalence of hepatitis B in Ghana is estimated
between 10 − 15% and out of every 100 Ghanaians, 13 may test positive for hepatitis B
[58, 60, 61, 62, 63]. In line with WHO’s health assembly Resolution 2010, for all member
states to generate reliable information as a foundation for building prevention and con-
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trol measures that match the local epidemiological profile and health systems capacities,
Ghana has produced and launched a policy document on viral hepatitis in 2015 [60, 64].
The Ministry of Health Ghana (MOHG) admitted in the policy document that there
are effective tools available to prevent and manage viral hepatitis, including hepatitis B
vaccination, surveillance, screening and treatment, but there are challenges to build the
capacity to extend these interventions country-wide [60, 64].
The document reports of scanty national data on specific types of viral hepatitis in Ghana.
There is also lack of policy and guidelines for service delivery and research agenda to guide
a response to viral hepatitis. Screening and vaccination programmes for hepatitis B are
left to private unauthorised persons who manage it in an uncontrolled and uncoordinated
manner. However surveillance data available at the Disease Surveillance Department,
captured by the Infectious Disease Surveillance Response (IDSR) standard case definition
for viral hepatitis, shows an annual increasing trend of reported clinical viral hepatitis
cases across the ten regions of Ghana [64]. It is estimated that there are about 2.5 million
Ghanaians living with hepatitis B with a high fatality rate due to misinformation and late
reporting [64]. It is also estimated that there is an eight-fold increase in risk of patients
infected with hepatitis B to develop cirrhosis than any other disease.
Studies available, although limited in geographic range, create a general basis for concern
with the threat of hepatitis B in Ghana [28, 65]. The disease is described as a hidden
epidemic and concerns have been raised for the needed national policy attention [15, 26,
65, 66, 67]. Recent surveys on prevalence of hepatitis B in Ghana however indicated
a limited availability of data and information. There is also a low level of awareness
which has given rise to many misconceptions about the disease in Ghana [15, 68]. Lack
of adequate data on prevalence of hepatitis B in Ghana has resulted in less financial and
political attention and commitment towards its inclusion in the National Health Insurance
Scheme (NHIS). There is also a lack of provision of universal access to vaccination against
hepatitis B in the national childhood immunisation programmes [27, 69, 70].
The health sector in Ghana is both public and private. Health care administration and
delivery in Ghana is the responsibility of the Ministry of Health (MOH) which formulates
and oversees the implementation of policies on behalf of government. The Ghana Health
Service (GHS) through its regional, district and sub-district/community branches imple-
ments the health policies in the public health sector which constitute the main health
delivery engine of Ghana. Private health care run mainly by religious bodies and private
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individuals also plays a significant role in health delivery in Ghana. The public health
sector is categorised into three: the primary level is in charge of the district, sub-district
and community health care delivery; the secondary level consists of the ten regional hospi-
tals, situated in the regional capitals, which receive referrals from the districts and provide
outreach support to the primary level; and the tertiary level which consists of the four
teaching hospitals namely Korle-Bu and Komfo Anokye, situated in Accra the capital and
Kumasi the second largest city of Ghana respectively, and Cape Coast and Tamale which
are responsible for tertiary health care and training of doctors [71].
1.5 Justification of study
The most recent works that used mathematical modelling to study hepatitis B in Ghana,
though extensive in content, are limited in scope [9, 19]. Each of the studies covered a part
(one district) of the country and did not include vertical transmission and the latent period
of the disease which are important in the study of hepatitis B. Although deterministic
compartmental modelling was applied to hepatitis B incidence data obtained from the
districts in which the studies were conducted, the parameter estimation methodology was
not transparent in any of the case studies. The pseudo-mass action incidence term βSI
used in these studies to model hepatitis B in Ghana was not appropriate for a population
whose size varies with time.
Studies have indicated that not accounting for the latent period in modelling hepatitis B
has an adverse impact on the results and the predictions of any such study [21, 24, 72, 73].
Vertical transmission of hepatitis B in high prevalence and endemic regions has also been
indicated in many studies as notable [1, 20, 21, 22, 23, 24]. Limitations of the use of the
pseudo mass-action incidence term βSI in studies also suggest that the standard (true)
proportionate incidence term βSIN gives a better result in modelling an infectious disease
in population with varying size [74, 75, 76]. Studies on hepatitis B related to Ghana have
failed to address these important concepts.
This study is motivated by these limitations and gaps, and seeks to address them in a
deterministic compartmental model that incorporates the proportionate incidence term,
latent period, vertical transmission and a vaccination component to study the incidence
and spread of hepatitis B in Ghana. A transparent hybrid optimization method was used
to estimate the parameters of the model using data gathered from health authorities of
Ghana. The findings would be useful in making relevant and informed policy recommen-
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dations to guide public health management decisions towards controlling the incidence
and spread of hepatitis B in Ghana, which by extension would apply to Africa and other
high prevalence regions of the world.
1.6 Research objectives
The objectives of the study are listed below.
1. To formulate an appropriate compartmental model, which incorporates the limita-
tions identified in models previously applied to hepatitis B in Ghana, to estimate
model parameters using hepatitis B incidence data from Ghana, and to use the model
to examine the transmission and spread of the pandemic of the disease in Ghana.
2. To subject the formulated model to sensitivity and stability analysis to assess its
veracity and to examine how robust the model would be in the face of perturbation.
3. To predict the future of the national hepatitis B pandemic on the basis of the model
developed and further examine the regional burden.
4. To investigate the impact of vaccination on the transmission and spread of hepatitis
B and interpret the results in relation to a management framework which can be
used by policy makers to take informed decisions.
The objectives outlined therefore focus on formulating an appropriate model to examine
the transmission and spread of hepatitis B in Ghana and do not need to include stages
of chronic infection and treatment interventions. These objectives were addressed in the
following manner in the thesis: Items 1 and 2 were addressed in Chapters 3 and 4, where
the model was presented and stability and sensitivity analysis were discussed respectively,
and parts of Chapters 5 and 6 where the model and parameter estimation method were
applied to the hepatitis B incidence data to estimate the national and regional parameters
respectively; Item 3 was addressed in Chapters 5 and 6 and item 4 was addressed in
Chapter 7.
1.7 Data collection
The main data for the study consisted of reported monthly incidence cases of hepatitis
B, aggregated and deidentified (not identified with any group of persons or individuals),
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for the ten regions of Ghana. These were categorised into cases of individuals aged less
than five years old (age< 5) and those aged five years or older (age≥ 5), covering the
period 2008 to 2014. Categorising the data into these age brackets was meant to divide
the population into two, accounting for the number of incidence cases assumed to be
vertically transmitted (age< 5) and those from the other routes (age≥ 5). These data were
collected from the Regional Informant Units (RIU) and the Center for Health Information
Management (CHIM) of Ghana Health Service (GHS) and neither involved face-to-face
interaction nor identified with the addresses of any respondents.
In addition, annual regional demographic data consisting of projected population figures
covering the period 2008 to 2014 and birth and death rates from the 2010 population
and housing census and Ghana Living Standards Survey (GLSS6) were sourced from
the Population Statistics Division (PSD) of the Ghana Statistical Service (GSS). This
dataset formed the parameter constants that were identified in the model for the parameter
estimation process, which in turn was used to determine the epidemiological threshold
parameter, R0 and the herd immunity threshold value H of the study.
1.8 Thesis outline
In Chapter 2, a theoretical framework that gives the basic structure underlying the concept
of modelling infectious disease generally, and hepatitis B in particular, as in a SEIR
deterministic compartmental model is reviewed. The classical SIR model and relevant
literature on some of its modifications including the SEIR adopted to use in this study
is reviewed. Also reviewed in this chapter is literature on vertical transmission, latent
and incubation periods of hepatitis B, which are important features in the epidemiology
of hepatitis B, as well as the epidemiological threshold parameter R0 and herd immunity
threshold value H.
The methodology of the research is outlined in Chapter 3. In this chapter the outline of
the SEIR model used in the study is presented and the system of ordinary differential
equation that defines the model is formulated. The epidemiological threshold parameter
R0, otherwise referred to as the basic reproduction number, is derived based on the con-
cept of spectral radius of the second generation matrix of the Jacobian of the model and
the corresponding herd immunity threshold value H is defined. Stability of the model in
terms of its disease-free and endemic equilibrium states is discussed analytically indicat-
ing a threshold value of the disease contact rate that defines a crossover between stability
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and instability of either equilibrium state. The parameter estimation method, which de-
scribes a hybrid method that combines a random search Genetic Algorithm and a modified
gradient search Levenberg Marquardt Algorithm is presented in Chapter 4.
The SEIR model is applied to the hepatitis B incidence data of Ghana in Chapter 5. The
methods discussed in Chapter 4 are used in this chapter to estimate the national parame-
ters for the model. The parameters of the model are used to calculate the epidemiological
threshold parameter R0 and the herd immunity threshold value H for Ghana, and also to
examine the model predictions of the state variables s, e and i representing the proportions
of the susceptible S, exposed E and infectious I populations respectively. The impact of
the model parameters on the epidemiological threshold parameter R0, and also on the
stability of the equilibrium states of the model are presented in a sensitivity analyses of
both R0 and the model to the key parameters of the model. Discussion of results and a
summary of findings from the national data analysis conclude the chapter.
In Chapter 6 the SEIR model is applied to the regional hepatitis B data to examine the
burden of the disease on each region. Methods discussed in Chapter 3 are used to estimate
the regional parameters for the model, which are then used to calculate the epidemiological
threshold parameter R0 and the corresponding herd immunity threshold values H for each
region. The parameters are also used to predict the state variables s, e and i of the model
for each region. A simple regression analysis is applied to discuss some potential factors
that influence the trend of incidence and spread and the associated burden of hepatitis B
across the ten regions of Ghana. A summary of findings from the regional data analysis
closes the chapter.
A modification of the SEIR model to include vaccination, a crucial intervention for con-
trolling hepatitis B pandemic, to examine its impact on the incidence and spread of the
disease in Ghana is presented in Chapter 7. Stability of the modified model is discussed
analytically with respect to the disease-free and endemic equilibrium states. The epi-
demiological threshold parameter Rv0 of the vaccination model is derived analytically and
subjected to sensitivity analysis, through simulation of the model over a range of possible
values of the vaccination rate k, based on the parameters estimated for the original SEIR
model presented in Chapter 5. Discussion of results and a summary of findings from the
application of vaccine to the SEIR model conclude the chapter.
Finally in Chapter 8 is presented the concluding remarks of the research. A summary
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and conclusion of the analysis of results is presented in a way that reflects the research
objectives of the study. The chapter also outlines some recommendations for policy con-
sideration, based on the main findings of the research. The chapter is concluded with
some constraints that were identified as potential limitations of the study, some research




2.1 Modelling hepatitis B
Mathematical modelling has been widely used as a tool to provide a theoretical frame-
work for understanding the dynamics of the spread and control of infectious disease in
a population [23, 77, 78]. Knowledge of the transmission characteristics of an infectious
disease in a population is essential in finding steps to eradicate it. Apart from its use in
planning, implementing, evaluating, and optimising measures of detection, prevention and
control programmes, mathematical modelling also contributes to the design and analysis
of epidemiological surveys. As experimental tools, the usefulness of mathematical models
combined with computer simulations in testing theories, assessing quantitative conjec-
tures, providing answers to specific scientific and epidemiological questions, examining
sensitivities to parameter changes, and parameter estimations from observed data cannot
be overemphasised [23].
In broad terms, parasites that cause infectious diseases are categorised into micro and
macro-parasites on biological grounds [1]. Most viral and bacterial diseases are classified as
caused by micro-parasites and compartmental modelling is prescribed as the most preferred
modelling approach, due to the typically short duration of such infections relative to the
expected life span of the host [1]. It is conceded, however, that there are important
exceptions where the duration of some micro-parasitic infections may be relatively long
and compartmental modelling is still preferred [1].
Many studies have used compartmental modelling to gain insight into the spread and
control of such infectious diseases [9, 17, 19, 21, 38, 79]. Stochastic and deterministic com-
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partmental models have been useful tools to study infectious diseases on a population scale.
Stochastic models are prescribed as more useful in studies conducted in small or isolated
populations in which individuals in the population are considered to be independent units
of observation and chance fluctuations or known heterogeneities are important [80, 81].
Deterministic or compartmental models, on the other hand, are deemed to be more useful
for studies of more complex systems involving nonlinear dynamics where individuals are
observed to be more interdependent [80, 81].
2.2 The classical deterministic compartmental model
The best known deterministic compartmental model that is used to describe the spread
of contagious epidemic diseases was developed by Kermack and Mckendrick and has since
been adopted and modified in most epidemiological studies [82]. The model divides the
population into three epidemiological compartments, namely the Susceptible (S) class,
individuals who are not yet infected at a time but are at risk of being infected; the
Infectious (I) class, individuals who are infected and can infect anyone in contact who is
not immune to the disease; and the Recovered or Removed (R) class, individuals who have
recovered or have been removed either by acquiring immunity to the infection or death after
being infected. The progression of infection through the epidemiological compartments is
illustrated by the flow diagram in Figure 2.1,where S(t), I(t) and R(t) are the number of
individuals in the population who are susceptible, infectious and removed at a given time
t respectively.
This model is thus called the SIR model after the designated compartments. Transmission
occurs when there is an adequate contact of a susceptible individual with an infectious
individual so that after infection the susceptible individual then moves into the infectious
compartment. An infectious individual enters into the removed or recovered compartment
after acquiring immunity to the infection or upon death, ending progression of infection.
The rate of transmission β is defined as the average number of individuals infected per unit
time, assuming all the contacts between susceptible individuals and infectious individuals
result in infection, and γ is the rate of recovery per unit time.
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Figure 2.1: The Classical SIR Model.










subject to S(t0) = S0, I(t0) = I0 and R(t0) = R0, where S0, I0 and R0 are the susceptible,
infectious and recovered populations at time t = t0. The following are the assumptions
underlying this classical deterministic compartmental model:
i. The total population size is considered as remaining constant, S(t)+I(t)+R(t) = N ,
since the course of an epidemic is relatively short compared to the life-span of an
individual, births and deaths including disease-induced are ignored.
ii. All the members of the community are initially susceptible to the disease.
iii. Complete immunity is conferred by a single infection and so there is no progression
from the recovered class into the susceptible class.
It is noted that for each particular set of infectivity, recovery and death rates, there
exists a critical epidemiological threshold value, often referred to as the basic reproduction
number, R0 that determines whether the disease dies out or persists in an epidemic. A
slight perturbation in these rates may cause a marked epidemic or vice versa [82]. The
epidemiological threshold value for the classical SIR model in Figure 2.1 is given by
R0 =
β
γ . Whenever R0 > 1, a typical infectious individual gives rise, on average, to
more than one secondary infection leading to an epidemic. When R0 < 1, an infectious
individual gives rise to less than one secondary infection and the disease decreases or dies
out [1, 83, 84]. The epidemiology of the infectious disease is determined by
i. The rate of transmission β which measures the risk of transmission per contact per
unit time.
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ii. The number of potentially infectious contacts an average individual in a population
makes per unit time defined by the bilinear (pseudo) mass action term βSI.
iii. The duration of the infectivity period 1γ .
The bilinear incidence term βSI represents horizontal transmission in the model and is
suitable for modelling infectious diseases in a population with constant size.
Other studies indicated that a time-dependent threshold value called the effective repro-
duction number, R(t) = S(t)N R0, is more appropriate and better quantifies the transmissi-
bility in a non-naive host population [83]. This value R(t), is defined as the mean number
of secondary infections caused by introducing a single infectious individual into a host pop-
ulation at a given susceptible fraction. The determination of R(t) by definition depends on
the accurate estimation of the susceptible fraction S(t)N which is often a challenge to come
by [83]. The upper bound of R(t) ≤ R0 can only be achieved when the entire population is
susceptible. The prevalence of an infection will increase or decrease depending on whether
R(t) is greater than or less than one respectively [1, 83]. At a critical susceptible fraction
sc =
Sc
N when the dynamical system of an infectious disease model is in equilibrium, the
effective reproduction number R(t) = 1 and so R0sc = 1, assuming the host population
is homogeneously mixed [1]. The rate of transmission is a function of many biological,
social and environmental factors and is therefore often best inferred indirectly from data
at the population level. However, host death and birth rates, disease-induced death rates,
recovery rates and rates of immunity can be measured directly by appropriate studies
[1, 83, 85].
2.3 Modifications of the classical model and other relevant
studies
Since the formulation of this simple but powerful standard model displayed in Figure 2.1,
modifications have emerged in various studies. One notable modification is the SEIR
model which introduces a latent period and the exposed class E into the SIR model. The
SIR model is a special case of the SEIR model in which the latent period is non-existent
and so fits well for short-term epidemics in a closed population [1, 72]. Some common
modifications include, but are not limited to SIS, SIRS, SEIR, SEIRS and SEIS (see
Table 2.1).
A SEIR model was modified into SEIAICR to study the transmission dynamics and
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control of hepatitis B in Gambia [86]. In this model, the infectious class I was split into
two classes, namely acute IA and chronic IC . The model was defined by a system of partial
differential equations and incorporated horizontal, perinatal and sexual transmission (see
Model 1 of Table 2.2). Age-specific rates of infection were estimated from cross-sectional
serological survey data on hepatitis B from Gambia using a maximum likelihood method
called the Grenfell and Anderson technique, which was not outlined in the paper [86, 87].
Other parameters such as proportions of infants infected from chronic carrier mothers,
latent period and duration of the carrier state were values obtained from an existing case
studies.
Table 2.1: Some common modifications of the SIR compartmental model
Model Systems Key Parameters
1. SIR dSdt = −βSI
dI
dt = βSI − γI
dR
dt = γI
β=rate of susceptible becoming
infectious, γ=rate of recovery.
2. SIRS dSdt = αR − βSI
dI
dt = βSI − γI
dR
dt = γI − αR
β=rate of susceptible becoming
infectious, γ=rate of recovery,
α=rate of recovered becoming
susceptible.
3. SIS dSdt = γI − βSI
dI
dt = βSI − γI
β=rate of susceptible becoming
infectious, γ=rate of infectious
becoming susceptible.
4. SEIR dSdt = −βSI
dE
dt = βSI − γE
dI
dt = γE − νI
dR
dt = νI
β=rate of susceptible becoming
exposed, γ=rate of exposed be-
coming infectious, ν=rate of re-
covery.
5. SEIRS dSdt = αR − βSI
dE
dt = βSI − γE
dI
dt = γE − νI
dR
dt = νI − αR
β=rate of susceptible becoming
exposed, γ=rate of exposed be-
coming infectious, ν=rate of re-
covery, α=rate of recovered be-
coming susceptible,
6. SEIS dSdt = αI − βSI
dE
dt = βSI − γE
dI
dt = γE − αI
β=rate of susceptible becoming
exposed, γ=rate of exposed be-



































Table 2.2: Summary of some compartmental models from the literature
Model Systems Key Parameters Key Points



























= [1 − p(a)]γ1IAg(a, t) + γ2ICg(a, t) +
q(a, t)Sg(a, t)− µg(a)Rg(a, t)
Force of infection (λi); λ1 =
0.159, λ2 = 0.144, λ3 = 0.116, λ4 =
0.089, λ5 = 0.030, Rates of
recovery(γi);γ1 = 4, γ2 = 0.025, Pro-
portion perinatal(acute,carrier)νc =
0.109, νy = 0.711
Force of infection is high-
est in the younger ages de-
clining through childhood,
and rising suggest trans-
mission is entirely horizon-
tal or sexual. Vertical, (in-
fected mothers),horizontal
and sexual modes were in-




= µK − αSI − µS − ρS
dI
dt
= αSI − (β + µ)I
dR
dt
= βI − µR + ρS
Recovery rate; β = 0.98415, Infec-
tious rate; α = 1.0058, Death/Birth
rate; µ = 0.0094, Vaccinated fraction;
ρ = 0.017051, N = 74775, S0 = 73475,
I0 = 25.
Vaccination impact on the
model was significant; in-
creasing vaccination could





= µK − βSI − µS − pS
dI
dt
= βSI − (γ + µ)I
dR
dt
= γI − µR + pS
Death/Birth rates; µ = 0.0219, Infec-
tious rate; β = 0.9842, Recovery rate;
γ = 2.5447, Vaccinated fraction; pS =
1.0× 10−4.
Vaccination class was in-
cluded. Increasing vacci-
nation could reduce rate of
transmission.
4. SHIHIHARH/SLILIALRL (General case)
dSH
dt = λ− αSH(t)− (ν1 + µ1)SH(t)
dSL
dt = ν1SH(t)− µ1SL(t)
dIH
dt = aαSH(t)− (γ + µ2 + ν2)IH
dIL
dt = (1− a)αSH(t) + ν2IH(t)− (γ + µ2)IL(t)
dRH(Aids)
dt = bγIH(t) + gγIL(t)− (ω + µ3 + ν3)RH(Aids)
dRL(Aids)
dt = (1−b)γIH(t)+(1−g)γIL(t)+ν3RH(t)−(ω+µ3)RL(t)
Death rates (non-AIDS); µ1 = µ2 =
µ3 = 1/3, Susceptible fraction; a = 0.9,
High risk Infective; b = 0.5, Low risk
infective; g = 0.1, Transfer rates from
High to Low risk; ν1 = ν2 = 0.1, ν3 =
0.5, AIDS development rate; γ = 0.1,
Death rate(AIDS); ω = 1, Transmission
rate; βc = 1, N = 100, 000;SH(0) =
99, 999; IH(0) = 1,SL(0) = IL(0) =
RL(0) = RH(0) = 0.
Approximate analytic
solutions to the model
showed close agreement
with numerical solutions
5. SEIR (General case)
dS
dt = b− λSI − pbE − qbI − bS
dE
dt = λSI + pbE + qbI − (ε+ b)E
dI
dt = εE − (γ + b)I
dR
dt = γI − bR
Infectious rate; λ, Removal from Ex-
posed; ε, Recovery rate; γ, Birth/Death
rates; b, Newborns(fractions);p, q
The latent period is
non-negligible.Vertical
transmission has signifi-
cant effect on model.
6. SEIaIcRM (General case)
dS
dt = δπ(1− ηIc)− δS − β(Ia + κIc)S + δ0R− pS
dE
dt = β(Ia + κIc)S − δE + δπηIc − γ1E + µ1M
dIa
dt = γ1E − δIa − qγ2Ia − (1− q)γ1Ia + µ2M
dIc
dt = qγ2Ia − δIc − γ3Ic
dR
dt = γ3Ic + (1− q)γ1Ia − δ0R− δR+
δ(1− π) + pS
dR
dt = γ3Ic + (1− q)γ1Ia − δ0R− δR+ δ(1− π) + pS
dM
dt = −(µ1 + µ2)M − δM
Death/Birth rates;δ = 0.0143,Transfer
rates (from latent to Infectious); γ1 =
6, γ2 = 4, γ3 = 0.34, Transmission rate;
β = 0.8, Loss of Immunity; δ0 =
0.03, Transfer to carrier; q = 0.005,
Vaccinated fraction; p = 0.3, Rates
(from Migrated class to Exposed/Acute
classes); µ1 = 0.23, µ2 = 0.56, Non-
immunized children; (η = 0.7, Rate of
infection (carriers) κ = 0 − 1 (all pa-
rameters sourced from literature).
Migration class was in-
cluded. The number of in-
fected persons is directly
proportional to the num-
ber of migrated persons.
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The study indicated that horizontal transmission was a major route of incidence and spread
of hepatitis B, complicated by the high age-dependent risk of developing into the chronic
carrier state. The high prevalence of chronic carrier state increases the rate of infection,
leading to hyperendemicity of hepatitis B in the population. The disease therefore persists
due to the long-lasting chronic carrier state, many years after immunisation, which calls
for proper design of immunisation programmes. The inclusion of age in modelling hepatitis
B would be very important when the purpose of study is to assess the risk of progression
from the acute stage to the chronic stage with its attendant age-dependent complications.
Obviously, the challenge would be the availability of adequate data to estimate parameters
of the model or the existence of reliable parameters to achieve the needed result.
A SIR model was applied to existing clinical incidence data to study the prevalence
and incidence of hepatitis B in the Tano North and Bosomtwe districts of the Brong
Ahafo and Ashanti regions of Ghana respectively [9, 19]. The model was defined by a
system of ordinary differential equations and parameters of the model were estimated
based on the incidence data, although the method of estimation was not provided (see
Models 2 and 3 of Table 2.2). The epidemiological threshold parameters calculated were
greater than unity, which indicated that hepatitis B persists in the districts. With an
introduction of a vaccination component into the model, the studies indicated that an
increase in vaccination reduced the rate of transmission and that the rate of transmission
of hepatitis B in childhood appeared to be a major determinant of endemicity of the disease
in that part of Ghana [19]. Both studies by the choice of the model did not incorporate
the latent period and vertical transmission, which other studies deemed important in
modelling hepatitis B [20, 21]. The pseudo mass action incidence rate βSI, which describes
horizontal transmission of the disease in a closed population with constant size was used.
The population size was assumed to be constant over the period of study. Although this
incidence term is widely used in modelling infectious diseases, the standard incidence term
βSI
N is considered more suitable, in reality, for a population with changing size [75].
A SIR model was modified into SSLIILRRL to include a low risk component SLILRL
to study a general case of HIV and AIDS epidemic over a period of fifty years [79]. The
model was defined by a system of ordinary differential equation (see model 4 of Table 2.2).
Parameter values were sourced from existing literature to solve the system of equations
in terms of the incidence cases of HIV and AIDS over the fifty year period. In the study,
numerical methods namely Euler, Taylor series, Predictor-Corrector and Runge-Kutta
(4th order) were compared against a linearised piece-wise analytical method which divided
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the time-scale into three stages, i.e. initial, mid and end. The objective of the study
was to develop approximate analytic solutions to compartmental models where previously
numerical methods were used. The study indicated that analytic approaches give more
insight into the dynamics of an epidemic and a clearer picture of sensitivity of results to
variation of parameter values than the numerical methods [79]. The study, for example,
indicated that analytic solutions allow explicit forms of the maximum likelihood function to
estimate parameter values whereas the numerical approaches do not. In a large parameter
space, the study indicated that analytic solutions are very good approximations to the
numerically derived results [79].
A SEIR model that incorporates vertical transmission was used in a theoretical study
for an infectious disease that spreads in the host population through both horizontal
and vertical transmission [20]. The incidence term was of the pseudo-mass action form
λSI, where λ, S and I were the transmission rate and the number of susceptible and
infectious hosts respectively. Vertical transmission was introduced into the model, via
the E class, as a fraction of offsprings of the infected hosts E and I who are infected
at birth and so stay latent before becoming infectious. The model was defined by a
system of ordinary differential equations displayed in Model 5 of Table 2.2. In the study,
the natural birth and death rates were assumed to be equal and disease-related death
assumed negligible so that the total population was constant. Compared to some SIR
models that incorporate vertical transmission, the model was considered suitable, by the
authors, for studying, infectious diseases such as hepatitis B, Chagas and AIDS that have
nonnegligible latent periods and can spread through both direct horizontal transmission
and vertical transmission [20].
Migration is also known to have a significant impact on the spread and control of hepatitis
B. A study modified the SIR into MSIAIcR by introducing a migration class M that
presents with hepatitis B and splitting the infectious class I into two, namely acute IA
and chronic IC classes, to examine the effect of immigrants with respect to transmission
and spread of hepatitis B on the host population [88]. Model 6 in Table 2.2 displays the
model for the study, which consists of a system of ordinary differential equations. In the
study, parameter estimates were either sourced from works by different authors in existing
literature or assumed and did not involve any dataset. Numerical simulation, which applied
the Runge-Kutta method of order 4 to vary the recruitment rate of infected migrants into
the model keeping all other parameters constant, indicated that the number of infected
population members increased with increased number of infected immigrants introduced
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into the population [88]. It was concluded that the number of infected individuals is
directly proportional to the number of individuals migrated with hepatitis B.
2.4 Results from other relevant studies
Time series and correlation analysis were used to assess the strength of impact of medical
intervention on some risk factors of hepatitis B in Kharkiv, Ukraine [89]. The result
indicated that, with increased medical intervention, the risk of vertical transmission was
reduced whilst other common risks such as drug usage, sexuality and injection of medicine
outside of health facilities increased. People aged between 20-29 years were found to
have the highest risk of infection. There was positive dependence between morbidity and
infection through dental procedures and injection. This result suggests that with medical
intervention which guarantees safety health practices, the risk of contracting HB through
vertical transmission and its associated morbidity can be minimised compared to the risk
involved in acquiring the disease through drug usage, sexuality and injections of drugs
outside health facilities. People aged between 20-29 years were found to have the highest
risk of infection compared to those outside this age bracket perhaps due to the higher
risk of indulging in drug use, sexuality and injections of drugs outside health facilities.
The study, however, suggested the need for deeper analysis of dependencies between risk
factors and symptoms for early identification of high risk individuals for preventive action
against morbidity due to hepatitis B [89].
An effective immunisation programmes simultaneously backed by a treatment regimen
would have the best result in controlling hepatitis B prevalence in a population [90].
The study used a generalised compartmental model to examine the effects of HBV drug
treatment and immunisation on the Inuit population of Canada. The model was applied to
simulate clinical trial data to determine an optimal strategy for hepatitis B control among
the Canadian Inuit population. Comparing the two interventions, the study revealed
that increasing immunisation decreases both prevalence and incidence whilst increasing
treatment decreases prevalence but barely decrease incidence. This result suggests that
with medical intervention which guarantees safety health practices, the risk of contracting
HB through vertical transmission and its associated morbidity can be minimised compared
to the risk involved in acquiring the disease through drug usage, sexuality and injections
of drugs outside health facilities. People aged between 20 − 29 years were found to have
the highest risk of infection compared to those outside this age bracket perhaps due to
the higher risk of indulging in drug use, sexuality and injections of drugs outside health
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facilities. The study thus indicated that a combination of immunisation and treatment is
optimal because it reduces both prevalence and incidence substantially [90].
In another situation, a theoretical study on chronic hepatitis B patients using clinical trial
data indicated that as soon as treatment was stopped, viral levels shot up [75]. In this
study, two virus infection models, one using the pseudo mass-action term and the other
using the standard proportionate incidence term, were applied to simulate the use of an
antiviral drug in a treatment of a group of HBeAg-positive chronic hepatitis B patients
for 48 weeks followed by a 24 week treatment-free follow-up. The study indicated that
although the simulation results achieved with both models were similar, the model with
the proportionate incidence term interpreted the clinical data better. Furthermore, if the
drug treatment was prolonged for three years followed by a seven year follow-up, the viral
load of patients reduced to significantly lower levels at the end point of the three years but
relapsed soon after stopping treatment for 10 days and then gradually increase thereafter
[75]. The study, however, suggested that further research into the quantitative analysis
of the dynamics of hepatitis B using more detailed assay data may give more insight into
finding optimal treatment strategies for affected patients [75].
The essence of disease transmission models is to be able to provide valid and reliable
predictions of the disease with time. Although all models are at best partial descriptions of
the mechanisms operating in reality, a good model must have assumptions that correspond
to reality as a basis for good prediction [57]. The underlying assumptions of a model
reflect the reality of the disease phenomenon and contribute immensely to the validity
of the predictions made [57]. Even though the basic virus infection model which hinges
on the pseudo mass-action βSI assumption is widely used, some studies indicated that it
may not be ultimately all-embracing to describe hepatitis B infection especially in the case
of a population that changes size with time [75]. Employing standard or proportionate
incidence functions like βSIN and
βSI
S+I in place of the pseudo mass-action in a study showed
results closer to that of a clinical trial [75]. Similarly, not accounting for certain unidentified
sub-populations which may be naturally immune or isolated may lead to underestimating
key parameters and thereby influence the prediction of an epidemic negatively [91].
2.5 Vertical transmission of hepatitis B
A vertically transmitted disease is caused by bacteria, viruses, or in minor cases parasites
transmitted directly from mother to embryo, foetus or baby during pregnancy or childbirth
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[7, 92]. Vertical transmission is also referred to as mother-to-child or perinatal infection
which pertains to transmission of infection immediately before or after birth [7]. It is
termed congenital if the vertically transmitted infection persists after childbirth. Vertical
transmission occurs through two main routes; transplacental where transmission is across
the placenta and during birth where transmission is across the female reproductive tract
[7].
Hepatitis B is classified as a vertically transmitted disease which occurs via three modali-
ties; intrauterine, at-birth and postpartum transmissions [7, 93]. Interuterine transmission
occurs only in rare cases, with very high maternal viral load, when the hepatitis B virus
crosses the placental barrier or there is a transplacental leakage of the maternal blood into
the foetal circulation [7, 93]. Transplacental leakage is not common since the hepatitis B
virus is a large virus and rarely crosses the placenta [94]. Transmission during delivery is
the most common case when the newborn is exposed to the mother’s infected body fluids
[7, 95]. Postpartum which is also in a minority refers to transmission of infection to the
baby after birth due to close contact with mother but not through breastfeeding [7, 96].
Prophylaxis can prevent at-birth and postpartum transmissions but not interuterine es-
pecially in cases where the maternal viral load is high [7, 93].
Neonatal and childhood exposure to hepatitis B have impacted significantly on the public
health burden globally. Vertical transmission as a route of spreading infectious diseases has
a significant impact on the determination of the epidemiological threshold parameter, the
basic reproduction number R0 [20]. The occurrence of vertical transmission of hepatitis
B is highly influenced by carrier mothers and the risk of transmission of the virus from
a carrier mother to her child [40, 97]. Some studies have indicated that there is a high
probability of transmission and risk for chronic hepatitis B carriage associated with child-
bearing women [40, 95]. Results from similar studies have also indicated that chronic
hepatitis B carriers mostly arise as a result of vertical transmission [90, 98, 99, 100].
Newborns exposed to HBeAg, have the highest risk of becoming chronically infected with
hepatitis B [40]. In a disease epidemiological modelling, vertical incidence is sometimes
assumed to be a fixed fraction of the newborns who are infected vertically [23].
Sub-Saharan Africa and East Asia are noted to have higher prevalence of carrier mothers
and greater risk of vertical transmission than any other developing country [40]. A survey
of hepatitis B in Ghana indicated that 15% of the disease carrier rate was acquired through
vertical transmission [14]. A study of hepatitis B in Tano-North district of Ghana (see
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Model 2 in Table 2.2), indicated that transmission of hepatitis B in childhood appeared to
be a major determinant of endemicity of the disease in that part of the country [19]. Some
studies have indicated that mother to child transmission of hepatitis B is a major public
health concern to regions of high endemicity [101]. Some other studies however indicated
that the exact mode of transmission of hepatitis B in Sub-Saharan Africa is uncertain,
although a covert perinatal transmission manifesting later during childhood cannot be
discounted [102]. It is noted that African infants may contract hepatitis B at birth, but
due to some genetically determined reasons they persistently test negative until the virus
is reactivated later during early childhood [102]. Furthermore, Africa with much of its
population living in vast rural areas with limited resources, inaccurate determination of
hepatitis B incidence rates results from under-reporting and poor quality data [102].
2.6 Latent and incubation periods of hepatitis B
A SEIR model used in a theoretical study of infectious diseases indicated that offspring
may already be infected at birth by their mothers, and these newborns stay in a latent
period before becoming infectious [20]. The study also indicated that using a model to
predict the disease prevalence for such infectious diseases that have this latent period,
but not accounted for, may therefore lead to inaccuracies [21]. In other related studies
a SEIR model was used to show that the latent period has a significant impact on the
epidemiological threshold parameter (basic reproduction number), R0, that is used to
determine whether an infectious disease epidemic persists or die out with time. Other
studies noted that ignoring the latent period often leads to underestimating the basic
reproduction number, R0, making predictions of the model less accurate [1, 20, 21, 22, 23,
24]. Some of the studies indicated that hepatitis B, like HIV/AIDS and Chagas diseases,
has a non-negligible latent period [20, 21].
The epidemiology of hepatitis B like all infectious diseases is characterised by different
stages in the course of infection [2]. The course of infection begins when the pathogen,
in this case, the HBV enters the host, a stage called exposure. The pathogen then moves
to the preferred tissue or organ which is the liver in the case of hepatitis B where it
can effectively multiply. Virus replication triggers the host’s immune response in defence.
This process, called infection, may not be clinically visible but laboratory diagnostics
may show signs such as increased sedimentation rate and change in orientation of white
blood cells [2]. The blood and body fluids of an infected individual become infectious
when the HBeAg marker is detected in a laboratory investigation. The time elapsed
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between infection (exposure) and the onset of the state of infectiousness is known as the
latent period [1, 2]. The latent period is therefore a period within the incubation period
stretching from the point when an individual becomes infected to the point when an
individual becomes infectious [1, 2].
An infected host may transmit infection without necessarily showing any symptoms of the
disease [2]. In many infectious diseases, the duration of symptoms and the period when
an infected host is infectious may not happen together [1]. The period between when
an individual becomes exposed (infection) and the time clinical symptoms begin to show
is known as the incubation period [1, 2]. With hepatitis B, the onset of infectiousness
occurs during the incubation period and may continue indefinitely especially in the case of
chronic infection [103]. Figure 2.2 shows the relationship between incubation, latent and
infectious periods of a typical infectious disease.
Figure 2.2: Diagrammatic illustration of the relationship between incubation, latent and
infectious periods (Modified from [1, 2]).
The incubation period of hepatitis B is 75 days on average, but varies from 30 to 180 days or
even more depending on the size of the viral load of the infected host [10, 11, 30]. It is also
noted that the natural course of hepatitis B is different from person to person [10, 11, 30].
Many infected hosts during the early stage of infection with hepatitis B, the acute infection
phase which spans the first 6 months, show no symptoms at all [104]. About 90% of adults
who contract hepatitis B are able to clear the virus at the acute stage of the infection and
about 90% of newborns who contract the disease at birth develop the chronic infection
[29, 92]. Studies on the characteristics of the dynamics of hepatitis B indicate that the
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disease can be cleared at the acute stage without the need for intervention or antiviral
treatment depending on the age and immune competence of the infected individual at the
time of infection [29, 92].
2.7 The epidemiological threshold parameter R0 of a com-
partmental epidemic model
The most important concern in the study of an infectious disease epidemiology is to deter-
mine the ability of the disease to increase or decrease in a population. In most epidemi-
ological models this concern is addressed by an epidemiological threshold parameter, also
known as the basic reproduction number, denoted by R0. An infectious disease epidemic
increases or decreases when R0 > 1 or R0 < 1 respectively. In a simple compartmental
model with a single infected compartment (m = 1), the epidemiological threshold param-
eter R0 is simply the product of the rate of infection and the mean infection period and
so its determination is also simple [1, 105, 106]. However, when the number of infected
compartments in a model is greater than one (m > 1), the determination of the threshold
parameter becomes more complicated.
In essence, a clear distinction must be made between the infected and uninfected compart-
ments based on both the epidemiological interpretation of the model and the structure of
the model equations. A more general epidemiological threshold parameter is defined as the
number of new infections caused by introducing a typical infective into a population at the
disease-free equilibrium [105]. For the purpose of this work, the next generation method
which defines the threshold parameter R0 as the spectral radius of the next generation
matrix is discussed in this section.
Let w = (w1, w2, w3, . . . , wn)
T , where wi ≥ 0 denotes the number of members in the ith
compartment of an epidemiological model, which has a total of n compartments. Classifi-
cation of the infected and uninfected compartments is determined based on the structure
of the model equations given by the epidemiological interpretation of the model. The com-
partments have to be arranged in such a way that the first m compartments correspond
to infected members and the remaining n−m are uninfected members. Denote by
W0 = {w ≥ 0|wi = 0, i = 1, 2, ...,m},
the set of all disease-free states of the model. Let Ai(w) be the rate of appearance of
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new infection in the ith compartment, B+i (w) be the rate of transfer of members of the
population into compartment i by all other means, and B−i (w) be the rate of transfer of
members out of compartment i. Note that the transfer rates B+i (w) and B
−
i (w) describe
the progression of infection through the n compartments of the model whilst Ai(w) involves
a recruitment of new infection into the model. Each of the functions Ai(w), B
+
i (w) and
B−i (w) is assumed to be at least twice continuously differentiable in each variable wi.
Then the disease transmission model is given by [105]
ẇi = gi(w) = Ai(w)−Bi(w), i = 1, 2, ..., n (2.2)




i and the underlying assumptions for all functions are [105]:
i. All functions are nonnegative since each of them moves members of the popula-





i ≥ 0 for i = 1, 2, ..., n.
ii. If a compartment is empty, then no outbound transfer can take place; that is if
wi = 0, then B
−
i = 0 for i = 1, 2, ...,m and for w ∈W0, B
−
i = 0 for i = 1, 2, ...,m.
By this assumption, gi ≥ 0 and hence the nonnegative cone wi ≥ 0, i = 1, 2, ..., n
is forward invariant and so for each nonnegative initial condition, there is a unique
nonnegative solution [105, 107]
iii. No new infection is introduced into the uninfected compartments; that is Ai = 0 for
all i > m.
iv. If the population is free of disease, then the population will remain free of disease.
This ensures that the set of all disease-free states W0 is invariant and there is no
immigration of infectives; that is if w ∈ W0 then Ai(w) = 0 and B+i (w) = 0 for
i = 1, 2, . . . ,m.
v. In the absence of new infection, the disease-free state of a system is stable and it
follows that all the eigenvalues of the Jacobian of the system have negative real parts;
that is if A (w) is set to zero, then all eigenvalues of the Jacobian matrix Dg(w0)
evaluated at the disease-free equilibrium w0, have negative real parts.
By conditions (i) - (v), the Jacobian matrix Dg(w0) can be partitioned using the following
lemma [105].
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Lemma 1 If w0 is a disease-free equilibrium of Equation (2.2) and gi(w) satisfies condi-

























, with 1 ≤ i, j ≤ m. (2.4)
Further, A is nonnegative and B is a nonsingular M-matrix.
Since A is nonnegative and B is a nonsingular M-matrix, B−1 and AB−1 are also nonneg-
ative. The components of the matrix B−1 determine the mean length of time an infected
individual introduced into a disease population spends in a compartment in their life time
whilst that of A determine the rate of new infections produced by this individual in the
compartment. Hence the product AB−1 known as the next generation matrix of the model
is the expected number of new infections generated as a result of a single infective intro-
duced into a population. The spectral radius of the next generation matrix is defined as




This is the biggest nonnegative or the dominant eigenvalue of the next generation matrix.
The following theorem states that R0 is the threshold parameter for the stability of the
disease-free equilibrium [105].
Theorem 1 Consider the disease transmission model given by Equation 2.2 with g(w)
satisfying conditions i - v. If w0 is a disease-free equilibrium of the model, then w0 is
locally asymptotically stable if R0 < 1, but unstable if R0 > 1 where R0 is defined by
Equation 2.5.
2.8 Herd immunity threshold
The spread of an infectious disease is driven by how quickly effective contacts are made
between the infectious and susceptible individuals in a population. High effective contact
rates most likely result in high infection rates and greater spread of the disease [108]. To
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stop or slow down the transmission and spread of an infectious disease requires that a
critical proportion of the population is immune to the disease [108]. The greater the pro-
portion of immunity achieved in a population, the smaller the likelihood for an infectious
individual to come into contact with an individual who is not immune since many chains
of infection are likely to have been broken [109, 110]. The implication is that the risk of
infection among susceptible individuals in a population is reduced by the presence and
proximity of immune individuals who serve as a barrier to transmission of the disease.
This process of creating transmission barriers is referred to as indirect protection or herd
effect and the threshold parameter that defines the critical proportion of the population
is called the herd immunity threshold value [109].
The herd immunity threshold value is the threshold proportion of immune individuals nec-
essary for the incidence of the disease to decline and protect the population from invasion
of new infection [108, 109, 110]. Given that the epidemiological threshold parameter (basic
reproduction number) is R0, then at the critical proportion of the susceptible population
sc [1], for R0 > 1, one has
R0 × sc = 1.
Let H denote the proportion of the population that is immune, then sc +H = 1 and so
R0(1−H) = 1
=⇒ H = 1− 1
R0
(2.6)
Equation 2.6 defines the herd immunity threshold for an infectious disease model whose
epidemiological threshold parameter is R0 [108, 111]. Since R0 is a measure of the incidence
and spread of the disease in a population, lower values of R0 require lower herd immunity




3.1 The SEIR deterministic model
The SEIR model is a modification of the SIR model in which the exposed class E is
introduced. This study adopts the SEIR model and incorporates the true mass-action
incidence term βSIN and the latent period which are found to be critical in modelling
hepatitis B. It is also assumed that a fraction of newborns of exposed and infectious hosts
α, accounting for vertical transmission, are infected at birth and like the host will stay
latent before becoming infectious.
The population is divided into four mutually exclusive compartments namely the Sus-
ceptible S, Exposed E, Infectious I, and Removed or Recovered R. After infection an
individual moves from the susceptible class into the exposed class, then into the infectious
class and then finally into the recovered or removed class by protective immunity, or may
die naturally in the course of progression through the model. Figure 3.1 illustrates the
progression of infection through the compartments of the model.
Figure 3.1: A model for the transmission of hepatitis B
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+ α(I + E)− µE − γE (3.1)
dI
dt
= γE − µI − νI
dR
dt
= νI − µR
subject to S(t), E(t), I(t), R(t) ≥ 0 and S(t) + E(t) + I(t) + R(t) = N(t), where λ is the
natural birth rate, µ is the natural death rate, γ the rate of removal from the exposed
class and ν the rate of recovery per unit time. The force of infection is β IN , where β is the
effective contact rate of an infectious individuals with a susceptible individual, and the
incident rate is β SIN . Furthermore,
1
λ+ν is the mean time-duration an infected individual
remains infectious and 1λ+γ is the mean latent period [23].
The underlying assumptions of the model are:
• The population has a homogeneous distribution which guarantees mass-action in
terms of mixing of hosts. Thus the local density of the total population is considered
constant though the total population size S(t) +E(t) + I(t) +R(t) = N(t) may vary
with time.
• Horizontal transmission of disease is taken to be the effective direct contact between
an infectious and a susceptible host, measured by the term β SIN , and referred to as
proportionate (bilinear true) mass-action or freely mixed [76].
• Vertical transmission is taken to come from a fraction α of the exposed and infectious
classes. Thus α(I + E) and λN − α(I + E) are the birth flux introduced into the
system via the exposed and susceptible compartments respectively.
• The recovered hosts have permanent immunity and cannot re-enter the susceptible
hosts.
From the model in Equation 3.1, let s(t) = S(t)/N(t), e(t) = E(t)/N(t), i(t) = I(t)/N(t)
and r(t) = R(t)/N(t) be the proportions of S - susceptible, E - exposed, I - infectious
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and R - recovered populations respectively in the total population of size N(t) in time t
















= λN − α(I + E)− βSI
N
− µS
and the population varying with birth and death by
dN(t)
dt




= λ− α(i+ e)− βsi− µs− s(λ− µ)
= λ− α(i+ e)− βsi− sλ (3.4)
Following the same procedure for e, i and r, the system in Equation 3.1 becomes
ds
dt
= λ− α(i+ e)− βsi− sλ
de
dt
= βsi+ α(i+ e)− γe− eλ (3.5)
di
dt








= λ− α(i+ e)− βsi− sλ
de
dt
= βsi+ α(i+ e)− γe− eλ (3.6)
di
dt
= γe− νi− iλ.
on the closed positively invariant set Σ = {(s, e, i) ∈ R3+ : 0 ≤ s+ e+ i ≤ 1} [112]. The set
Σ is positively invariant with respect to the system in Equation 3.6 in the sense that for all
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t ≥ 0, (s(t), e(t), i(t)) ∈ Σ whenever (s(0), e(0), i(0)) ∈ Σ [113]. The system in Equation 3.6
is therefore well-posed since given an initial state (s0, e0, i0) ∈ Σ, all solutions to Equation
3.6 remain in Σ. The dynamics of the system are therefore discussed in Σ whose boundary
and interior are denoted by ∂Σ and Σ̊ respectively. Disease eradication in this regard is
considered to be achieved when the sum of the proportions of e(t) + i(t) → 0 as t → ∞.
The system in Equation 3.6 has two equilibrium solutions: the disease-free proportion
equilibrium Q0 = (1, 0, 0) and the endemic proportion equilibrium Q
∗ = (s∗, e∗, i∗) where
s∗ =
(λ+ γ)(λ+ ν)− α(λ+ γ + ν)
βγ
e∗ =
λβγ + αλ(λ+ γ + ν)− λ(λ+ γ)(λ+ ν)
βγ(λ+ γ)
i∗ =
λβγ + αλ(λ+ γ + ν)− λ(λ+ γ)(λ+ ν)
β(λ+ γ)(λ+ ν)
. (3.7)
The stability discussions of the model in this thesis will refer to disease eradication and
persistence that involve the proportions e and i of the exposed and infectious cases and
not the absolute cases E and I respectively of the population. Although the same outcome
cannot be guaranteed for the proportionate and absolute cases, studies indicate that the
former can be used to predict the infectious disease spread in a population in the same
manner as the absolute case [114]
3.2 The epidemiological threshold parameter and herd im-
munity threshold value
In this section, the epidemiological threshold parameter R0 and hence the herd immunity
threshold value H of the model in Equation 3.6 are derived, using the methods involving
the spectral radius of the second generation matrix of the model discussed in Section
2.7. The model in Equation 3.6 has two infected compartments, the exposed e and the
infectious i, represented by the second and third equations respectively and one uninfected
compartment S represented by the first equation of the system. The proportions of S, E
and I in the total population of N are given by s, e, i ≥ 0 respectively. Thus the number of
infected compartments is m = 2 (E, and I from Fig 3.1) corresponding to the second and
third equations of Equation 3.6. From Equation 3.6, the rate at which new infection (new
appearance) is introduced into the model and the rate of progression of already existing
infection through the model are given by
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respectively. The corresponding partial derivatives of A and V with respect to the infected








γ + λ 0
−γ ν + λ
]
(3.9)
respectively where A and B are 2× 2 matrices corresponding to the submatrices A and B





























Since the second generation matrix AB−1 is upper triangular, the eigenvalues of AB−1
are
ξ1 = 0, ξ2 =
βγ + α(λ+ γ + ν)
(λ+ γ)(λ+ ν)
(3.12)
Therefore the spectral radius is given by
ρ(AB−1) =
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Hence, the herd immunity threshold value of the model in Equation 3.6 is given as [108, 111]
H = 1− 1
R0
= 1− (γ + λ)(λ+ ν)
βγ + α(γ + λ+ ν)
(3.14)
The result in Equation 3.14 is important in the epidemiology of hepatitis B as it defines a
threshold proportion of the population needed to be immune in order for the transmission
and spread of the disease to decline and to protect the population from invasion of new
infection. The value of the herd immunity threshold H, however, is a function of the
epidemiological threshold parameter R0 that determines the intensity of the transmission
and spread of the disease, which in turn depends on the parameters of the model in
Equation 3.6.
3.3 Stability analysis
To analyse the stability of the model in the neighbourhood of the equilibrium points, the
linearised form of the system in Equation 3.6 is determined first. The key to linearising
such a system of nonlinear differential equations is to construct the Jacobian matrix
J(s, e, i) =

−(βi+ λ) −α −(α+ βs)
βi α− λ− γ α+ βs
0 γ −(λ+ ν)
 (3.15)
whose eigenvalues at the equilibrium solutions can be used to determine the stability of
those solutions.
3.3.1 The disease-free equilibrium state
At the disease-free equilibrium Q0 = (1, 0, 0), the Jacobian is
J(1, 0, 0) =
∣∣∣∣∣∣∣∣
−λ −α −(α+ β)
0 (α− λ− γ) β + α
0 γ −(λ+ ν)
∣∣∣∣∣∣∣∣ (3.16)
and its characteristic equation is
(λ+ ξ)[((α− λ− γ)− ξ)((λ+ ν) + ξ) + γ(β + α)] = 0 (3.17)
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and so the eigenvalues are
ξ1 = −λ (3.18)
and
ξ2&3 =







4 = ((λ+ ν)− (α− γ − λ))2 + 4((λ+ ν)(α− γ − λ) + γ(α+ β))
= (λ+ ν)2 − 2(λ+ ν)(α− γ − λ) + (α− γ − λ)2 + 4(λ+ ν)(α− γ − λ) + 4γ(α+ β))
= (λ+ ν)2 + (α− γ − λ)2 + 2(λ+ ν)(α− γ − λ) + 4γ(α+ β)
= ((λ+ ν) + (α− γ − λ))2 + 4γ(α+ β)
= (α+ ν − γ)2 + 4γ(α+ β),
and so
ξ2 =
(α− γ − ν − 2λ) +
√
(α+ ν − γ)2 + 4γ(α+ β)
2
ξ3 =
(α− γ − ν − 2λ)−
√
(α+ ν − γ)2 + 4γ(α+ β)
2
. (3.19)
In Equation 3.19, α− γ − ν − 2λ is always negative and real since the birth rate of babies
with hepatitis B is less than the overall birth rate of the population, α < λ. Furthermore,
(α+ν−γ)2+4γ(α+β) is positive since α, γ, λ ≥ 0, and so the eigenvalues ξ2 and ξ3 are real.
The eigenvalues ξ2 and ξ3 are both negative if (α+ν−γ)2 +4γ(α+β) < (α−γ−ν−2λ)2.
In this case the three eigenvalues ξ1, ξ2 and ξ3 are negative, the disease-free equilibrium
state is asymptotically stable and the equilibrium point is a sink node. Otherwise if
(α+ ν − γ)2 + 4γ(α+ β) > (α− γ − ν − 2λ)2, the eigenvalue ξ2 is positive whilst ξ1 and
ξ3 are both negative and so the disease-free equilibrium state is unstable and the point is
a saddle point. Crossover from stability to instability occurs when
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(α+ ν − γ)2 + 4γ(α+ β) = (α− γ − ν − 2λ)2
=⇒ 2αν − 2αγ − 2γν + 4αγ + 4βγ = −2αγ − 2αν − 4αλ+ 2γν + 4γλ+ 4λν + 4λ2
=⇒ 4αν − 4γν + 4αγ + 4γβ = −4αλ+ 4γλ+ 4λν + 4λ2
=⇒ γβ = −αλ+ γλ+ νλ+ λ2 − αν − αγ + γν
=⇒ β = γ(λ− α+ ν) + λ(λ+ ν − α)− αν
γ
=⇒ β = (λ+ ν − α)(γ + λ)− αν
γ
(3.20)
Equation 3.20 defines a threshold value β∗ = ((λ + ν − α)(γ + λ) − αν)/γ of β for the
crossover of the disease-free equilibrium state from stability to instability. At this threshold
value, the eigenvalue ξ2 is zero whilst the other two eigenvalues ξ1 and ξ3 remain negative.
For β < ((λ + ν − α)(γ + λ) − αν)/γ, all eigenvalues are negative and for β > ((λ + ν −
α)(γ + λ)− αν)/γ, one eigenvalue is positive.
In summary
i. If β < ((λ+ ν − α)(γ + λ)− αν)/γ, then ξ2 < 0.
ii. If β = ((λ+ ν − α)(γ + λ)− αν)/γ, then ξ2 = 0.
iii. If β > ((λ+ ν − α)(γ + λ)− αν)/γ, then ξ2 > 0.
Hence there is a threshold value
β∗ =
(λ+ ν − α)(γ + λ)− αν
γ
(3.21)
of β such that if β < β∗, ξ1, ξ2, ξ3 < 0 and Q0 is asymptotically stable and if β > β
∗,
ξ1, ξ3 < 0 and ξ2 > 0 so that Q0 is unstable (saddle). The corresponding thresholds for γ,









γ − α+ λ
− λ,
α = λ− γ(β − ν)
γ + λ+ ν
λ =
(α− γ − ν)±
√
(α+ γ + ν)2 + 4γ(β − ν)
2
, (3.22)
respectively, ignoring the negative sign in the expression for λ, since λ ≮ 0. Furthermore,
if β < β∗, then from Equations 3.13 and 3.21
β < β∗
⇐⇒ β < (λ+ ν − α)(γ + λ)− αν
γ
⇐⇒ γβ < (λ+ ν − α)(γ + λ)− αν
⇐⇒ γβ < (λ+ ν)(γ + λ)− α(γ + λ+ ν)
⇐⇒ γβ + α(γ + λ+ ν) < (λ+ ν)(γ + λ)
⇐⇒ γβ + α(γ + λ+ ν)
(λ+ ν)(γ + λ)
< 1
⇐⇒ R0 < 1 (3.23)
In conclusion, the statement β < β∗ is equivalent to the restriction R0 < 1. By the same
analogy, the condition β > β∗ is also equivalent to the restriction R0 > 1. Hence if β < β
∗,
R0 < 1 and the disease-free equilibrium is locally asymptotically stable; and if β > β
∗,
R0 > 1 and the disease-free equilibrium is unstable.
3.3.2 Global stability of disease-free equilibrium
Local stability of the disease-free proportion equilibrium Q0 has been established to be
equivalent to all real parts of the eigenvalues of the characteristic equation of the Jacobian
matrix in Equation 7.12 being negative, which is guaranteed by the threshold parameter
R0 < 1. In this section, the parameter restriction R0 < 1 is used to show the global
stability of the disease-free equilibrium Q0 in Σ in the sense of Lyapunov and LaSalle as
given by the following theorems [115, 116].
Theorem 2 (LaSalle’s Theorem) Let Ω ⊂ D ⊂ Rn be a compact positively invariant
set with respect to an autonomous system of equations ẋ = f(x), f(0) = x0. Let V :
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D → R be a continuously differentiable function such that V̇ (x(t)) ≤ 0 in Ω. Let E ⊂ Ω
be the set of all points in Ω where V̇ (x) = 0. Let M ⊂ E be the largest invariant set in E.
Then every solution starting in Ω approaches M as t→∞, that is
lim
t→∞
 infz∈M ||x(t)− z||︸ ︷︷ ︸
dist(x(t),M)
 = 0.
The inclusion of the sets in this theorem is M ⊂ E ⊂ Ω ⊂ D ⊂ Rn and a formal proof of
this theorem can be found in [115].
Theorem 3 The disease-free equilibrium Q0 = (1, 0, 0) of Equation 3.6 is globally asymp-
totically stable in Σ if R0 ≤ 1.
Proof. Let R0 ≤ 1 and V (s(t), e(t), i(t)) = γe + (λ + γ − α)i, where V : R3+ −→ R is a
scalar function that is continuous and has continuous derivatives in R. Differentiating V
with respect to time t and using Equation 3.6 where dedt = e
′ and didt = i
′ gives
V̇ (s, e, i) = γe′ + (λ+ γ − α)i′
= γ[βsi+ α(i+ e)− γe− eλ] + (λ+ γ − α)[γe− νi− iλ]
= γ[(βs+ α)i− (λ+ γ − α)e] + (λ+ γ − α)[γe− (λ+ ν)i]
= i[γ(βs+ α)− (λ+ γ − α)(λ+ ν)]
= i[γβs+ γα− (λ+ γ − α)(λ+ ν)]
= i[γβs+ α(λ+ γ + ν)− (λ+ γ)(λ+ ν)]. (3.24)
Equation 3.24 can be written in the form
V̇ (s, e, i) = i
[





















= i[γβ(s− 1) + (R0 − 1)(λ+ γ)(λ+ ν)]. (3.25)
Since R0 ≤ 1 and s ≤ 1 in Σ, it follows that
40
3.3. Stability analysis
γβ(s− 1) + (R0 − 1)(λ+ γ)(λ+ ν) ≤ 0 (3.26)
Hence for i ≥ 0 in Σ,
V̇ (s, e, i) ≤ 0 ∀(s, e, i) ∈ Σ. (3.27)
Furthermore, V̇ = 0 if i = 0 or
γβ(s− 1) + (R0 − 1)(λ+ γ)(λ+ ν) = 0
and so s = 1 and R0 = 1.
But if s = 1, it follows that i = 0 which then implies that i = 0 is the necessary and
sufficient condition for V̇ = 0 regardless of the value of R0. The set E = {(s, e, i)|0 ≤
s+ e ≤ 1, i = 0} is the set of all points in Σ where V̇ (x) = 0 and {Q0} is invariant, since
(s(0), e(0), i(0)) = Q0 implies (s(t), e(t), i(t)) = Q0, ∀t ∈ R. For any trajectory (s, e, i)
starting in E to remain in E requires that i′ = 0. But if i = 0, it follows from the third
equation of the system in Equation 3.6 that
i′ = γe
so that
L = {(s, e, i)|0 ≤ s ≤ 1, i = e = 0}
is the only positively invariant subset of E because the system in Equation 3.6 reduces to
s′ = (1− s)λ
e′ = 0
i′ = 0 (3.28)
and so all trajectories (s, e, i) starting on the s-axis remain on the s-axis for t ≥ 0 and
in fact approach the singleton {Q0} ⊂ L ⊂ E as t −→ ∞. But for t < 0, all trajectories
(s, e, i) starting in L move in the negative s-direction and so ultimately fall outside of the
closed positive set Σ as t −→ −∞ thereby making the set L only positively invariant, not
invariant. Thus, the maximum invariant set in E is the singleton {Q0} ⊂ L ⊂ E ⊂ Σ.
Hence by Theorem 2, setting Ω = Σ, M = Q0 and D = R3+
lim
t→∞
||(s(t), e(t), i(t))−Q0|| = 0.
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Hence Q0 is globally asymptotically stable when R0 ≤ 1.
3.3.3 The endemic equilibrium state
At the endemic state Q∗ = (s∗, e∗, i∗), the characteristic equation is
det(J(s∗, e∗, i∗)− ξI) =
∣∣∣∣∣∣∣∣
−(βi∗ + λ)− ξ −α −(α+ βs∗)
βi∗ (α− λ− γ)− ξ α+ βs∗
0 γ −(λ+ ν)− ξ




which when expanded and simplified can be written in the form
ξ3 + a2ξ
2 + a1ξ + a0 = 0 (3.31)
where the constant coefficients a2, a1 and a0 are respectively
a2 = βi
∗ + γ + ν + 3λ− α,
a1 = 3λ
2 + 2γλ+ 2λν + 2λβi∗ + γβi∗ + νβi∗ + γν − αγ − αν
− 2αλ− γβs∗,
a0 = (λ+ βi
∗)(λ+ γ − α) + αβi∗)(λ+ ν)− αγλ− γλβs∗ (3.32)
Substituting s∗ and i∗ from Equation 3.7, the coefficients a2, a1 and a0 become
a2 =
(λ+ ν)(γν + λν + γ2 + 2λ2) + γλ(3λ+ β) + 2γλν + γν(λ− α)
(γ + λ)(λ+ ν)
,
a1 =
λ(αγ2 + αλ2 + βγ2 + αν2 + βγν + αγν + 2αγλ+ 2βγλ+ 2ανλ)
(λ+ ν)(γ + λ)
,
a0 = λ(βγ + αν)− λ(λ+ ν − α)(λ+ γ). (3.33)
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By making the substitution ξ = x− a2/3, Equation 3.31 is reduced to
x3 + px+ q = 0 (3.34)
where




2a32 − 9a1a2 + 27a0
27
(3.35)




+ q = 0
















which gives three conjugate pairs of solutions of v in the form of cube roots. Each conjugate
pair of solutions gives a single solution when substituted into x = v−p/3v and subsequently
into ξ = x− a2/3 to obtain the eigenvalues of the endemic equilibrium [117].






























































27 < 0. There are three real and distinct roots.
Using Equations (3.33) and (3.35), it can be numerically verified for the parameters







from which it follows that Equations 3.31 and 3.34 have three distinct real roots. The
condition in Inequality 3.39, however, could not be analytically verified due to difficulty
in simplifying p and q in Equation 3.35 with respect to the coefficients a0, a1 and a2 in
Equation 3.33.
3.3.4 Characterisation of the eigenvalues of the endemic equilibrium
state
There are several approaches to characterising the eigenvalues of the Jacobian of the en-
demic equilibrium state for the purpose of stability analysis. These approaches include,
but are not limited to, the Routh-Hurwitz criterion and the spectral properties of the
second additive compound matrix of the Jacobian, which are routinely used in stability
discussions of the endemic state [74, 119]. However, due to challenges associated with
determining the coefficients of the characteristic equation of the Jacobian of the endemic
state, approaches like the Routh-Hurwitz and other similar methods are technically dif-
ficult to use [74]. In view of this difficulty, stability of the endemic equilibrium state of
the model in Equation 3.6 of this study is analysed using Descartes’ rule of signs for a
polynomial function to characterise the eigenvalues of the Jacobian of the endemic state.
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Descartes’ rule of signs is a technique for determining an upper bound on the number of
positive or negative real roots of a polynomial. The rule is applied by counting the number
of sign changes in the sequence formed by the polynomial’s coefficients. If a coefficient is
zero, that term is simply omitted from the sequence [120, 121, 122, 123]. Descartes’ rule
is stated in the following theorem.
Theorem 4 (Descartes’ rule: positive roots) If the terms of a single variable poly-
nomial with real coefficients are ordered by descending variable exponent, then the number
of positive roots of the polynomial is either equal to the number of sign differences between
consecutive nonzero coefficients, or is less than it by an even number. Multiple roots of
the same value are counted separately.
The proof of Theorem 4 can be found in [120, 121, 122]. Since a2 > 0 and a1 > 0, three
cases arise when the Descartes’ rule of signs is applied to Equation 3.31.
i. If a0 < 0, the equation
ξ3 + a2ξ
2 + a1ξ + a0 = 0
has a single sign difference between the coefficient of ξ and the constant a0, and so
there is only one positive root, say ξ1 > 0 since there cannot be negative number of
positive roots. The remaining two roots ξ2 and ξ3 must be negative since a0 6= 0.
ii. If a0 = 0, there is no sign change in the coefficients of the equation
ξ3 + a2ξ
2 + a1ξ = 0,
which means there is no positive root. Since a0 = 0 one of the roots is zero, say
ξ1 = 0, and so the remaining two roots ξ2 and ξ2 must be negative.
iii. If a0 > 0, the equation
ξ3 + a2ξ
2 + a1ξ + a0 = 0
has no sign difference in the coefficients. All the signs of the constant coefficients are
the same (positive), which means there is no positive root. Since a0 6= 0, all three
roots ξ1, ξ2 and ξ3 must be negative.
From Equation 3.33 λ−α > 0, a2 > 0 and a1 > 0. The constant a0 can attain either sign
and
a0 = λ(βγ + αν)− λ(λ+ ν − α)(λ+ γ) = 0,
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if
β =
(λ+ ν − α)(λ+ γ)− αν
γ
.
which is equal to the threshold value β∗ in Equation 3.21 that defines the crossover of the
disease-free equilibrium state from stability to instability.
The preceding analysis, subject to Inequality 7.33, shows that the characteristic polyno-
mial, Equation 3.31, of the Jacobian of the model at the endemic state has three distinct
real eigenvalues with one positive and two negative (ξ1 > 0, ξ2 < 0, ξ3 < 0) if a0 < 0;
one zero and two negative (ξ1 = 0, ξ2 < 0, ξ3 < 0) if a0 = 0; or all three negative
(ξ1 < 0, ξ2 < 0, ξ3 < 0) if a0 > 0. As the value of a0 goes from negative to positive,
there is a transition of the endemic state from instability to stability where a0 = 0 and
β = ((λ + ν − α)(λ + γ) − αν)/γ define the threshold for the crossover. This is consis-
tent with the Routh-Hurwitz criterion, which is routinely used to discuss the stability of
dynamical systems.
3.3.5 Validating the threshold value β∗ for stability crossover between
equilibrium states
In the stability analysis of the equilibrium states Q0 and Q
∗ of the model in Sections 3.3.1
and 3.3.3 respectively, β∗ = ((λ + ν − α)(γ + λ) − αν)/γ was determined as a threshold
value in each case for the crossover from stability to instability and vice versa. In order
to verify whether the threshold values of β∗ as obtained in Sections 3.3.1 and 3.3.3 are in
fact the same crossover value for the two equilibrium states Q0 and Q
∗ of the model to
switch stability, the value of β∗ = ((λ+ ν −α)(γ + λ)−αν)/γ was substituted into s∗, e∗
and i∗ in Equations 3.7 and also in Equations 3.33.




(γ + λ)(λ+ ν)− α(γ + λ+ ν)
(γ + λ)(λ+ ν − α)− αν
=
(γ + λ)(λ+ ν)− α(γ + λ+ ν)
(γ + λ)(λ+ ν)− α(γ + λ+ ν)
= 1
e∗ =
λ((γ + λ)(λ+ ν − α)− αν)− λ(γ + λ)(λ+ ν) + αλ(γ + λ+ ν)
(λ+ ν − α)(γ + λ)2 − αν(γ + λ)
= 0
i∗ =
γ(λ((γ + λ)(λ+ ν − α)− αν)− λ(γ + λ)(λ+ ν) + αλ(γ + λ+ ν))
(γ + λ)2(λ+ ν)((λ+ ν − α)− αν)
=
γ(λ(γ + λ)(λ+ ν)− αλ(γ + λ+ ν)− λ(γ + λ)(λ+ ν) + αλ(γ + λ+ ν))
(γ + λ)2(λ+ ν)((λ+ ν − α)− αν)
= 0. (3.40)
and so (s∗, e∗, i∗) = (1, 0, 0). By a similar substitution of the value of β∗ into Equation
3.33, it can also be verified that the coefficient a0 = 0 whilst a1, a2 > 0, and the eigenvalues
of the characteristic Equation 3.31 are ξ1 = 0, ξ2 < 0 and ξ3 < 0 as indicated by case (ii)
of the application of the Descartes’ rule of signs to Equation 3.31 (see Appendix D).
Equation 3.40 shows that when β∗ = ((λ + ν − α)(γ + λ) − αν)/γ, the endemic Q∗ and
disease-free Q0 equilibrium points coincide at (1, 0, 0). In effect at the threshold value of
β∗ as the disease-free state loses stability the endemic state gains stability and vice versa.
The discussions and results in Subsections 3.3.1 and 3.3.5 show that
i. If β < β∗, R0 < 1 and the endemic equilibrium state is unstable whilst the disease-
free state is asymptotically stable.
ii. If β = β∗, R0 = 1 and both the endemic and disease-free equilibrium states coincide
at the point (1, 0, 0) where stability changes from one to the other.
iii. If β > β∗, R > 1 and the endemic equilibrium is asymptotically stable whilst the
disease-free state is unstable.
In essence at any given time in the dynamical system, exactly one of the equilibrium states
is stable; either the disease-free state Q0 is stable or the endemic state Q
∗ is stable. The
threshold value of β∗ = ((λ + ν − α)(γ + λ) − αν)/γ defines a crossover point where the
two equilibrium states coincide.
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3.3.6 Disease persistence
By Theorem 3, the global dynamics of Equation 3.6 in Σ is determined for R0 ≤ 1. From
an epidemiological perspective, this result implies that the sum of the latent and infectious
fractions which constitute the infected fraction of the population e + i −→ 0 as t −→ ∞
and so the disease tends to die out of the population. The opposite is the case when
R0 > 1 and so the disease is said to persist in the population. This occurs when the
disease is endemic in that the infected fraction of the population persists above a certain
critical value for a sufficiently long time. Endemicity of disease is therefore discussed under
uniform persistence which is defined in Definition 1 [116]
Definition 1 The system in Equation 3.6 is uniformly persistent if there exists a constant







inf i(t)} ≥ c
.
Uniform persistence of Equation 3.6 follows from Theorem 4.3 of [113]. In order to ease
flow of discussion, Theorem 4.3 is briefly stated here whilst reference to detailed definitions
including proof can be found in [113].
Let X be a metric space with the euclidean metric d, and let Ω be a closed subset of X
with boundary ∂Ω and interior Ω̊. Let F = (Ω,R, π) be a continuous flow defined on Ω
so that ∂Ω is invariant under F , where R is the set of real numbers, π : Ω× R −→ Ω is a
continuous map such that π(x, 0) = x and π(π(x, t), f) = π(x, t+ f) for all x ∈ Ω, t, f ∈ R,
and π(∂Ω×R) ⊂ ∂Ω [113, 124, 125]. Denote the restriction of the flow F of the dynamical
system to the boundary ∂Ω of the set Ω by ∂F . Define the positive/omega-limit set of the
orbit of F through a point x ∈ Ω by Λ+ω (x) = {y|y = limn→∞Ftn(x),with tn → +∞}
[113, 124, 125]. Analogous to this is the negative/alpha-limit set which is defined as
Λ−α (x) = {y|y = limn→∞Ftn(x),with tn → −∞} [113, 124, 125]. The flow F is said to
be point dissipative if for each x ∈ Ω, Λ+ω (x) 6= ∅ and the invariant set Fx = ∪x∈ΩΛ+ω (x)
has a compact closure [113, 126].
Next let N be the maximal invariant subset of ∂F on ∂Ω. Suppose N is a closed invariant
set and there exists a cover {Ni}i∈A of N , where A = {1, 2, . . . , k} is a nonempty index set,
Ni ⊂ ∂Ω, N ⊂ ∪i∈ANi and Ni(i ∈ A) are pairwise disjoint closed and isolated invariant
sets. Furthermore, let W+(Ni) = {x ∈ X : Λ+ω (x) 6= ∅,Λ+ω (x) ⊂ Ni} denote a stable
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manifold of Ni with W
−(Ni) being the analogous unstable set. N1 is chained to N2,
denoted by N1 −→ N2, if there exists x /∈ N1 ∪ N2 such that x ∈ W+(N1) ∩W−(N2).
A chain of isolated invariant sets is a finite sequence N1, N2, ..., Nk with N1 −→ N2 −→
. . . −→ Nk is called a cycle if Nk = N1. Applying the following hypothesis [113]:
(H)
(a) All Ni are isolated invariant sets of the flow F .
(b) {Ni}i∈A is acyclic, that is, any finite subset of {Ni}i∈A does not form a cycle
(c) Any compact subset of ∂Ω contains at most finitely many sets of {Ni}i∈A.
and defining S[∂Ω, ε] = {x : x ∈ X, d(x, ∂Ω) ≤ ε} for any ε > 0 and ∂Ω ⊂ X, Theorem 4.3
of [113] is given as
Theorem 5 Let Ω be a closed positively invariant subset of X on which a continuous
flow F is defined. Suppose there is a constant ε > 0 such that F is point dissipative on
S[∂Ω, ε]∩ Ω̊ and the assumption (H) holds. Then the flow F is uniformly persistent if and
only if
W+(Ni) ∩ S[∂Ω, ε] ∩ Ω̊ = ∅
for any i ∈ A, where W+(Ni) = {x ∈ X : Λ+ω (x) 6= ∅,Λ+ω (x) ⊂ Ni} is the stable manifold
of Ni.
The following proposition is made.
Proposition 1 The system in Equation 3.6 is uniformly persistent in Σ̊ if and only if
R0 > 1.
Proof. The proof of this proposition is based on Theorem 5. From Theorem 2 and also
the fact that the asymptotic stability of Q0 precludes any kind of persistence for R0 ≤ 1,
it follows that R0 > 1 is a necessary condition. It suffices to show that R0 > 1 is also
a sufficient condition for the system in Equation 3.6 to be uniformly persistent. This
requires to show that the system in Equation 3.6 satisfies all the conditions of Theorem 5
when R0 > 1. Following from Definition 1 and Theorem 5, given that X = R3, Ω = Σ,
and x = (s, e, i) ∈ Σ is the component populations whose interactions are modelled by
the flow F , the singleton N = {Q0} is the maximal invariant subset of ∂F on ∂Σ as
established by the global stability results of the disease-free equilibrium in Subsection
3.3.2. Furthermore, Σ is a closed positively invariant subset of R3 and the positive s-
axis, Ns = {(s, e, i) ∈ Σ|0 ≤ s ≤ 1, e=i=0}, which is the stable manifold W+(Ns) of
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Ns of the flow F on ∂Σ, is a cover of {Q0}. In fact the singleton {Q0} is the least
cover of itself. Hence the hypothesis (H) holds for the system in Equation 3.6 in that
{Q0} being a closed invariant set has a cover that is acyclic and any compact subset of
∂Σ contains at most finitely many subsets of the cover. Thus when R0 > 1, the result
W+(Ns) ∩ S[∂Σ, ε] ∩ Σ̊ = ∅ holds. It was established in Subsection 3.3.5 of this study
that exactly one of the equilibrium states is stable at any given time. In the absence of a
periodic solution, the endemic equilibrium is the only attractor in Σ̊. In the setting of the
system in Equation 3.6, it can be observed that the necessary and sufficient condition for
uniform persistence is equivalent to the result that Q0 is unstable. See the phase portrait
of the dynamical system of Equation 3.6 displayed in Figure 5.7 of Chapter 5.
In conclusion, Theorem 3 and Proposition 1 establish R0 as the epidemiological threshold
parameter of the model in Equation 3.6; if R0 ≤ 1 the disease is kept under control or else





The parameters β, γ and ν (Figure 3.1) of the model in Equation 3.6 are critical in the
calculation of the epidemiological threshold parameter R0, in Equation 3.13, of an infec-
tious disease epidemic in compartmental modelling. The inverse problem methodology is
used to estimate a vector θ = (β, γ, ν) ∈ R3, by minimising the difference between the
model predictions and the observed data, using the least squares method [83, 127, 128].
The parameter estimation procedure for this study therefore involves solving a nonlinear
least squares problem of the form
min
θ∈R3





[Yi − h(ti,θ)]2 (4.2)







dt i = 1, 2, ..., n





where yj , j = 1, ..., n is the observed incidence value of hepatitis B in month j. A hybrid
method which combines a Genetic Algorithm (GA) and a modified Levenberg Marquardt
(LM) algorithm is used to solve this nonlinear least squares optimisation problem [129].
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The GA is applied first, and starts with a randomly generated population of candidate
solutions P0 = {θz}Kz=1, K being the population size. These solutions are coded as binary
strings of 0’s and 1’s which through processes of crossover, mutation, migration and elimi-
nation evolve a progressively better population of solutions. The GA, being a nongradient
method, provides a global search of the solution space to identify solutions which are
hoped to be close to optimal. Following the GA, a modified version of the LM algorithm
which is a gradient method is applied to refine the solution generated by the GA. The flow
diagram illustrating the process is displayed in Figure 4.1.
Figure 4.1: A flow chart illustrating a hybrid algorithm combining a Genetic Algorithm
(GA) and a modified Levernberg-Marquardt Algorithm (LM).
4.1 Genetic algorithm overview
Genetic Algorithms (GA) are numerical randomised search processes which mimic the
biological concept of evolution. The concept states that the survival of an organism is
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by the rule “survival of the fittest” and it is implemented alongside the process of repro-
duction, crossover and mutation [130, 131]. Numerical optimisation adopts this concept
to optimise an objective function of a physical problem. Potential solutions (satisfying
problem constraints) are encoded as binary strings called chromosomes [130, 131]. A set
of chromosomes is randomly defined at the start of the algorithm to form a population
[130].
At each stage of the process, each new solution (chromosome) is passed through a fitness
test using the objective function to assess the suitability or optimality of the solution with
respect to the problem and to provide a basis for selecting which solutions to return for
the next generation [130, 131]. Chromosomes in the population employ a process called
crossover to produce new chromosomes called offspring whose genes are a combination
of the parent chromosomes [131]. In a generation, some chromosomes also mutate in
the genes. Crossover and mutation are respectively controlled by crossover and mutation
rates defined by the user of the algorithm. Chromosomes with higher fitness value will
have greater probability of being returned in the next generation and being selected for
crossover [131]. The process runs through several generations until a predefined termina-
tion criterion, for example maximum number of generations or no improvement after a
predefined number of generations, is satisfied. The most optimal solution from the final
population is retained as the solution to the problem [130, 131]. It is however important
to retain diversity in the population during the algorithm in order to avoid being trapped
in local minima.
4.1.1 The GA phase of the hybrid method
The GA used in this study is a modification of a free version registered with GNU General
Public License [132] in which a rate of migration is introduced and the rate of crossover
is unrestricted (100%). In this study the input variables for the GA are population size
P0, chromosome length C, rate of mutation Rm, rate of crossover Rc, rate of migration
Rg and number of generations N
∗ which are arbitrarily chosen.
The process of estimation by the GA can be summarised in the following steps:
1. Initialise population and evaluate fitness;
2. Generate new population or next generation by:
i. Crossover or breeding of pairs of solutions (chromosomes).
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ii. Mutation within sub-chromosomes (genes).
iii. Migration of new solutions (chromosomes) into algorithm.
iv. Evaluation of fitness values of new solutions (chromosomes).
v. Selection of solutions (chromosomes) for the next generation of the algorithm,
by roulette method.
3. Repeat step 2 until algorithm terminates after a predetermined condition is satisfied
and the best solution is returned.
The initialisation stage introduces the initial population of size P0 made up of chromosomes
θ = (β, γ, ν) expressed as binary strings of length C into the algorithm. A fitness value




, of each of the chromosomes is computed using a
fitness function f(P ) to end the initialisation process.
Parent chromosomes are selected randomly from the initial population of size P0 according
to the probability Pselection. Pairs of selected parent chromosomes are mated through
crossover at the rate of (100%) to create new solutions (chromosome) called offspring.
This process interchanges bits of genes in each pair of parent chromosomes at certain
crossover (cut) points determined by random integers generated in the interval [1, C]. A
new set of chromosomes (offspring) forming a population of size P1 is generated as an
addition to the existing population P0.
The mutation process takes the population of size P1 generated by crossover and randomly
mutates some of the chromosomes at the rate Rm. This is done by first generating random
numbers to correspond with each position of a bit of a gene in the population of size P1.
A bit of a gene is selected for mutation if its random number is less than the rate of
mutation Rm. The mutation process replaces a 0 with a 1 and vice versa. A new set
of solutions (chromosomes) forming the population of size P2 is migrated at a rate of Rg
to maintain variability in the population. The fitness values SSE−1 and probability of
selection (P (selection)) of members of the two newly generated populations P1 and P2 are
evaluated.
A new population of size equal to the initial population P0 is then selected from the
combined population Pcomb = P0 ∪ P1 ∪ P2 by a roulette method. The new population
of solutions (chromosomes) is returned as the next generation of the algorithm. Steps 1
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and 3 of the process are repeated until a predetermined convergence/termination criterion
is met and the best solution θ = (β, γ, ν) in the final population is returned as the best
solution of the problem. This solution is then passed on to the Levenberg-Marquardt
phase of the algorithm as an initial parameter value θ = (β, γ, ν) for the next stage of the
parameter estimation process.
4.2 The Levenberg Marquardt phase of the hybrid method
The LM algorithm combines two minimisation methods, the gradient-descent (GDM) and
the Gaussian-Newton (GNM) methods. The GDM reduces the SSE by updating the
parameters in the steepest descent direction whilst the GNM reduces the SSE iteratively
by assuming that the least squares function is locally quadratic and finding the minimum
of the quadratic, to solve a nonlinear least squares problem of the form
min
θ∈R3
L(θ), θ = (β, γ, ν) (4.3)





= (Y − h(θ))T (Y − h(θ))
= Y TY − 2Y Th(θ) + h(θ)Th(θ), (4.4)
Y = (Y1, Y2, ..., Yn)
T and h(θ) = (h(t1,θ), h(t2,θ), ..., h(tn,θ))
T [133, 134, 135, 136, 137].
The LM algorithm minimises Equation (4.4) iteratively starting from an initial guess of
the parameter vector θ = (β, γ, ν). In each iteration step, θ is replaced by a new estimate
θ + δ. In order to determine the step vector δ the cumulative incidence function h(θ) is
linearised about θ as
h(θ + δ) ≈ h(θ) + JLMδ




which represents the local sensitivity of the function h(θ) to variation in the parameter θ.
Using the linearisation of h(θ), the sum of squares function L can be approximated about
θ as
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L(θ + δ) ≈ Y TY + hT (θ)h(θ)− 2Y Th(θ)− 2(Y − h(θ))TJLMδ + δTJTLMJLMδ (4.5)
[133, 136, 137, 138]. Taking the derivative of L with respect to δ and setting the result to
zero results into the GNM
d
dδ
L(θ + δ) = −2JTLM [Y − h(θ)− JLMδ] = 0
so that
(JTLMJLM )δ = J
T
LM [Y − h(θ)]. (4.6)
The system of equations (4.6) when solved yields the step vector
δ = (JTLMJLM )
−1JTLM (Y − h(θ)) (4.7)
which specifies the length of the step that moves the parameter estimate θ in the direction
of greatest descent [134, 137, 139]. A damped version of equation (4.6)
(JTLMJLM + σI)δ = J
T
LM [Y − h(θ)] (4.8)
is the Levenberg algorithm [134, 139], where I is the identity matrix and σ is a non-negative
damping factor.
The damping term is adjusted at each iteration to ensure a reduction in the SSE given by
L. If the value of L has increased due to an update, the step is retracted (weights reset to
the previous values) and σ is increased by a factor of ten. If the value of L has decreased
as a result of an update however, the step is accepted (weights kept at their new values)
and σ is decreased by a factor of ten.
With small values of σ, the step is close to the exact quadratic step which approximates the
Gaussian-Newton update in Equation 4.7, whilst the matrix (JTLMJLM +σI) will be nearly
diagonal if σ is set to large values and so the step will choose the gradient descent update
δ approximately in the steepest descent direction JTLM (Y − h(θ)) [134, 137, 138]. The
damping process also improves the condition of the Hessian matrix JTLMJLM (curvature
matrix), by reducing the ratio of the largest eigenvalue to the smallest eigenvalue, thereby
stabilising the process through regions of the parameter space where the Jacobian is rank
deficient and so the Hessian matrix is singular [140].
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Iteration stops when one of the following is achieved:
• The length of the calculated step δ falls below predefined limits.
• The reduction of sum of squares from θ to the latest parameter vector θ + δ falls
below predefined limits.
• The magnitude of the gradient JTLM (Y − h(θ)) falls below predefined limits.
• A maximum number of iterations is completed.
The last parameter vector θ = (β, γ, ν) is selected as the solution [133, 134].
The Levenberg algorithm however is limited in the sense that if the damping factor σ is
large, the inverse of the matrix (JTLMJLM+σI) is not used at all. The Levenberg algorithm
in Equation (4.8) is thus modified into
(JTLMJLM + σdiag(J
T
LMJLM ))δ = J
T
LM [Y − h(θ)] (4.9)
which is the Levenberg-Marquardt (LM) algorithm, where the identity matrix I is re-
placed with the diagonal matrix made up of the diagonal elements of (JTLMJLM ). By this
modification, each component of the gradient is scaled according to the curvature of the
slope [133, 136, 137, 139]. The LM algorithm is therefore more reliable than the Levenberg
algorithm in obtaining appropriate solutions to nonlinear inverse problems. Furthermore,
in contrast to the Gauss-Newton search direction, the LM search direction mainly has
components in the direction of eigenvectors corresponding to the largest eigenvalues of the
Hessian (JTLMJLM ) [137]. The LM, however, is a local gradient-based search method which
does not include constraints. Hence the LM was modified to account for the nonnegativity
constraint, θ = (β, γ, ν) ≥ 0, of Equation (4.1).
4.2.1 Nonnegativity modification to the LM
The standard LM algorithm determines the solution to Equation 4.1 without the nonneg-
ativity constraint on θ = (β, γ, ν) ≥ 0, which is critical to this study. To address this
limitation, the LM was modified to impose a nonnegativity constraint on the parameter
estimates of θ. There are two main cases that are considered in the modification process.






i ), i = 1, 2, 3, ... are the current solution
and step respectively, let θi+1 = θi + δi be an update of θi by a step of size δi after the
ith iteration. Furthermore, let U = {θ|θ ≥ 0} be the domain of interest such that its
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compliment is U′ = {θ|θ  0} and its boundary is ∂U = {θ : θ1 × θ2 × θ3 = 0}, then two
modifications are made.
1. When the current solution is located on the boundary of the solution domain, θi ∈
∂U, and the current step δi of the algorithm in Equation 4.9 places the new solution
outside the solution domain, θi+1 ∈ U′, then the solution θi+1 is projected back
onto the boundary ∂U by setting δi = δ
∗
i , where δ
∗
i = proj∂Uδ, in order for the new
solution θi + δi to remains inside the solution domain (see Figure 4.2).
Figure 4.2: Diagrammatic illustration of projecting back solution onto the boundary of
solution domain
2. When the current solution lies in the interior of the solution domain θi ∈ U\∂U,
and the current step δi of the algorithm in Equation 4.9 places the new solution
outside the solution domain, θi+1 ∈ U′, then the current step δi is rescaled back
onto the boundary ∂U by a factor δ∗∗i = min(tδi(1) , tδi(2) , tδi(3))δi where tδi = −θi/δi
and i = 1, 2, 3, ... so that the search direction is retained and the solution (θi + δ
∗∗
i )
remains in the solution domain (Figure 4.3).
Figure 4.3: Diagrammatic illustration of rescaling back solution onto the boundary of
solution domain.
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4.2.2 Summary
This chapter discussed a hybrid optimisation method applied to the incidence data to
estimate the parameters vector θ = (β, γ, ν) of the model in Equation 3.6. The hybrid
method consists of a GA and a modified LM algorithm. The GA being a randomised
global search method was applied first to identify solutions from the solution space of the
model in Equation 3.6, solutions which are hoped to be close to optimal. The modified LM
algorithm was applied after the GA to refine the solution randomly generated by the GA.
The LM algorithm was modified to impose a nonnegativity constraint which is critical to
this study but is absent in the standard LM algorithm. The GA as a randomised search
process might not find the most optimal solution to the defined problem and so it may be
difficult to have a good solution that reflects what the algorithm is expected to achieve.
The nonnegativity restriction included in the LM algorithm may also impact the accuracy
of refining the solution generated by the GA. However, the impact of these limitations are
minimised by the combined GA and LM algorithm complementing each other although
the computational cost may be high.
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Application of the SEIR model to
hepatitis B data of Ghana
5.1 Introduction
The SEIR model which incorporates latent period and vertical transmission was applied
to study the transmission and spread of hepatitis B in Ghana. In the study, hepatitis B
incidence data obtained from the Regional Health Informant Units (RHIU) and Centre
for Health Information Management (CHIM) of the Ghana Health Service (GHS) and
demographic data from the Ghana Statistical Service (GSS) were used.
In this chapter, the descriptive statistics of the national data are presented showing the
time series and cumulative incidence plots of the data to give an overall idea of the struc-
ture of the data. The process of estimating the model parameters applying the methods
described in Chapter 4 is presented. For the estimated parameters, the epidemiological
threshold parameter R0 and its corresponding herd immunity threshold value H are com-
puted and used to predict the state of hepatitis B in Ghana and the estimated percentage
of the population needed to be immune to control the disease. Discussion of the behaviour
of the dynamical system of the model, with respect to the disease-free and the endemic
equilibrium states, is aided by plots of the predictions of the proportions of the state
variables s, e and i and phase portraits of the dynamical system of the model. Sensitiv-
ity of the model stability to the key parameters and their impact on the epidemiological
threshold parameter R0 is discussed.
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5.2 National data description
The main data for the study consist of reported monthly incidence cases of hepatitis B,
categorised into cases of persons aged less than 5 years that are assumed to be vertically
transmitted and those aged 5 years and above that come from horizontal routes of trans-
mission. These age brackets were based on existing categorisation as provided by the data
management systems of GHS and the data were available from 2008 to 2014. The data
for the period 2008 to 2014 were aggregated and deidentified for the ten regions of Ghana.
Summary statistics of the data are displayed in Table 5.1.
Table 5.1: Summary of monthly hepatitis B incidence data collected during 2008− 2014.
Monthly incidence Standard Total
Region Min. Max. Mean Median deviation incidence
Ghana 372 2, 789 1, 368.18 1, 371 630.54 114, 927
Vertical Transmission 28 323 103.93 83 68.51 8, 730
(Incidence aged< 5)
All other routes 341 2, 611 1, 264.25 1, 288.5 579.6 106, 197
(Incidence aged≥ 5)
A total of 114, 927 hepatitis B incidence cases consisting of 8, 730 cases assumed to be
vertically transmitted and 106, 197 cases from horizontal transmission, were recorded for
the study period 2008 − 2014. The data range from 372 cases a month to 2, 789 cases a
month with a mean monthly value of 1, 368.18 and standard deviation of 630.54. The time
series plot of the incidence data displayed in Figure 5.1 shows a fluctuating but increasing
trend over the stated period 2008 − 2014. The corresponding cumulative incidence plot
of the data displayed in Figure 5.2 also shows an increasing rate of monthly incidence
numbers.
Inherent challenges associated with capturing and compiling hepatitis B data in poorly-
resourced countries globally often leads to underestimation and under-reporting of the
true cases and limits utility of such case reporting data [50]. Ghana is not an exception to
these challenges in data compilation due to the inefficient tools used by the health systems
in disease surveillance as cited in Section 1.4 of this thesis. The Ghana Health Service in
its annual report of 2014 indicated that 7, 581 out of 51, 052 suspected viral hepatitis cases
were laboratory confirmed [59]. This observation translates into approximately 1 in every
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7 persons reporting an incidence of viral infection to a designated health facility to be
captured into an official database. In order to address these limitations in data collection
and make meaningful conclusions, the data used in this estimation process were scaled by
a factor of 7.
Figure 5.1: Time series plot of hepatitis B incidence data from 2008 to 2014.
Figure 5.2: Cumulative incidence plot of hepatitis B incidence data from 2008 to 2014.
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In addition to the hepatitis B incidence data, demographic parameter constants of pro-
jected total population N = 27, 075, 827 (2014), birth rate λ = 24.9 per 1, 000 population
and death rate µ = 6.6 per 1, 000 population were obtained from the Ghana Statistical
Service (GSS) [141]. Vertical transmission rate which represents the number of newborns




× λ = 0.076λ,
where incidence age less than 5 represents the number of incidence cases via vertical
transmission whilst total incidence from data, (incidence (aged < 5) + incidence (aged ≥
5)) corresponds to total infection (I + E) in the model.
5.3 Parameter estimation for national hepatitis B data
The initial state (s0, e0, i0) of (s, e, i) for the estimation process was not known and needed
to be estimated. Preliminary sensitivity analysis performed showed that varying the ini-
tial condition (s0, e0, i0) in the model produces varying parameter estimates which im-
pacts on model predictions. The initial condition was therefore estimated by generating
combinations of (s0, e0, i0) from ranges of values of s0 ∈ [0.4, 0.8], e0 ∈ [0.1, 0.5] and
i0 ∈ [0.005, 0.045] increasing in steps of 0.05, 0.05 and 0.005 respectively, and applied to
the nonlinear least squares method discussed in Chapter 4 to fit the model in Equation
3.6 to the observed cumulative hepatitis B incidence data. The choice of the intervals for
the initial values of s0, e0 and i0 was based on the values obtained from the preliminary
sensitivity analysis of the parameter estimation process, assuming that not less than 40%
of population were susceptible at the start of the study when prevalence was estimated
between 10− 15%.
In each fitting, the hybrid method was used to identify an optimal set of parameters
(β, γ, ν) yielding a least-squares error between the resulting model predictions and the ob-
served data. For each combination of the initial state variables (s0, e0, i0), this optimisation
process was run 20 times to increase the likelihood of approximating the true optimum
set of parameters (β, γ, ν) since the GA is a random search method. The estimated initial
susceptible, exposed and infectious proportions obtained by the fitting process were 0.55,
0.40 and 0.04 respectively.
Using the methodology in Chapter 4, the parameters estimated for the model are β =
0.0480, γ = 0.1254 and ν = 0. The mean latent and infectious periods were calcu-
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lated as 6.7 months and 40.2 months respectively. A birth rate of λ = 24.9 per 1, 000
population and vertical transmission rate α = 0.076λ per 1, 000 population were esti-
mated from demographic and incidence data discussed in Section 5.2. The epidemiolog-
ical threshold parameter was calculated as R0 = 1.6854 and so the endemic equilibrium
Q∗ = (0.5741, 0.0706, 0.3553) was found to be asymptotically stable. This means the
spread of hepatitis B in the population is increasing with time. The herd immunity
threshold value was calculated as H = 0.4067 which means that approximately 41% of the
population is required to be immune in order to keep the disease under control. Figure 5.3
shows a plot of the model fitted to the cumulative hepatitis B incidence data from 2008
to 2014.
Figure 5.3: Model fit to cumulative hepatitis B incidence data.
In validating the estimation process for the national parameters of (β, γ, ν), the model was
fitted to the first 5 years of cumulative incidence data, based on which prediction of the last
2 years of study period was evaluated. The root-mean-square error between the the data
and the model predictions for the last was calculated as 1.0904× 104. Figure 5.4 displays
the fitted plot where the portion marked red represents the cumulative incidence for the
first 5 years whilst the portion marked green is for the predicted cumulative incidence for
the last 2 years of study period.
The model predictions of the state variables s, e and i over a period of 36 months, that
is 3 years, based on their estimated values for the study period of 84 months or 7 years is
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Figure 5.4: Model validation of estimation process: Fit for the first 5 years (red) used in
predicting the last 2 years (green).
displayed in Figure 5.5.
Figure 5.5: Disease curves of s, e and i for the study period of 84 months and the next 36
months of model predictions.
65
Chapter 5. Application of the SEIR model to hepatitis B data of Ghana
Figure 5.5 displays the path traced by the state variables s, e and i of the model over a
total of 120 months or 10 years, which consists of the first 84 months (7 years) of estimation
based on the incidence data and the next 36 months (3 years) of prediction. Starting from
the initial state (s0, e0, i0) = (0.55, 0.4, 0.04), the exposed proportion e declines whilst the
infectious i and susceptible s proportions increase within about 7 months of latent period
from the start of the study. The sharp decrease in the exposed proportion is influenced by
the sharp increase in the infectious proportion, which causes the susceptible proportion
increase during the latent period. This describes the stage immediately after infection,
when rapid viral replication takes place, leading to an individual becoming infectious as
prescribed in the dynamics of the transmission of hepatitis B. The susceptible proportion
peaks thereafter and begins to decrease gently whilst the infectious proportion continues to
increase until the end of the infectious period in about month 40 when the three variables
stabilise at the endemic state Q∗(s∗, e∗, i∗) = (0.5741, 0.0706, 0.3553). From Figure 5.5, the
disease is predicted to remain persistent in the population with time unless an intervention
is applied to control it.
5.4 Sensitivity of model stability to key parameters
Let each of the estimated parameters (β, γ, ν) = (0.0480, 0.1254, 0) and the parameter
constants λ = 0.0249 and α = 0.0019 of the model in Equation 3.6 be designated as the
baseline values denoted by θ̃baseline, and let θ̃threshold denote the corresponding threshold
values. Note that the threshold parameters were calculated from Equations 3.21 and
3.22 using the estimated parameters of the model. For each of the estimated parameters,
θ̃baseline, the percentage difference from the corresponding threshold value θ̃threshold was
computed as displayed in Table 5.2 by the formula
%4θ̃ = 4θ̃
θ̃baseline
× 100, where 4θ̃ = θ̃threshold − θ̃baseline,
to examine the quantum of change in each of the model parameters needed to shift model
stability from endemic state to disease-free state. Note that “−” in percent change means
a decrease whilst “ + ” means increase.
From Table 5.2, the contact rate β, latent rate γ and vertical transmission rate α need
decreases of about 42.59%, 81.74% and 901.91% respectively to shift the endemic state Q∗
of the model from stability to instability. Conversely, the birth rate λ needs an increase
of 55.08% to change the endemic state from stability to instability whilst the required
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percentage increase in the recovery rate ν cannot be quantified. In terms of percentage
change from the baseline values, the model stability is more sensitive to changes in the
values of β, γ and λ compared to ν and α, but β, γ and α require decreases whilst ν and λ
require increases. The negative threshold value of α = −0.0152 cannot be achieved since
α ≥ 0, that is the endemic state would be stable even with α = 0.
Table 5.2: Percentage differences in baseline parameters.
Key model Threshold value Baseline value Percentage change
parameter (θ̃threshold) (θ̃baseline) in Baseline value
β 0.0276 0.0480 −42.59
γ 0.0229 0.1254 −81.74
ν 0.0173 0 ∞
λ 0.0386 0.0249 55.08
α −0.0152 0.0019 −901.91
Note: “− ” in percentage change means decrease and “ + ” otherwise.
From Table 5.2 the contact rate β, latent rate γ and vertical transmission rate α need
decreases of about 42.59%, 81.74% and 901.91% respectively to shift the endemic state Q∗
of the model from stability to instability. Conversely, the birth rate λ needs an increase
of 55.08% to change the endemic state from stability to instability whilst the required
percentage increase in the recovery rate ν cannot be quantified. In terms of percentage
change from the baseline values, the model stability is more sensitive to changes in the
values of β, γ and λ compared to ν and α, but β, γ and α require decreases whilst ν and λ
require increases. The negative threshold value of α = −0.0152 cannot be achieved since
α ≥ 0, that is, the endemic state would be stable even with α = 0.
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Table 5.3: Rates of change in Q∗ = (s∗, e∗, i∗) with respect to β, γ, ν, λ and α.
Key model Rates Magnitude of change
parameters s∗ e∗ i∗ (Euclidean Norms)
β −11.95 1.98 9.97 15.69
γ −0.76 −0.34 1.10 1.38
ν 24.64 −4.08 −34.82 42.86
λ 28.77 −2.40 −26.37 39.10
α −24.95 4.13 20.82 32.76
Note: “− ” means decrease in rates and “ + ” otherwise.
The partial derivatives of the endemic proportion variables Q∗ = (s∗, e∗, i∗) with respect
to the model parameters, β, γ, ν, α and λ, calculated at the baseline values and the
corresponding magnitudes of change (Euclidean norms) as displayed in Table 5.3, were
used to examine how rapidly the equilibrium state changes to impact model stability as
the parameters change. In this instance, the signs “ - ” and “ + ” mean a decrease and
an increase respectively. The following were the results:
• Unit increases in β, γ and α cause a decrease in the susceptible population and
an increase in the infectious population and tend to shift equilibrium towards the
endemic state Q∗. The magnitudes of change in the endemic state Q∗ per unit
changes in β, γ and α are 15.69, 1.38 and 32.76 respectively. A unit increase in
α has the biggest impact on the shift in equilibrium towards the endemic state Q∗
followed by β and then γ.
• Conversely, unit increases in ν and λ cause an increase in the susceptible population
and a decline in the infectious population and tend to shift equilibrium towards
disease-free state Q0 more rapidly. The magnitudes 42.86 and 39.10 of change in
Q∗ per unit changes in ν and λ respectively indicate that an increase in ν shifts
equilibrium towards the disease-free state Q0 more rapidly than λ.
5.5 Sensitivity analysis of the epidemiological threshold pa-
rameter R0
The impact of the model parameters α, β, γ, ν and λ on the epidemiological threshold
parameter R0 was examined. This was to investigate the sensitivity of the threshold
parameter R0 to each of the model parameters. The baseline parameters β = 0.0480,
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((a)) ((b))
((c)) ((d))
Figure 5.6: Sensitivity of R0 to model parameters: (a) R0 versus α; (b) R0 versus β; (c)
R0 versus γ; (d) R0 versus ν.
γ = 0.1254, ν = 0, λ = 0.0249 and α = 0.0019 were held fixed in Equation 3.13, whilst
each of the model parameters was varied in turn over the interval [0, 1] to produce a
corresponding set of values for R0. Figure 5.6 displays the plots of each of the parameters
against R0.
From Figures 5.6(a) and 5.6(b), R0 varies linearly as α and β with positive slopes of 30
and 40 respectively. The slope of 40 in the variation of R0 with respect to α compared to
the slope of 30 in the variation of R0 with respect to β, displayed in Figures 5.6(a) and
5.6(b) respectively, indicate that α has a larger impact on R0 than β for a given magnitude
of change. This means R0 is relatively more sensitive to α than β. Hence any intervention
targeted at reducing the rate α of vertical transmission would have much more impact
in reducing the epidemiological threshold parameter R0, that is used to determine how
widespread hepatitis B is in the population, relative to the rate β of transmission through
all other routes.
In Figures 5.6(c) and 5.6(d), R0’s relation to γ and ν is hyperbolic. As γ increases R0
increases sharply for γ ∈ [0, 0.2] until it begins to level off close to R0 = 2. As ν increases
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however, R0 decreases steeply for ν ∈ [0, 0.2] and begins to level off close to R0 = 0.
Although R0 increases with respect to γ, the overall impact of γ on R0 compared to that
of α and β, discussed in the last paragraph and illustrated in Figures 5.6(a) and 5.6(b)
respectively, is less due to its tendency to stabilise the value of R0 with time. Invariably,
the rate of change of R0 with respect to γ reduces to approximately zero when R0 is
stabilised at R0 ≈ 2. The effect of the latent rate γ on the epidemiological threshold
parameter R0 relative to the other parameters of the model is significant, although the
impact is seen to be greater only if γ < 0.2. This indicates that the latent rate γ and so
the latent period is important in modelling hepatitis B in a population. The decrease in
the epidemiological threshold parameter R0 with respect to the rate of recovery ν, relative
to the other parameters of the model, surely reflects the natural dynamics of any disease
including hepatitis B. In fact the key intervention to control an epidemic of a disease in
a population requires the increase of the rate of recovery ν that tend to populate the
immune class R and deplete the infectious class I of the model.
5.6 Phase portraits
Phase portraits of the SEIR model in Equation 3.6 were produced using the estimated
parameters to examine the flow of the dynamical system in relation to the disease-free
and endemic equilibrium states. Figure 5.7(a) displays a phase portrait for the threshold
parameters β∗ = 0.0276, γ∗ = 0.0229 and ν∗ = 0.0173 of the model indicated in Table 5.2.
Note that the threshold parameters were calculated from Equations 3.13 and 3.22 using
the estimated parameters of the model. Figure 5.7(b) displays a phase portrait for the
estimated parameters β = 0.0480, γ = 0.1254 and ν = 0 of the model. The dynamics of
the model in the neighbourhood of the two equilibrium points were examined using the
two plots, with the initial state of (s0, e0, i0) ∈ Σ = {(s, e, i) ∈ R3+|0 ≤ s+ e+ i ≤ 1}.
Figure 5.7(a) shows that if the model parameters are at the threshold, all solutions (s, e, i)
starting from the interior of the closed positive set Σ are attracted to the disease-free
equilibrium point Q0 = (1, 0, 0). Figure 5.7(b) however shows that all solutions (s, e, i)
starting from within the closed positive set Σ tend to the endemic equilibrium point
Q∗(s∗, e∗, i∗) = (0.5741, 0.0706, 0.3553), except those starting on the invariant s-axis that
tend to remain on the axis and ultimately approach the disease-free equilibrium point
Q0. It is worth mentioning from in Figure 5.7(b), that even solutions starting sufficiently





Figure 5.7: Phase portraits of the SEIR model (a) Threshold and below R0 ≤ 1 (Disease-
free state). (b) Above threshold R0 > 1 (Endemic state).
In the case when β∗ ≤ 0.0276, all solutions starting from within the closed positive set
Σ approach the disease-free equilibrium state Q0 and thereby make it stable whilst the
endemic state Q∗ is infeasible and unstable. In the opposite case where β∗ > 0.0276, all
solutions starting from within the closed positive set Σ approach the endemic equilibrium
stateQ∗, which now is valid and stable whilst the disease-free equilibrium stateQ0 becomes
unstable. The parameter value of β∗ = 0.0276 therefore is a threshold of the crossover
from stability to instability between the two equilibrium states Q0 and Q
∗. Although this
threshold value of β∗ = 0.0276 may be low in terms of the epidemiology of hepatitis B, it
reflects the incidence of the disease in the population of Ghana based on the incidence data
used in the study. The threshold value of β∗ = 0.0276 describes a point in the modelling
process where stability shifts between the disease-free and endemic equilibrium states.
5.7 Discussion
A basic reproduction number of R0 = 1.6854 indicates that the expected proportion
of infection caused by a single infective in the population is greater than one and so
the transmission and spread of hepatitis B in the population is increasing with time.
This result is consistent with reports by WHO, GHS and MOHG of increasing spread of
hepatitis B and the associated burden in Ghana and by extension the Sub-Saharan Africa
and emphasises the need to control it. A herd immunity threshold value of 0.4067 was
calculated, which means that a critical proportion of about 41% of the population is needed
to be immune to hepatitis B in order to bring the disease under control. Furthermore,
the latent period of 6.7 ≈ 7 months agrees with literature on the incubation period of
the HBV which spans between 30 to 180 days or more depending on the viral load of the
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infected person.
Stability analysis of the model indicates that the endemic proportion equilibrium of Q∗ =
(0.5741, 0.0706, 0.3553) is asymptotically stable, which means hepatitis B is at a state
where about 57.4% of the population are susceptible, 7.1% are exposed and 35.5% are
infectious. The 0% recovery rate indicates that none of the infected persons could clear
hepatitis B at the acute stage. Otherwise, it could also be possible that recovery was
significantly low as to be rounded zero or could be a numerical artefact in the parameter
estimation process. Stability, however, switches between the disease-free Q0 and endemic
Q∗ states at a threshold contact rate of β = 0.0276 ≈ 0.028. In essence if the contact rate
through effective vaccination was reduced to 0.028, or below, it would provide adequate
measure of protection for individuals in the population who are not immune thereby
reducing the spread of hepatitis B in the population.
Sensitivity analysis of the model in Equation 3.6 with respect to quantum of change from
the baseline parameters indicates that stability is most sensitive to the hepatitis B contact
rate β followed by birth rate λ, latent rate γ and vertical transmission rate α whereas
that of the recovery rate cannot be quantified. Apart from the birth rate which requires
an increase of 55.08%, the contact rate, latent rate and vertical transmission rate need to
decrease by 42.59%, 81.74% and 901.91% respectively to shift stability from endemic state
to the disease-free state. A higher birth rate is not desirable due to its socioeconomic and
cultural implications on a society. However, a greater proportion of the population can be
immunised to disrupt chains of infection that would reduce the chances of contact with
infectious individuals to keep the disease from spreading. This strategy targets reducing
the contact rate β and vertical transmission rate α.
Rates of change of endemic proportion variablesQ∗(s∗, e∗, i∗) with respect to model param-
eters indicate that unit increases in contact rate β, latent rate γ and vertical transmission
rate α increase the infectious population and decrease the susceptible population and tend
to shift equilibrium to the endemic state Q∗. Sensitivity analysis of the epidemiological
threshold parameter R0 with respect to the model parameters further indicated that R0
is most sensitive to the rate of change in the vertical transmission rate α. The sensitivity
analysis indicated that the rate of vertical transmission α has a linear relationship with
the epidemiological threshold parameter R0 with the greatest positive slope, compared
to the rest of the model parameters. Vertical transmission was found to have the most
impact of shifting the model to the endemic state, followed by the contact rate and latent
72
5.8. Summary
rate. This means that the rate at which newborns are infected with hepatitis B at birth
is higher than infection through the other modes of transmission.
Vertical transmission of hepatitis B most likely occurs during birth when there is a break in
the maternal-foetal barrier, and so can be reduced if screening and immunisation of women
of child-bearing age are effectively conducted to ensure that the HBV is not passed on
to the child at birth. Conversely, the rates show that unit increases in birth rate λ and
recovery rate ν increase the susceptible population and decrease the infectious population
and tend to drive equilibrium towards the disease-free state more rapidly, although control
of both of them may not be practically achievable.
5.8 Summary
In summary, the results of the study show that hepatitis B is increasing with time in Ghana
and that emphasises the need to control it. This is consistent with reports by WHO, GHS
and MOHG, and also agrees with studies of parts of Ghana and Sub-Saharan Africa of the
disease burden in those regions. The contact rate, latent rate and vertical transmission
rate have been identified as driving the disease spread in the population. Mother-to-child
transmission was found to have a larger impact on the spread of hepatitis B in Ghana,
compared to other routes of transmission, due to its high impact on stability shift towards
endemic state. Policy intervention must therefore target reducing vertical transmission
rate although horizontal transmission driven by the disease contact rate should not be
neglected.
To control the spread of the disease, an estimated critical proportion (Herd immunity
threshold) of about 41% of the population needs to be immune to effectively disrupt chains
of infection. This would reduce the number of effective contacts between infectious and
susceptible individuals in the population, reduce the spread and hence bring the disease
under control. Since there is no known cure for hepatitis B, national policy intervention
should aim at nationwide mass screening and immunisation designed to factor in the latent
period of the disease, complemented with antiviral treatment of chronic carriage to reduce
disease complications and liver damages.
The intervention programmes are recommended to target each member of the population,
particularly women of child-bearing age and newborns in order to prevent mother-to-child
transmission and eradicate the chronic carriage state of hepatitis B from the population
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with time. It is also recommended that these intervention programmes for hepatitis B
should be included in the national health insurance scheme (NHIS) of Ghana, which
hitherto was not part, to ensure affordability and accessibility to all.
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Application of the SEIR model to
regional hepatitis B data in Ghana
6.1 Introduction
Analysis of the incidence and spread of hepatitis B in Ghana as a whole, based on the
SEIR model used in Chapter 4 of this work, indicated that the disease persists but did
not show the individual regional burden. Ghana is made up of ten administrative regions
as displayed in Figure 1.2 which also consist of districts, metropolitans and municipalities
that see to the implementation of government policies and programmes. Varying but
limited resource allocation to the various regions demands varying strategies at building
preventive and control measures suitable to the local disease epidemiological profile. The
report in this chapter presents an analysis of the incidence and spread of hepatitis B in
terms of its distribution in the ten regions of Ghana, using the SEIR model in Equation
3.6. It is expected that the knowledge about the burden of hepatitis B in the various regions
in Ghana would be useful in formulating an informed policy to manage the distribution of
health resources, particularly in the implementation of hepatitis B control interventions,
to meet the health needs of each region.
In this chapter, the formulated model was applied to the various regional data to analyse
the dynamics of the incidence and spread of hepatitis B in order to examine the impact
of the disease on each region. This involved estimating the key model parameters for
each region, applying the methods outlined in Chapter 4, and using them to calculate the
corresponding epidemiological threshold parameters R0 and their herd immunity threshold
values H. These threshold parameters were used to examine the differences in transmission
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and spread of hepatitis B within the regions of Ghana thereby showing the trend across
the country. A simple correlation analysis was performed to examine the association
between the trend of transmission and spread of hepatitis B and poverty inequalities across
the country. The incidence and spread of the disease was also analysed with respect to
disparities in health resource allocation across the country and the prevalence differentials
of hepatitis B between Ghana and its neighbouring countries. A summary of the findings
concludes the chapter.
6.2 Regional data description
Recall that the national hepatitis B incidence data of Ghana were formed by aggregating
the deidentified regional data. The regional data consist of reported monthly incidence
cases of hepatitis B, categorised into cases of persons aged less than 5 years and cases
of persons aged 5 years and above, that covers the period from 2008 to 2014. The data
were obtained from the Regional Health Informant Units (HIU) and Centre for Health
Information Management (CHIM) of the Ghana Health Service (GHS). The data summary
is displayed in Table 6.1.
Table 6.1: Summary of regional monthly hepatitis B incidence data collected during 2008−
2014.
Monthly incidence Standard Total
Region Minimum Maximum Mean Median deviation incidence
Greater Accra 6 745 129.2 98.5 139.34 10, 853
Brong Ahafo 10 404 145.06 122.5 81.31 12, 185
Upper East 10 586 103.12 69 99.49 8, 661
Upper West 24 869 173.32 104 188.36 14, 559
Ashanti 21 949 181.29 154.5 137.92 15, 228
Eastern 32 428 143.74 128.5 87.81 12, 074
Western 28 743 173.39 152 108.99 14, 565
Central 22 769 136.95 91.5 146.44 11, 504
Northern 29 327 108.25 90.5 55.32 9, 093
Volta 8 535 73.87 36.5 101.25 6, 205
From Table 6.1 Ashanti region recorded the highest number of 15, 228 incidence cases over
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the 2008 − 2014 period, with a mean monthly incidence of 181 cases. Next to Ashanti
are Western and Upper West with 14, 565 and 14, 559 cases respectively, both regions
recording a mean monthly incidence of approximately 173. The least number of 6, 205
incidence cases was recorded for Volta region with a mean monthly incidence of about 74.
Followed closely are Upper East region with 8, 661 incidence cases and monthly mean of
103 and Northern region with 9, 093 cases and monthly mean of 108. The overall monthly
minimum of 6 and a maximum of 949 incidence cases were recorded for Greater Accra and
Ashanti regions respectively, which show similar variability of monthly incidence cases with
standard deviation of 139 for Greater Accra and 138 for Ashanti. The largest monthly
incidence variability, measured in terms of standard deviation, of 188 was recorded for
Upper West region and the least of 55 was recorded for Northern region.
The time series plots of hepatitis B incidence data for each region are displayed in Figure
6.1. The time series plots generally show an increasing but fluctuating trend although
the specific features differ from region to region across the country. There is no regular
pattern except for Northern, Western and Brong Ahafo regions where the time plots show
a steady increase. In the case of Upper West and Central regions, the time plots show
sharp and drastic increase in 2014 after levelling off from 2008. These sharp increases in
incidence cases in the Western and Central region may be as a result of increased reporting
or increased awareness about HB. The plot for Eastern region shows a steady increase until
2014 when it dipped down sharply whilst those of the remaining regions show gentle and
irregular but fluctuating increase over the period 2008− 2014.
Due to the effect of inadequacies in data collection and compilation in Ghana as in other
poorly-resourced countries [50], the data were scaled in order to minimise these limitations
and to make meaningful conclusions. The scaling was done to reflect the assumption made
with respect to reporting rates of hepatitis B incidence cases of the regions, given in the
Ghana Health Service (GHS) annual reports of 2014 on viral hepatitis as displayed in
Table 6.2 [59]. The scale factors were calculated as a ratio of suspected cases of hepatitis
B to number of laboratory confirmed cases reported by GHS for each region, except in
the case of Northern region which did not have any records and so the national values
were applied. These ratios are assumed for lack of better data statistics to represent and
reflect the reporting rates of hepatitis B in the regions of Ghana. The calculated values
of the scale factors are displayed together with other input parameters for the parameter
estimation process later in Table 6.4 of Section 6.3 of this work.
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Figure 6.1: Time series plot of hepatitis B incidence data for the regions of Ghana 2008−
2014.
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Table 6.2: Reported viral hepatitis cases and deaths by region, Ghana 2014
Region Suspected cases Laboratory Confirmed cases Deaths CFR
Greater Accra 14791 878 14 0.1
Brong-Ahafo 2413 1339 47 1.9
Upper East 1583 212 11 0.7
Upper West 8812 1784 17 0.2
Ashanti 6117 698 3 0.0
Eastern 171 52 0 0.0
Western 5199 1062 9 0.2
Central 8003 902 7 0.1
Northern - - - -
Volta 3963 654 0 0.0
Ghana (Total) 51052 7581 108 0.2
Data source: GHS DHIMS2, 2014; CFR means Crude Fatality Rate
In addition to the incidence data, demographic data consisting of the projected annual
regional population from 2008 to 2014 were obtained from the Ghana Statistical Service
(GSS). Birth and death rates and poverty headcount by regions were also sourced from
GSS’ population and housing census and Ghana Living Standards Survey (GLSS6) of 2010.
In the survey report, poverty head count was defined as the percentage of the population
living below the national poverty line which was fixed at an income of GhC1, 314.00 (GhC
- Ghana Cedis). Table 6.3 shows a summary of the poverty head count by region in Ghana.
From Table 6.3, the least poverty headcount of 6.6 by census and 5.6 by GLSS6 were
recorded for Greater Accra region whilst the highest of 69.4 and 70.7 by the census and
GLSS6 respectively were recorded for the Upper West region. The three highest poverty
headcount values of 69.4, 45.9 and 44.2 were recorded for Upper West, Upper East and
Northern regions respectively which constitute the three northern regions of Ghana. The
four least poverty headcount values of 6.6, 13.6, 19.2 and 19.6 were recorded for Greater
Accra, Ashanti, Western and Central regions respectively which are situated in the south-
ern part of the country.
Figure 6.5(c) shows the regional distribution of poverty headcount in Ghana. The map
shows high poverty levels in the three northern regions (namely Upper West, Upper East
and Northern) and Volta region, but low to middle poverty levels in the southern regions
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Table 6.3: Ghana poverty headcount (HC) by region (poverty line = GHC1,314.00).
Census GLSS6
95% CI
Poverty Std. Absolute Poverty Std. lower Upper
Region headcount Error difference headcount Error limit limit
Greater Accra 6.6 0.0015 1.0 5.6 0.0151 2.65 8.57
Brong Ahafo 28.6 0.0036 0.7 27.9 0.0215 23.64 32.09
Upper East 45.9 0.0137 1.5 44.4 0.0388 36.8 52.01
Upper West 69.4 0.0102 1.3 70.7 0.0275 65.29 76.07
Ashanti 13.6 0.0035 1.2 14.8 0.0169 11.43 18.07
Eastern 22.0 0.0097 0.3 21.7 0.0242 16.91 26.4
Western 19.2 0.0040 1.7 20.9 0.0252 15.94 25.82
Central 19.6 0.0072 0.8 18.8 0.0223 14.44 23.19
Northern 44.2 0.0062 6.2 50.4 0.0318 44.12 56.59
Volta 33.3 0.0028 0.5 33.8 0.0343 27.12 40.57
Source: Ghana Statistical Service, 2010 Population and Housing Census and GLSS6.
and regions in the middle belt respectively.
6.3 Regional parameters estimation
The initial state variables (s0, e0, i0) of the model in Equation 3.6 were estimated for each
region, using a similar method applied to the process of estimating the national parameters
of the model in Section 5.3. The method involved generating all combinations of (s0, e0, i0)
from ranges of values of s0 ∈ [0.4, 0.8], e0 ∈ [0.1, 0.5] and i0 ∈ [0.005, 0.045] increasing in
steps of 0.05, 0.05 and 0.005 respectively, and applying the combined Genetic algorithm
(GA) and a Levenberg-Marquardt (LM) algorithm to fit the model to each regional data
set. In order to improve the estimation of the parameters (β, γ, ν), the optimisation process
was run 20 times for each combination of initial state variables (s0, e0, i0) for each region.





using the various regional data. A summary of the estimated initial state variables
(s0, e0, i0) and the calculated values of α and other demographic input parameters for
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each region that were used for the regional estimation process are displayed in Table 6.4.
The demographic data consisting of regional population and birth rates were obtained
from the Ghana Statistical Service.
Table 6.4: Summary of input parameters for estimation
Population Initial values
Region projections λ α s0 e0 i0 Scale
Greater Accra 4, 416, 861 22.7 0.065788λ 0.55 0.4 0.02 16
Brong Ahafo 2, 547, 144 26.3 0.101436λ 0.5 0.35 0.02 2
Upper East 1, 170, 820 22.7 0.058538λ 0.55 0.4 0.04 7
Upper West 758, 725 23.1 0.043616λ 0.5 0.45 0.01 5
Ashanti 5, 175, 581 25.7 0.075584λ 0.55 0.15 0.03 9
Eastern 2, 899, 417 25.4 0.074623λ 0.55 0.35 0.015 3
Western 2, 763, 926 26.8 0.074974λ 0.5 0.15 0.02 5
Central 2, 276, 168 26.5 0.081798λ 0.55 0.4 0.04 9
Northern 2, 736, 822 24.0 0.08831λ 0.55 0.15 0.03 7
Volta 2, 330, 363 24.2 0.12087λ 0.55 0.15 0.04 6
Ghana 27, 075, 827 24.9 0.076λ 0.55 0.40 0.04 7
∗λ is birth rate per 1, 000 population; ∗α is vertical transmission rate per 1, 000 population.
Using the methodology described in Section 5.3 and the input parameters in Table 6.4,
the parameters β, γ and ν of the model in Equation 3.6 were estimated for each region.
These estimated parameters were then used to calculate the corresponding epidemiological
threshold parameters R0 and herd immunity threshold values H for the various regions.
Table 6.5 displays the values of the estimated parameters β, γ and ν, their epidemiological
threshold parameters R0 and herd immunity threshold values H by region.
From Table 6.5, the maximum value of R0 = 3.7212 and the corresponding maximum
value of H = 0.7312 were calculated for Upper West region whilst the least values of
R0 = 1.3669 and H = 0.2684 were calculated for Volta region. The range between the
least and the maximum of the threshold values R0 and H across the regions are 2.3543
and 0.4628 respectively, which represent a percentage difference of about 172% relative to
the lowest value in both cases. All the regions except Western region had an estimated
recovery rate of ν = 0. A recovery rate of ν = 0.0378 was estimated for Western region.
The highest hepatitis B contact rate of β = 0.1308 was estimated for Western region whilst
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the minimum of β = 0.0359 was estimated for Volta region. Upper West, Upper East and
Western regions have high values whilst Volta region has a low value with respect to R0,
H and β most likely because they are all border points with either high or low incidence
country. Similarly, the highest latent rate of γ = 0.7698 was estimated for the Northern
region whilst the minimum rate of γ = 0.1255 was estimated for Volta region.
Table 6.5: Summary of regional parameters estimated
Estimated parameters
Region β γ ν R0 H
Greater Accra 0.0416 0.2744 0 1.7595 0.4316
Brong Ahafo 0.0475 0.2894 0 1.7572 0.4309
Upper East 0.0602 0.3413 0 2.5456 0.6071
Upper West 0.0899 0.3925 0 3.7212 0.7312
Ashanti 0.0404 0.2672 0 1.5119 0.3386
Eastern 0.0422 0.3083 0 1.6104 0.3790
Western 0.1308 0.1848 0.0378 1.8057 0.4462
Central 0.0603 0.1234 0 1.9580 0.4892
Northern 0.0422 0.7698 0 1.7940 0.4426
Volta 0.0359 0.1255 0 1.3669 0.2684
Ghana 0.0480 0.1254 0 1.6854 0.4067
Plots of the model fitted to the cumulative incidence data were produced for each region
and are displayed in Figure 6.2.
6.4 Regional model predictions
The model values of the state proportion variables s, e and i for each of the ten regions
were examined over a period of ten years (120 months), which include the first 7 years
(84 months) of study period and the next 3 years (36 months) of prediction. Figure 6.3
displays the plots for the model values of s, e and i against time, based on the respective
estimated parameters for the ten regions. Starting from the initial state values s0, e0 and
i0 presented in Table 6.4 for the various regions, the plots illustrate changes in s, e and i
for latent periods varying from 1 to 7 months until after infectious periods varying between
15 to 44 months when the three variables finally stabilise at the respective endemic states
values Q∗ = (s∗, e∗, i∗) displayed in Table 6.6.
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Figure 6.2: Model fit to regional cumulative HB incidence data (2008 - 2014).
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From Table 6.6, the endemic susceptible proportions s∗ range from 0.2601 to 0.7055, the
endemic exposed proportions e∗ range from 0.01407 to 0.0902 and the endemic infectious
proportions i∗ range from 0.2468 to 0.6988. Regions with higher proportions of susceptible
endemic state values have lower proportions of infectious state values and vice versa. Volta
region has the highest endemic susceptible proportion of s∗ = 0.7055 and therefore the
least endemic infectious proportion of i∗ = 0.2468, whilst Upper West region has the
least endemic susceptible proportion of s∗ = 0.2601 and so the highest infectious endemic
proportion of 0.6988.
Figures 6.5(d) and 6.5(e) show the distribution of infectious and latent periods of hepatitis
B respectively across Ghana. Whilst the infectious periods are high in the three northern
regions (Upper East, Upper West and Northern), Volta and Greater Accra regions, the
latent periods are low in the three northern regions with Volta and Central regions showing
the highest latent period. The middle belt and the southern regions show low infectious
periods but high latent periods in contrast to the pattern shown with respect to the three
northern regions. Volta and Central regions show the highest latent periods whilst Upper
East and Greater Accra regions show the highest infectious periods. With the exception
of Volta, Central and Greater Accra regions, the distribution of the infectious and latent
periods show a reverse trend with respect to each other. Whilst the infectious period
shows an increase from south to north, the latent period shows a decrease from south to
north across the regions of Ghana.
The regional distribution of the endemic susceptible, exposed and infectious proportions
are displayed in Figures 6.5(f), 6.5(h) and 6.5(g) respectively. The three northern regions
show relatively high endemic infectious proportions, but relatively low endemic susceptible
proportions. The trend of endemic infectious proportions decrease from north to south
whilst that of the endemic susceptible proportions increase from north to south across
the regions of Ghana. Unlike the endemic susceptible and infectious proportions, the
distribution of the endemic exposed proportions of the regions displayed in Figure 6.5(h)
shows no definite pattern.
6.5 Regression analysis
Linear regression analysis was used to examine the relationship among R0, H, poverty









Figure 6.3: Regional model predictions of the state variables s, e and i over 120 months.
85
Chapter 6. Application of the SEIR model to regional hepatitis B data in Ghana
Table 6.6: Regional endemic state values with corresponding latent and infectious periods.
Endemic values Latent Infectious
Region s∗ e∗ i∗ period period
Greater Accra 0.551559 0.034255 0.414186 3.4 44.1
Brong Ahafo 0.542686 0.038095 0.419219 3.2 38.0
Upper East 0.378539 0.038749 0.582712 2.7 44.1
Upper West 0.260055 0.041124 0.698821 2.4 43.3
Ashanti 0.643577 0.031266 0.325157 3.4 38.9
Eastern 0.602528 0.03025 0.367222 3.0 39.4
Western 0.544531 0.057686 0.165009 4.7 15.5
Central 0.489379 0.090266 0.420355 6.7 37.7
Northern 0.534483 0.014075 0.451443 1.3 41.7
Volta 0.70554 0.047582 0.246878 6.7 41.3
Ghana 0.5741 0.0706 0.3553 6.7 40.2
ŷ = β0 + β1x+ ε (6.1)
where ŷ is the dependent/response variable, x the independent variable, β0 the intercept,
β1 the slope and ε the error or noise, testing the hypothesis
H0 : β1 = 0, Ha : β1 6= 0.
In addition to the estimated statistics of the analysis, correlation coefficients for each pair
of variables were computed. The summary of the results is displayed in Table 6.7.
The p-values of 0.0257, 0 and 0.0027 for categories H versus poverty, H versus s∗ and
H versus i∗ respectively in Table 6.7 are less than the significance level p < 0.05, which
indicates that there is association between herd immunity H and poverty, H and s∗ and
H and i∗ respectively. The correlation coefficients of 0.6948, −0.9993 and 0.8341 for the
relation between H and poverty, H and s∗ and H and i∗ respectively, indicate that there is
a positive correlation between H and poverty and H and i∗ whilst the correlation between
H and s∗ is negative. This implies that H increases with increases in poverty and i∗, but
H declines as s∗ increases and vice versa. The associations between H and poverty, H
and s∗ and H and i∗ are illustrated in Figures 6.4(a), 6.4(c) and 6.4(e) respectively.
Similarly in Table 6.7, R0 shows a positive linear relationship with poverty and i
∗ and a








Figure 6.4: Linear regression of (a) Herd immunity on Poverty. (b) R0 on Poverty. (c)
Herd immunity on s∗. (d) R0 on s
∗. (e) Herd immunity on i∗. (f) R0 on i
∗. (g) Herd
immunity on e∗. (h) R0 on e
∗. (i) s∗ on i∗. (j) e∗ on i∗.
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Table 6.7: Calculated correlation coefficient values and summary statistics of regression
analysis among Herd immunity threshold (H), poverty headcount (poverty), epidemiolog-
ical threshold parameter R0 and the endemic state proportion variables s
∗, e∗ and i∗.
Category Correlation Coefficient Standard t-values p-values df
coefficient (β1) Errors
H on Poverty 0.6948 0.0049 0.0018 2.7325 0.0257 8
H on s∗ −0.9993 −0.9700 0.0137 −75.1973 < 0.0001 8
H on i∗ 0.8341 0.7176 0.1678 4.2765 0.0027 8
H on e∗ 0.1034 0.0160 2.2761 0.2941 0.7762 8
R0 on Poverty 0.7912 0.0292 0.0080 3.6594 0.0064 8
R0 on s
∗ −0.9530 −5.1214 0.5754 −8.9009 < 0.0001 8
R0 on i
∗ 0.8327 3.7374 0.8787 4.2536 0.0028 8
R0 on e
∗ 0.0520 0.0015 11.9212 0.1474 0.8865 8
s∗ on i∗ −0.8469 −0.7074 0.1570 −4.5049 0.0020 8
s∗ on e∗ −0.1034 −0.6499 2.2095 −0.2941 0.7761
e∗ on i∗ −0.1740 −0.0231 0.0463 −0.4999 0.6306 8
0.7912), (p = 0.0028, correlation = 0.8327) and (p = 0, correlation = −0.9530) respec-
tively. The correlations between R0 and poverty, R0 and s
∗ and R0 and i
∗ are illustrated
in Figures 6.4(b), 6.4(d) and 6.4(f) respectively, in which R0 increases as poverty and
i∗ increase and R0 declines as s
∗ increase and vice versa. There is no significant statis-
tical evidence of association between H and e∗, R0 and e
∗ and e∗ and i∗ as indicated
by the p-values of 0.8865, 0.7762 and 0.6306, and illustrated by Figures 6.4(g), 6.4(h)
and 6.4(j) respectively. However there is a negative correlation between s∗ and i∗ with
(p = 0.0020, correlation = −0.8469) and illustrated in Figure 6.4(i).
The correlation results above indicate that the spread and burden of hepatitis B in the
population of Ghana is associated with the poverty levels of the people, since the two
variables have a positive correlation. Regions with high levels of poverty would experience
increased spread of hepatitis B compared to less poor regions. The results also indicate that
regions which require higher levels of herd immunity to control hepatitis B have increasing
percentage of infectious population and so there is declining percentage of susceptible
population. Regions which have decreasing percentage of infectious population would
have increasing percentage of susceptible population and so require lower herd immunity
to keep the disease under control.
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6.6 Discussion of results
6.6.1 The threshold parameters and their implications on the trend of
disease
The computed regional values of the epidemiological threshold parameter R0 are all greater
than unity, which indicates that hepatitis B persists in all ten regions of Ghana. With
a minimum value of R0 = 1.3669 and a maximum of R0 = 3.7212, the threshold value
R0 shows a variability, in terms of range, of 2.3543 which represents a percentage change
of about 172% across Ghana. The extent of variability of R0 indicates that the intensity
of incidence and spread of hepatitis B vary significantly from region to region across the
country. The corresponding herd immunity threshold values H also show that controlling
the disease requires different percentages of the population to be immune in each region
across the country. The value of H ranges from a minimum of 0.2684 to a maximum of
0.7312 across the regions of Ghana.
Apart from Volta, Ashanti and Eastern regions with values of R0 = 1.3669, R0 = 1.5119
and R0 = 1.6104 respectively that are lower than the overall national value of R0 =
1.6854, the values of the remaining seven regions are greater than the national value.
The Greater Accra and Brong Ahafo regions have an approximate value of R0 = 1.76
which indicates that the spread and burden of the disease in the two regions are similar.
The epidemiological threshold parameters R0 and herd immunity threshold values H,
calculated for the regions, show that the spread of the disease and its associated burden
is highest in Upper West region (R0 = 3.7212, H = 0.7312) and lowest in Volta region
(R0 = 1.3669, H = 0.2684).
The values of the threshold parameters and their herd immunity values also show an
increasing trend from south to north of Ghana, indicating that the spread of the disease and
the associated burden increase from the south to the north across the three main ecological
zones, i.e. Coastal savanna, Rain forest and Northern savanna, of the country [142].
Although Western and Central regions are situated in the southern part of the country,
they have high values of (R0 = 1.8057, H = 0.4462) and (R0 = 1.9580, H = 0.4892)
respectively that deviate from this increasing trend of disease from south to north. Apart
from the Western region which showed some recovery of disease of 0.0378, the rest of the
regions have zero recovery indicating that none of the infected persons could clear the
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Figure 6.5: Regional distributions of (a)Epidemiological threshold parameter R0; (b) Herd immunity threshold value H; (c) Poverty
inequality (by poverty headcount); (d) Infectious period; (e) Latent period; (f) Estimated endemic susceptible proportion s∗; (g)
Estimated endemic infectious proportion i∗. (h) Estimated endemic exposed proportion e∗;
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Although this may be a numerical artefact, studies on the characteristics of the dynamics of
hepatitis B however indicate that the disease can be cleared at the acute stage without the
need for intervention or antiviral treatment. The clearance of hepatitis B at the acute stage
according to studies depend on the age and immune competence of the infected individual
at the time of infection [29, 92]. A visual representation of the regional distribution of
the incidence and spread of hepatitis B with respect to the epidemiological threshold
parameters R0 and herd immunity threshold values H across the country is displayed in
Figures 6.5(a) and 6.5(b) respectively.
6.6.2 Influence of poverty and health sector inequalities on trend of
disease
Poverty and health sector inequalities influence the pattern of incidence and spread of
hepatitis B across the regions of Ghana, as poverty and ill-health are generally intertwined
[144, 145, 146]. Since poverty is characterised by a lack of essential goods and services
and also low levels of education and awareness, poor people tend to have worse health
outcomes than otherwise better-off people [144]. This for example is evident in the longer
term illness indicators such as long standing illness and self-assessed health, as in the
case of chronic hepatitis and hepatocellular carcinoma, complicated with high levels of
morbidity and mortality which show inequality to the disadvantage of the poor [144]. The
various factors that have direct influence on health outcomes in a population generally
tend to be worse in poorer communities.
The Ghana poverty and inequality report indicated that the highest poverty rates con-
tinue to be observed in the Northern, Upper East and Upper West regions [147]. Table
6.3, sourced from GSS population and housing census and GLSS6 of 2010, displays the
estimates of poverty headcount of Ghana by region. Figure 6.5(c) illustrates the regional
poverty inequality distribution, based on the estimates of poverty headcount of Ghana
presented in Table 6.3. Figure 6.5(c), shows that poverty levels reduce from north to
south of the country. Volta region however deviates from this trend since it is among the
top five poorest regions by virtue of its poverty headcount, although it is situated in the
south-eastern part of the country.
The location of health facilities as well as the availability of health personnel to man these
facilities also affects the pattern of incidence and spread of hepatitis B in Ghana. Health
staff concentration in urban areas especially Kumasi and Accra and inadequate supply of
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logistics to health care facilities across the country remain a challenge to health delivery
particularly in the vast rural settings [59]. The Ghana Health Service (GHS) acknowledged
challenges of provision of accessible, affordable and quality health care to regions in the
north of the country [59, 71].
The poor by their predisposition to illnesses tend to use health services more than the
better-off, but it turns out mostly that the utilisation of the health service is insufficient
for their greater medical needs due to unavailability or inaccessibility of health facilities,
services and logistics [144]. Access to medical care and cost of screening, diagnosis and
treatment of viral hepatitis compound the challenges in hepatitis and liver cancer man-
agement in poor communities. In fact surveillance programs and routine HBV screening
for the general population are virtually absent in poor communities which usually form
the vast rural areas of Sub-Saharan Africa [148]. For example, poor children in poor com-
munities are typically far less likely to be immunised against an infectious disease than
better-off children [144].
The transmission and spread of hepatitis B increase from south to north as shown by
the distribution of the epidemiological threshold parameters and herd immunity threshold
values in Figures 6.5(a) and 6.5(b) respectively, reflects the poverty and health sector
differentials across the country. It is however worth noting that although Volta region
is not the richest region, it presents the least incidence and spread of hepatitis B whilst
Western and Central regions are not rated among the poorest regions but the intensity of
hepatitis B is considerably high. This shows that the incidence and spread of hepatitis B
in Ghana is not determined by poverty and health sector inequalities alone.
6.6.3 Prevalence differentials of hepatitis B between Ghana and neigh-
bouring countries
Apart from poverty inequalities across the country, differentials in prevalence of hepatitis
B between Ghana and the neighbouring countries most likely contribute to the pattern
of incidence and spread of the disease in Ghana. Some studies have indicated that mi-
gration across health and disease disparities influence the epidemiology of certain diseases
globally and in communities receiving migrants [3, 149, 150, 151]. Granted that specific
disease-based outcomes may vary between migrant groups, yet by general epidemiological
principles moving a population from the risk environment or establishing disease trans-
mission outside of the usual environmental constraints impact on the epidemiology of the
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condition in the receiving region and on the local community [149]. The health charac-
teristics of migrants usually reflect their place and country of origin and thus carry with
them most of these characteristics when they move, although they are also subject to other
prevalent conditions that affect their health [3].
Some studies indicated that increased volumes of movement of people across regions of
different hepatitis B prevalence have changed the hepatitis B epidemiology between both
immigration and emigration countries [150]. In recent years, hepatitis B prevalence has
been a major public health concern to countries which hitherto did not have such con-
cerns mostly due to increased migration from high or intermediate hepatitis B prevalence
regions [150, 151]. Ghana is bounded on the north by Burkina Faso, on the east by Togo
and on the west by Ivory Coast. Global infection rates of hepatitis B reviewed in 2006 by
WHO’s National Centres for Disease Control and Prevention (CDCP) indicated that hep-
atitis B prevalence for Burkina Faso, Ghana, Ivory Coast and Togo were 12%, 12%, 12%
and 8% respectively [152]. However, other reports indicated that hepatitis B is hyperen-
demic in Burkina Faso with prevalence of around 14.5% whereas Ivory Coast is considered
intermediate endemicity [152].
Volta and Western regions provide the main official exits to Togo and Ivory Coast respec-
tively where much interaction with respect to socioeconomic activities take place among
people travelling on either side of the borders. Lower prevalence of hepatitis B in Togo
could most likely be an influence on a lower transmission and spread of the disease in
Volta region compared to a considerably higher prevalence in Ivory Coast, which could
also impact a higher transmission and spread in Western region with respect to the epi-
demiological threshold parameters of the two regions. Since Upper East and Upper West
are also the main official exits to Burkina Faso where similar interactions of people moving
to and from both countries across the border, the high spread of hepatitis B would most
likely be attributable to the hepatitis B hyperendemicity status of Burkina Faso.
6.7 Summary
The epidemiological threshold parameter R0, calculated for each of the ten regions of
Ghana, is greater than unity. This indicates that hepatitis B is persistent throughout
Ghana, although the incidence and spread and the associated burden differs from region
to region across the country. The corresponding herd immunity threshold values H for
the various regions are also indicative that different immunity levels are required to bring
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hepatitis B in each region under control. The incidence and spread and the associated
burden of hepatitis B, based on the values of R0, show a general increasing trend from
south to north across the regions of Ghana. Exception to this trend are Western and
Central regions which have relatively high values of R0 but are situated in the southern
part of Ghana. Values of R0 for Eastern, Ashanti and Volta regions compared to the
national value indicate that the incidence and spread of hepatitis B and the associated
burden in the three regions is lower than that of broader Ghana. The remaining seven
regions have higher values of R0 and therefore experience higher burden compared to the
national burden.
Poverty and health sector inequalities potentially impact the trend of incidence and spread
of hepatitis B and the associated burden across the regions of Ghana. Poverty and ill-
health are intertwined and poor people tend to have worse health outcomes. Ghana poverty
and inequality report of 2010 indicated an increasing trend of poverty from south to north
across the regions of Ghana. A simple correlation analysis between poverty headcount and
values of both R0 and H show a strong positive association. This implies that as poverty
headcount increases, R0 and H increase. Poor communities most likely face challenges
of provision of accessible, affordable and quality health care due to the unavailability of
health facilities and logistics and also health personnel. Poor communities are most likely
disadvantaged with regards to access to medical care and cost of screening, diagnosis and
treatment of hepatitis B and thus are the most vulnerable to advanced liver disease and
death due to late reporting.
Differentials in prevalence of hepatitis B is another area that potentially impact the pattern
of incidence and spread of the disease across both regional and international borders of
Ghana. Since the health characteristics of migrants usually reflect their region and country
of origin, most of these characteristics are brought to bear on their new settlements.
Potential interregional and international influences of disparities in prevalence of hepatitis
B show in a subtle way in the pattern of incidence and spread of the disease in regions
of Ghana that have direct economic and/or social border activities with neighbouring
countries. For example, border activities between Upper East and Upper West regions of
Ghana and Burkina Faso, which is reported to be a hepatitis B hyperendemic country,
most likely have a relative influence on the high incidence and spread pattern of the disease
in the three northern regions of Ghana. Similarly, the intermediate endemicity status of
Ivory Coast potentially influences the relatively high pattern of incidence and spread of
hepatitis B in Western, Central and Brong-Ahafo regions on the western border with Ivory
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Coast. It is also most likely that the low to intermediate hepatitis B prevalence in Togo
impact the relatively low pattern of incidence and spread of the disease in Volta, Greater
Accra and eastern regions on the eastern border of Ghana with Togo.
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Impact of vaccination on the
hepatitis B model (SEIR) of
Ghana
7.1 Introduction
Global control of the prevalence of hepatitis B is a major goal of WHO, with a special
emphasis on prevention of the disease in Africa which is an endemic region [148]. Al-
though there are other forms of intervention for the control and prevention of hepatitis B,
vaccination is known to be the major and most effective one, especially when universally
incorporated in national infant immunisation programmes [12, 148, 153, 154]. The depth
of hepatitis B prevalence is determined by the depth of chronic infection existing in a pop-
ulation, and infected infants have the highest risk of developing chronic infection [154].
There is no treatment for acute hepatitis B. Treatment for chronic hepatitis B, although
available and important, will keep down viral replications and slow the progression of cir-
rhosis, reduce incidence of liver cancer and sustain long term survival of the infected person
but it does not prevent the development of the disease [12, 153]. The key to preventing
the spread of hepatitis B therefore is to ensure that fresh or new incidence of the infection
is completely cut off from a population, essentially at the early stages of life where there
is a high likelihood of developing into chronic infection. In fact WHOs recommendation
with respect to the WHAs resolution in 2010, that calls for public health intervention to
prevent and control viral hepatitis, emphasised the need to administer hepatitis B vaccine
to all infants as soon as possible after birth [12, 153].
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In this chapter, vaccination as an intervention was introduced into the SEIR model with
vertical transmission, to examine its impact on the incidence and spread of hepatitis B
and the associated burden on the population of Ghana. The SEIR model of hepatitis B
for Ghana in Equation 3.1 was modified to include a vaccination component that moves
vaccinated susceptible members directly into the recovered compartment R. The epi-
demiological threshold parameter Rv0 of the modified model was analytically determined.
Sensitivity of Rv0 to the rate of vaccination was performed to examine the impact of vac-
cination on the incidence and spread of hepatitis B, in the case of Ghana and also for
each of the ten regions of Ghana. Stability analysis of the modified model was discussed
analytically with respect to the equilibrium states of the model. A summary of the results
concludes the chapter.
7.2 The vaccination model
The vaccination model is a modification of the SEIR model in which a vaccination com-
ponent determined by the rate of vaccination k is introduced. Progression of infection
through the modified model is similar to that of the existing model in Equation 3.1,
except that now vaccinated susceptible individuals are transferred directly into the recov-
ered class by gaining immunity. In essence, a nonvaccinated susceptible individual moves
into the exposed class after being exposed to the pathogen, the exposed individual then
moves into the infectious class and finally moves into the recovered class by permanent
immunity, or may die naturally in the course of progression through the model. Birth
fluxes of λN −α(E+ I) and α(E+ I) via the susceptible and exposed classes respectively
are recruited into the model, where α is the rate of vertical transmission. The disease
progression in the model is illustrated by the flow diagram in Figure 7.1.
Figure 7.1: A model for transmission of hepatitis B with vaccination.
The vaccination model is represented by the system of nonlinear ordinary differential
equations
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dS
dt
= λN − α(I + E)− βSI
N






+ α(I + E)− µE − γE
dI
dt
= γE − µI − νI
dR
dt
= νI + kS − µR, (7.1)
subject to S(t), E(t), I(t), R(t) ≥ 0, S(t) +E(t) + I(t) +R(t) = N(t) and dNdt = (λ−µ)N ,
where k ≥ 0 is the rate of vaccination. The remaining parameters are defined as in the
original model in Equation 3.1 stated in Chapter 3 of this thesis. Using the proportions
of the state variables S(t), E(t), I(t) and R(t) in N(t) and by determining r from r =
1− (s+ e+ i), the system in Equation 7.1 becomes
ds
dt
= λ− α(i+ e)− βsi− ks− sλ
de
dt
= βsi+ α(i+ e)− γe− eλ
di
dt
= γe− νi− iλ (7.2)
defined on the closed positively invariant set, Σ = {(s, e, i) ∈ R3+|0 ≤ s + e + i ≤ 1}
[112]. The vaccination model, like the original SEIR model, is also well-posed because
any solution of the system in Equation 7.2 with initial state of (s0, e0, i0) ∈ Σ remains
in Σ, that is invariant. The model has two equilibrium states; a disease-free equilibrium










(λ+ γ)(λ+ ν)− α(λ+ γ + ν)
βγ
e∗v =
βγλ+ α(λ+ k)(λ+ γ + ν)− (λ+ k)(γ + λ)(λ+ ν)
βγ(γ + λ)
i∗v =
βγλ+ α(λ+ k)(λ+ γ + ν)− (λ+ k)(γ + λ)(λ+ ν)
β(λ+ γ)(λ+ ν)
. (7.3)
The assumptions of the model include all the assumptions of the original model from
Chapter 3. In addition, the susceptible proportion of the population is assumed to be
vaccinated at the rate k ≥ 0 with a vaccine efficacy of 100%. This means that the effect of
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the vaccine is not expected to wane within the period of study and so the entire vaccinated
susceptible proportion moves into the recovered class.
7.3 The epidemiological threshold parameter Rv0 of the vac-
cination model
The threshold parameter Rv0 is defined as the spectral radius of the next generation matrix
AB−1 evaluated at the disease-free state Qv0 = (λ/(λ+ k), 0, 0). From Equation 3.6, the
rate of appearance of new infection A into the infected compartments and the rate of
transfer into B+ and transfer out B− of the infected compartments by all other means,












Note that the transfer from E to I is not considered to be new infection, but rather the
progression of an infected person through the various compartments. Hence the partial
derivatives of A and B with respect to e and i, evaluated at the disease-free state Qv0 =
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The spectral radius of the next generation matrix AB−1 is obtained from the eigenvalues
of AB−1 given by
ξ1 = 0, ξ2 =
α(λ+ k)(λ+ ν) + αγ(λ+ k) + βγλ
(λ+ k)(λ+ γ)(λ+ ν)
Therefore the epidemiological threshold parameter Rv0 is the dominant eigenvalue ξ2 of
the next generation matrix FV −1 given by [105]
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Rv0 =
βγλ+ α(λ+ k)(λ+ γ + ν)
(λ+ k)(λ+ γ)(λ+ ν)
. (7.8)
Regardless of the presence of vaccination in the model, the disease is said to die off in the
population when the epidemiological threshold parameter Rv0 < 1. When Rv0 > 1, the
disease is said to persist. Recall also that in the absence of the intervention, k = 0 and so
Rv0 reverts to the threshold parameter of the original model without vaccination
R0 =
βγ + α(λ+ γ + ν)
(λ+ γ)(λ+ ν)
. (7.9)
The herd immunity threshold of the vaccination model is given by
Hv = 1−
(λ+ k)(λ+ γ)(λ+ ν)
βγλ+ α(λ+ k)(λ+ γ + ν)
(7.10)
7.4 Stability analysis of the vaccination model
The Jacobian of the system in Equation 7.2 is
J(s, e, i) =

−(βi+ λ+ k) −α −(α+ βs)
βi α− λ− γ α+ βs
0 γ −(λ+ ν)
 , (7.11)
the eigenvalues of which are then used to discuss the stability of the model in Equation
7.2 at the two equilibrium solutions, namely the disease-free state Qv0 =
(
λ
λ+k , 0, 0
)
and







The disease-free and endemic equilibrium solutions of the vaccination model in the entire
stability analysis will refer to disease eradication and persistence with respect to the in-
fected proportions e and i of the population and not the absolute cases E and I respectively
as indicated for the original model in chapter 3 [114].
7.4.1 Stability of the disease-free state
At the disease-free equilibrium state Qv0 =
(
λ
λ+k , 0, 0
)
the Jacobian of the system in
Equation 7.2 is given by
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0 α− λ− γ α+ β λλ+k
0 γ −(λ+ ν)
 (7.12)
The characteristic equation of the Jacobian is
(λ+ k + ξ)
[








⇒ (λ+ k + ξ)
[








Hence the eigenvalues of the disease-free state are
ξ1 = −(k + λ)
ξ2 =











4v = (λ+ k)[(λ+ k)(α+ ν − γ)2 + 4γ(αλ+ kα+ βλ)] (7.15)
From Equation 7.14, ξ1 < 0 and ξ3 < 0 since α < λ and α, β, γ, ν, λ ≥ 0, but ξ2 = 0 if
(λ+ k)2(2λ+ γ + ν − α)2 = (λ+ k)[(λ+ k)(α+ ν − γ)2 + 4γ(αλ+ kα+ βλ)]
=⇒ k = λ[(λ+ ν)(α− λ− γ) + γ(α+ β)]
(λ+ ν)(λ+ γ − α)− αγ
This defines a threshold value of
k∗ =
λ[(λ+ ν)(α− λ− γ) + γ(α+ β)]
(λ+ ν)(λ+ γ − α)− αγ
(7.16)
such that ξ2 < 0 if k > k
∗ and ξ2 > 0 if k < k
∗. It follows from the above analysis that
the eigenvalues of the disease-free state Qv0 are:
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i. All negative, that is, ξ1 < 0, ξ2 < 0 and ξ3 < 0, if k > k
∗ which means that the
disease-free state Qv0 is asymptotically stable;
ii. One zero and two negative, that is, ξ1 < 0, ξ2 = 0 and ξ3 < 0, if k = k
∗;
iii. One positive and two negative, that is, ξ1 < 0, ξ2 > 0 and ξ3 < 0, if k < k
∗, which
means the disease-free state Qv0 is unstable.




















βγλ[(λ+ ν)(λ+ γ − α)− αγ] + αλγβ(λ+ γ + ν)
λγβ(λ+ γ)(λ+ ν)
=






In conclusion, if the vaccination rate k = k∗, Rv0 = 1 as expected. The disease-free
equilibrium state Qv0 =
(
λ
λ+k , 0, 0
)
is stable if the vaccination rate k > k∗. The disease-
free equilibrium state is however unstable if the vaccination rate k < k∗. Moreover from
Equation 7.16, if k > k∗
k >
λ[(λ+ ν)(α− λ− γ) + γ(α+ β)]
(λ+ ν)(λ+ γ − α)− αγ
Since λ > α, it implies that (λ+ ν)(λ+ γ − α)− αγ > 0 and so
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k[(λ+ ν)(λ+ γ − α)− αγ] > λ[(λ+ ν)(α− λ− γ) + γ(α+ β)]
=⇒ k[(λ+ ν)(λ+ γ)− α(λ+ γ + ν)] > −λ[(λ+ ν)(λ+ γ − α)− αγ] + βγλ
=⇒ k[(λ+ ν)(λ+ γ)− α(λ+ γ + ν)] > −λ[(λ+ ν)(λ+ γ)− α(λ+ γ + ν) + λγβ
=⇒ (λ+ k)(λ+ ν)(λ+ γ) > λγβ + α(λ+ k)(λ+ γ + ν)
=⇒ λγβ + α(λ+ k)(λ+ γ + ν)
(λ+ k)(λ+ ν)(λ+ γ)
< 1
=⇒ Rv0 < 1 (7.18)
Hence if k > k∗, the epidemiological threshold parameter Rv0 < 1. The same analogy
can be used to show that if k < k∗, Rv0 > 1. From the above discussions, the following
conclusions can be made, that
• If k > k∗, Rv0 < 1 and the disease-free equilibrium is asymptotically stable;
• If k = k∗, Rv0 = 1; and
• If k < k∗, Rv0 > 1 and the disease-free is unstable.
7.4.2 Global stability of the disease-free equilibrium state
In Section 7.4.1, the stability of the disease-free proportion equilibrium Qv0 for the vac-
cination model was established on the basis that the real parts of all the eigenvalues of
the Jacobian in Equation 7.11 are negative for k > k∗. It was therefore concluded that
the disease-free equilibrium state is asymptotically stable if Rv0 < 1. In this section,
discussion of the global stability of the disease-free equilibrium state of the vaccination
model also follows from the methods applied to the model without vaccination in Chap-
ter 3. The methods are applied to show that the restriction on the threshold parameter
Rv0 < 1 also guarantees the global stability of the disease-free equilibrium state Qv0 of
the vaccination model in the closed positive set Σ in the sense of Lyapunov and LaSalle if
Rv0 ≤ 1 − βγk(λ+k)(λ+γ)(λ+ν) . In this regard, Theorem 3 can be restated and used to prove
this result as follows:
Theorem 6 The disease-free equilibrium Qv0 = (
λ
λ+k , 0, 0) of the vaccination model in
Equation 7.2 is globally asymptotically stable in Σ if Rv0 ≤ 1− βγk(λ+k)(λ+γ)(λ+ν) .
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Proof. Let Rv0 ≤ 1− βγk(λ+k)(λ+γ)(λ+ν) and choose the scalar function V (s(t), e(t), i(t), k(t))
= γe + (λ + γ − α)i, where V : R3+ −→ R has continuous derivatives in R. Then from
Equations 3.24, 7.2 and 7.8











βγs(λ+ k)− βγ(λ+ k)
(λ+ k)(λ+ γ)(λ+ ν)
+
βγ(λ+ k) + α(λ+ k)(λ+ γ + ν)
(λ+ k)(λ+ γ)(λ+ ν)
− 1
]




(λ+ k)(λ+ γ)(λ+ ν)
+
βγλ+ βγk + α(λ+ k)(λ+ γ + ν)
(λ+ k)(λ+ γ)(λ+ ν)
− 1
]






βγλ+ α(λ+ k)(λ+ γ + ν)
(λ+ k)(λ+ γ)(λ+ ν)
+
βγk
(λ+ k)(λ+ γ)(λ+ ν)
− 1
]






























(λ+ k)(λ+ γ)(λ+ ν)
))
(λ+ γ)(λ+ ν) ≤ 0 (7.20)
It follows that for i ≥ 0
V̇ (s, e, i) ≤ 0 ∀(s, e, i) ∈ Σ. (7.21)
From Equation 7.19, i = 0 is a necessary and sufficient condition for V̇ = 0, which means
that E = {(s, e, i) ∈ Σ|i = 0} is the set of all points in Σ such that V̇ = 0. However, from
the vaccination model in Equation 7.2, if i = 0
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s′ = λ− αe− ks− sλ
e′ = αe− γe− eλ
i′ = γe (7.22)
which means that if e > 0, i′ > 0 and no solutions starting in the set {(s, e, i) ∈ Σ|i =
0, e > 0} remains in {(s, e, i) ∈ Σ|i = 0, e > 0}. Thus the set {(s, e, i) ∈ Σ|i = 0, e > 0} is
not an invariant subset of E. If e = i = 0, Equation 7.22 further reduces to
s′ = λ− ks− sλ
e′ = 0
i′ = 0 (7.23)
From Equation 7.23, if s = λλ+k , s
′ = 0 which implies that {( λλ+k , 0, 0)} is an invariant
subset of E. If s 6= λλ+k , then solving the first equation in Equation 7.23 subject to










exp (−(λ+ k)t). (7.24)








Hence the set {(s, e, i)|s 6= λλ+k , e = 0, i = 0} is only positively invariant and not invariant.
Thus the singleton {Qv0} is the maximum invariant subset of Σ. Using a similar argument
in Subsection 3.3.2, by setting Ω = Σ, M = Qv0 and D = R3+ in Theorem 2
lim
t→∞
||(s(t), e(t), i(t))−Qv0|| = 0.
Hence Qv0 is globally asymptotically stable in Σ when Rv0 ≤ 1− βγk(λ+k)(λ+γ)(λ+ν) .
7.4.3 Stability of the endemic equilibrium state











defined by Equation 7.3, the Jacobian of the vaccination model in Equation 7.2 is given
by
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−(λ+ k + βi∗v) −α −(α+ βs∗v)
βi∗v (α− λ− γ) βs∗v + α
0 γ −(λ+ ν)
 . (7.25)
The characteristic equation of the model is
ξ3 + ξ2(−α+ γ + k + 3λ+ ν + βi∗v)
+ ξ(−αγ − αk − 2αλ− αν + γk + 2γλ+ γν + 2λk + νk + 2λν + 3λ2 + βγi∗v + 2βλi∗v
+ βνi∗v − βγs∗v)− βγλs∗v − βγks∗v + βγνi∗v + βγλi∗v − αλν − kαν − kαλ− αγλ− kαγ
+ βλνi∗v + βλ
2i∗v + kλν + γλν + γν + kγλ− αλ2 + λ3 + λ2ν + kλ2 + γλ2) = 0 (7.26)
which is of the form
ξ3 + a2ξ
2 + a1ξ + a0 = 0 (7.27)
where the coefficients a2, a1 and a0 are given by
a2 =
γ2λ+ γ2ν + 3γλ2 + 4γλν + βγλ+ γν2 − αγν + kαγ + 2λ3 + 3λ2ν + λν2
(γ + λ)(λ+ ν)
+
kαλ+ kαν
(γ + λ)(λ+ ν)
a1 =
αλ3 + kαγ2 + 2αγλ2 + αγ2λ+ 2βγλ2 + βγ2λ+ kαλ2 + kαν2 + αλν2 + 2αλ2ν
(γ + λ)(λ+ ν)
+
kαγν + αγλν + βγλν + 2kαλν + 2kαγλ
(γ + λ)(λ+ ν)
a0 = αλ
2 − γλ2 − kλ2 − λ2ν − λ3 + kαγ + αγλ+ βγλ+ kαλ+ kαν + αλν − kγλ
− kγν − γλν − kλν (7.28)
From Equation 7.28, a2 > 0 and a1 > 0 since α, β, γ, ν, λ, k ≥ 0 and α < λ, but a0 = 0 if
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a0 = αλ
2 − γλ2 − kλ2 − λ2ν − λ3 + kαγ + αγλ+ βγλ+ kαλ+ kαν + αλν
(7.29)
− kγλ− kγν − γλν − kλν = 0 (7.30)
=⇒ k = λ[(λ+ ν)(α− λ− γ) + γ(α+ β)]
(λ+ ν)(λ+ γ − α)− αγ
= k∗ (7.31)
That is the threshold value of the rate of vaccination for the disease-free equilibrium state
Qv0 of the model. Furthermore from Equations 7.3 if k = k
∗, the endemic state coordinates
are e∗v = i
∗
v = 0 and
s∗v =
(λ+ ν)(λ+ γ)− α(λ+ γ + ν)
βγ
=
(λ+ ν)(λ+ γ − α)− αγ
βγ
=
λ[(λ+ ν)(λ+ γ − α)− αγ]
λβγ
=
λ[(λ+ ν)(λ+ γ − α)− αγ]
λ[(λ+ ν)(λ+ γ − α)− αγ]− λ[(λ+ ν)(λ+ γ − α)− αγ] + λβγ
=
λ[(λ+ ν)(λ+ γ − α)− αγ]





Hence if k = k∗, Q∗v = Qv0 = (
λ
λ+k , 0, 0) is a common threshold point where stability
changes between the endemic equilibrium and the disease-free equilibrium states of the
vaccination model in Equation 7.2. It can also be shown that a0 > 0 if k < k
∗, a0 < 0 if
k > k∗ and a0 = 0 if k = k
∗. It follows from the discussion above, that the coefficients of
the characteristic equation in Equation 7.27 are
i. All positive, that is, a2 > 0, a1 > 0 and a0 > 0, if k < k
∗.
ii. One zero and two positive, that is a2 > 0, a1 > 0 and a0 = 0, if k = k
∗.
iii. One negative and two positive, that is, a2 > 0, a1 > 0 and a0 < 0, if k > k
∗, and
Using the methods described in Subsection 3.3.3, it can be numerically verified for β, γ, ν ≥
0 conditional upon
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that the characteristic Equation 7.27 has three distinct real roots.
Applying the Descartes’ rule for polynomials in Theorem 4 [155] to Equation 7.27 , it
follows that
• If k < k∗, all the eigenvalues are negative, that is, ξ1 < 0, ξ2 < 0 and ξ3 < 0 and so
the endemic state is asymptotically stable.
• If k = k∗, One eigenvalue is zero and two are negative, that is, ξ1 < 0, ξ2 = 0 and
ξ3 < 0 and there is stability crossover between the endemic and disease-free states.
• If k > k∗, one eigenvalue is positive and two are negative, that is, ξ1 < 0, ξ2 > 0 and
ξ3 < 0 and so the endemic state is unstable.






v) of the model
is stable if the vaccination rate k < k∗ and unstable if the vaccination rate k > k∗.
Furthermore, using Equations 7.8 and 7.16, it can be shown that Rv0 > 1 if k < k
∗
From Sections 7.4.1 and 7.4.3, it has been established that the vaccination model has two
equilibrium solutions, namely the disease-free state Qv0 =
(
λ
λ+k , 0, 0
)
and the endemic






v). The disease-free equilibrium state Qv0 is global asymptotically
stable if the vaccination rate k is greater than a threshold value k∗ and Rv0 ≤ 1, where
all the eigenvalues of the characteristic equation in Equation 7.13 are negative, whilst the
endemic equilibrium state Q∗v is unstable. The endemic state Q
∗
v is asymptotically stable
if the vaccination rate k is less than the threshold value k∗ where all the eigenvalues of the
characteristic equation in Equation 7.26 are negative and Rv0 > 1, whilst the disease-free
state Qv0 is unstable. If the vaccination rate k is equal to the threshold value k
∗, the
dynamical system of the vaccination model is at a crossover point where stability shifts
between the disease-free equilibrium and the endemic equilibrium states. At this threshold
value of k∗, the epidemiological threshold parameter Rv0 = 1.
7.5 The threshold parameter Rv0 as a function of the vacci-
nation rate k
The plot of the threshold parameter Rv0 as a function of the vaccination rate of k ≥ 0
was produced, using Equation 7.8, to examine the impact of k on Rv0. The national and
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regional plots were produced based on the national and regional parameters respectively,
estimated from the model without the vaccination component in Chapters 5 and 6. These
plots are displayed in Figures 7.2 and 7.3. In all the plots as k increases over the interval
[0, 1], Rv0 declines until it flattens off beyond the estimated herd immunity threshold
values H.
Figure 7.2: Vaccination rate versus basic reproduction number.
For the national plot in Figure 7.2, the fixed parameters were β = 0.0480, γ = 0.1254
and ν = 0. The birth rate λ = 0.249 and vertical transmission rate α = 0.076λ were also
the same values used in the parameter estimation of the model without the vaccination
component. As k increases from 0, the threshold parameter Rv0 drops sharply from the
national value of Rv0 = 1.6854 until it levels off at a vaccination rate of about k = 0.4,
which is analogous to having achieved the herd immunity threshold of the population.
By achieving a vaccination rate of about k = 0.4, that is higher than the estimated
contact rate, the threshold parameter would be stabilised at a value way below unity,
which indicates that the spread of hepatitis B is under control in the population. At the
value of Rv0 = 1, the rate of vaccination k attains a threshold value k
∗ = 0.0185 that is a
crossover point of the model where stability shifts from the endemic equilibrium state Q∗v
to the disease-free equilibrium state Qv0. This means that when the vaccination rate is
k > 0.0185, the epidemiological threshold parameter is Rv0 < 1 and the transmission and
spread of the disease would decline in the population. However when the vaccination rate
is k < 0.0185, the threshold parameter is Rv0 > 1 which means that the transmission and
spread of the disease would increase in the population.
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For the regional plots in Figure 7.3, the fixed parameters β, γ, ν, λ and α used as input
values for the simulation process, herd immunity values H and the threshold values of k∗
are shown in Table 7.1. The threshold values k∗ for the regions range from a minimum
of 0.01 for Volta region to a maximum of 0.0657 for Upper West region. Three regions
namely Volta, Ashanti and Eastern have threshold values of k∗ = 0.01, k∗ = 0.0142 and
k∗ = 0.0167 respectively that are less than the national value of k∗ = 0.0185. This is
consistent with the herd immunity threshold values of H = 0.2684, H = 0.3386 and
H = 0.3790 for Volta, Ashanti and Eastern regions respectively that are also less than the
national herd immunity threshold value of H = 0.4067.
Table 7.1: Input parameters for regional Rv0 − k∗ plots and vaccination threshold k∗ and
herd immunity threshold H values.
Input parameters Threshold values
Region β γ ν λ α k∗ H
Greater Accra 0.0416 0.2744 0 22.7 0.065788λ 0.0184 0.4316
Brong Ahafo 0.0475 0.2894 0 26.3 0.101436λ 0.0222 0.4309
Upper East 0.0602 0.3413 0 22.7 0.058538λ 0.0373 0.6071
Upper West 0.0899 0.3925 0 23.1 0.043616λ 0.0657 0.7312
Ashanti 0.0404 0.2672 0 25.7 0.075584λ 0.0142 0.3386
Eastern 0.0422 0.3083 0 25.4 0.074623λ 0.0167 0.3790
Western 0.1308 0.1848 0.0378 26.8 0.074974λ 0.0223 0.4462
Central 0.0603 0.1234 0 26.5 0.081798λ 0.0276 0.4892
Northern 0.0422 0.7698 0 24.0 0.08831λ 0.0209 0.4426
Volta 0.0359 0.1255 0 24.2 0.12087λ 0.0100 0.2684
Ghana 0.0480 0.1254 0 24.9 0.076λ 0.0185 0.4067
Note: λ and α are per 1, 000 population.
The values of k∗ for the rest of the regions are above the national value as is the case
of their corresponding values of H, except for Greater Accra region whose vaccination
threshold value approximates the national value of k∗ = 0.0185. Comparing the two
quantities, a simple linear regression analysis showed that there is a positive correlation
between H and k∗ with p-value less than 0.0001 and a correlation coefficient of 0.9599.
The result of the regression analysis and the coefficient of correlation indicate that the
herd immunity threshold value H increases as the vaccination threshold k∗ increases. This
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means that a region with high herd immunity threshold value requires a high vaccination
threshold and vice versa. For each of the regions, the value of Rv0 levels off way below
unity when the rate of vaccination k > k∗ is also in excess of the corresponding disease
contact rate β which can be seen in Figure 7.3. Clearly in Table 7.1, the disease contact
rate β for each region is greater than the corresponding threshold vaccination rates k∗.
The stabilisation of the value of Rv0 way below unity indicates that the disease is under
control in the population. This also indicates that if the rate of vaccination k was greater
than the contact rate β, the disease would be kept under control with time. It may not
therefore be sufficient to achieve a rate of vaccination of k > k∗, but also to ensure that
the rate of vaccination exceeds a value, which is likely to be the contact rate k > β, that
is equivalent to having achieved the herd immunity threshold of the population in order
to bring the disease under control.
7.6 Summary
Vaccination is the most important measure of intervention regarding prevention of hepati-
tis B in a population. In fact there is no cure for hepatitis B. Although acute hepatitis B
has no treatment, treatment of chronic hepatitis B keeps down viral replication and slows
progression of cirrhosis and liver damage, and thus sustains the life of an individual who
is chronically infected. Since the depth of the prevalence of hepatitis B is a function of
the depth of chronic infection in a population, it suffices to focus the attention of policy
makers on vaccination that targets a complete cut off of the disease from a population.
In view of this importance, a vaccination component was included in the original SEIR
model to examine the impact of vaccination on the transmission and spread of hepatitis
B in Ghana.
In the modified model, vaccinated susceptible individuals are progressed directly into the
recovered compartment by gaining immunity. The vaccine was assumed to have a 100%
efficacy and was not expected to wane within the period of study. All other conditions
pertaining to the original model were maintained in the new model, in addition to a vacci-
nation rate of k ≥ 0. Stability analysis of the vaccination model in Equation 7.2 indicated
that the modified model has a disease-free equilibrium state Qv0 = (
λ
λ+k , 0, 0) that is glob-
ally asymptotically stable when the epidemiological threshold parameter Rv0 ≤ 1 and a
unique endemic equilibrium state Q∗v = (s
∗, e∗, i∗) when Rv0 > 1. The stability analysis
further indicated that there exists a certain threshold value of the rate of vaccination k∗
such that if k > k∗, the threshold parameter Rv0 < 1 and the disease-free equilibrium
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Figure 7.3: Regional plots of basic reproduction number against vaccination rate
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state Qv0 is stable whilst the endemic equilibrium state Q
∗ is unstable; and if k < k∗,
Rv0 > 1 and the disease-free equilibrium state is unstable whilst the endemic equilibrium
state is stable. If k = k∗, Rv0 = 1 and there is a crossover point in the dynamics of the
model in Equation 7.2 where the disease-free and endemic equilibrium states coincide and
stability shifts between the two equilibrium states.
The impact of vaccination on the model was examined based on the impact of the rate
of vaccination k on the epidemiological threshold parameter Rv0. By holding the key
parameters β, γ, ν, α and λ in the vaccination model fixed at the values estimated for the
original model, the epidemiological threshold parameter Rv0 was varied for 0 ≤ k ≤ 1 and
a plot of Rv0 as a function of k was produced for Ghana as a whole and also for each of
the ten regions of Ghana. Variation in Rv0 with respect to k ≥ 0 traces a path resembling
a hyperbola starting from the value calculated for Rv0 in the original model and declining
until it flattens off way below unity when k is greater than the disease contact rate β for
Ghana and each of the ten regions of Ghana.
In conclusion, the vaccination model is well-posed in that any solution starting within the
set Σ remains in the set Σ. The system has a disease-free equilibrium state Qv0, that
is global asymptotically stable for Rv0 ≤ 1, and a unique endemic equilibrium state Q∗v
for Rv0 ≤ 1 and Rv0 > 1 respectively. Thus the disease is said to be decreasing in the
population when Rv0 ≤ 1 and is increasing when Rv0 > 1. An increase in the rate of
vaccination k in excess of a threshold value k∗ causes Rv0 to decline below unity, so that
the disease free equilibrium state Qv0 becomes stable and the disease is under control.
When k is greater than the disease contact rate β, the value of Rv0 levels off and disease
begins to die off in the population. A rate of vaccination k below the threshold value of
k∗ invariably causes Rv0 to remain above unity, so that the endemic equilibrium state is
stable and so the disease persists in the population. On the basis of the incidence data
used the following recommendation
1. An effective vaccination intervention regarding prevention and control of hepatitis
B in Ghana must target at the national disease contact rate of β = 0.0480, way
in excess of the national vaccination threshold value of k∗ = 0.0185 with regional
values as displayed in Figure 7.1. A vaccination rate greater than the threshold
value of the vaccination rate k∗ would cause the decline of the disease, but achieving
a vaccination rate in excess of the disease contact rate would adequately reduce
the contact rate β, vertical transmission rate α and the latent rate γ that have been
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indicated as driving the transmission and spread of hepatitis B and bring the disease
under control in Ghana.
2. A vaccination intervention must target at the following groups of people who are
often described as priority population [64, 156].
a. All women at child bearing age; in order to prevent transmission of hepatitis B
from mother to child. In this regard, screening of pregnant women for hepatitis
B is therefore crucial. Especially those who have been diagnosed with the
chronic infection must be referred to clinicians with the requisite expertise to
manage the disease condition during the entire period of gestation.
b. Infants soon after birth to prevent the newborn from contracting the disease
during birthing. After completing the course of vaccination, any child born to a
mother who is diagnosed of chronic hepatitis B must be referred to a paediatric
service with expertise in viral hepatitis to be assessed and managed for chronic
hepatitis B.
c. Unvaccinated adults who are at higher risk of infection. These include, but are
not limited to, men who have sex with men, sex workers, people who inject
drugs, partners and other household and intimate contacts of people diagnosed
with chronic hepatitis B infection, people in custodial settings and people di-
agnosed with HIV and/or hepatitis C infection.
d. Healthcare workers and emergency services workers.
e. People travelling to and from high prevalence countries and communities.





8.1 Summary of analysis and conclusion
High prevalence of hepatitis B and its associated burden, constitute a major public health
concern to Ghana in the Sub-Saharan Africa. In spite of the serious threat posed to
life and socioeconomic development, very little attention has been given to control and
prevent hepatitis B in this West African country. Apart from the significant gaps re-
ported in the evidence quantifying the burden of the disease on Ghana, there are many
misconceptions leading to stigmatisation and public outcry for national policy attention.
Although through WHO’s assistance, tools and resources are available for the prevention
and control of hepatitis B, Ghana faces challenges to build capacity towards extending
these interventions country-wide. These challenges as outlined in the GHS annual report
of 2014 include, but are not limited to, lack of a working policy on hepatitis B, lack of
health infrastructure and equipment, inadequate health financing and financial arrange-
ments, inadequate and disproportionate concentration of human resources for the health
sector, poor health information system and inadequate collaboration of the health sector
with other relevant sectors of the economy of Ghana.
As a contribution, this thesis sought to formulate an epidemiological model to study the
transmission and spread of hepatitis B in Ghana in order to provide knowledge to address
some of the challenges that constrain the implementation of available interventions. The
Hepatitis B incidence data used in the study were obtained from HIU and CHIMG of the
GHS. Due to inherent inadequacies in the collection and compilation of the hepatitis B
incidence data from a poorly-resourced country like Ghana, the national and regional data
were scaled by a factor corresponding to the regional disease reporting rates presented in
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the 2014 report of the GSS in order to make meaningful conclusions. The main objectives
of the study were:
1. To formulate an appropriate compartmental model, which incorporates the limita-
tions identified in models previously applied to hepatitis B in Ghana, to estimate
model parameters using hepatitis B incidence data from Ghana, and to use the model
to examine the transmission and spread of the pandemic of the disease in Ghana.
2. To subject the formulated model to sensitivity and stability analysis to assess its
veracity and to examine how robust the model will be in the face of perturbation.
3. To predict the future of the national hepatitis B pandemic on the basis of the model
developed and further examine the regional burden.
4. To investigate the impact of vaccination on the incidence and spread of hepatitis
B, and interpret the results in a way that will be useful to policy makers in taking
informed decisions towards the prevention and control of the disease in the public
health setting of an economy.
Generally, the disease was found to persist in Ghana with the disease intensity increasing
from south to north across the ten regions of the country. This trend of the disease was
found to have a significant association with poverty inequalities and health sector differ-
entials across the regions of the country. Other possible factors that are widely believed
to have impacted the disease pattern include, but are not limited to, the intra and interre-
gional and also international hepatitis B prevalence disparities mainly driven by migration
of the population. The introduction of a vaccination component in the model showed that
an increase in vaccination rate reduces the epidemiological threshold parameter way below
unity, indicative of a significant impact of vaccination on the transmission and spread of
hepatitis B in the population of Ghana. In the ensuing sections, a summary of discussions
and conclusion of results of the study, as well as, some limitations and recommendations
for possible future work on hepatitis B in Ghana and by extension the Sub-Saharan Africa
are presented.
8.1.1 The formulated compartmental model
A SEIR deterministic compartmental model that incorporates vertical transmission and
the proportionate mass-action term was employed to model the transmission and spread
of hepatitis B in Ghana. The model was defined by a system of ordinary differential
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equations which divided the population N(t) into S(t) - susceptible, E(t) - exposed, I(t) -
infectious and R(t) - recovered compartments such that S(t) +E(t) + I(t) +R(t) = N(t).
With a fraction α of births presenting with hepatitis B, birth fluxes of α(I + E) and
λN − α(I + E) due to vertical transmission were recruited into the model through the
exposed and susceptible compartments of the model respectively. In addition to vertical
transmission and the mass-action term, the model also addressed the latent period which
many studies have indicated as a very important feature in modelling hepatitis B.
The model has two equilibrium solutions, namely the disease-free Q0 = (1, 0, 0) and en-
demic equilibrium Q∗ = (s∗, e∗, i∗) states, where s∗, e∗ and i∗ are given in Equation 3.7.
Stability analysis of the model was in terms of the proportions of the population instead
of the absolute numbers and disease persistence meant uniformly persistence. Both the
proportionate and absolute numbers of the population can be used to predict the spread
of infectious diseases in a population in the same manner although the same outcome can-
not be guaranteed. The stability analysis indicated that the disease-free equilibrium state
Q0 is globally asymptotically stable when R0 ≤ 1 and unstable when R0 > 1, and the
unique endemic equilibrium state Q∗ is asymptotically stable when R0 > 1 and unstable
when R0 ≤ 1. A threshold contact rate β∗ defines a crossover point in the dynamical sys-
tem where stability shifts between the disease-free and endemic equilibrium states. The
disease-free equilibrium is stable whilst the endemic equilibrium is unstable if the contact
rate β < β∗, and the disease-free state is unstable whilst the endemic state is stable if
β > β∗. The endemic and the disease-free states coincide when β = β∗
8.1.2 Parameter estimation
The model parameters (β, γ, ν) ∈ R3+ were estimated by minimising the difference between
the observed and predicted data by a least squares approach. This nonlinear least squares
optimisation problem was solved using a hybrid method that combines a GA and a mod-
ified LM algorithm. As a nongradient randomised search method, the GA is applied first
to provide a global search of the solution space and identify solutions that are closed to
optimal. The LM algorithm, being a gradient method, is then applied to refine the solution
generated by the GA. The initial state variables (s0, e0, i0) were estimated as part of the
process of estimating the model parameters (β, γ, ν). This was because the initial state
variables were not known, and preliminary sensitivity analysis showed some variations in
the model predictions due to the choice of the initial conditions.
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8.1.3 Analysis of national and regional results
The initial state variables estimated for Ghana (national) were (s0, e0, i0) = (0.55, 0.40,
0.04), which indicated that at the start of the study in 2008, the estimated initial sus-
ceptible, exposed and infectious percentages of the population were 55%, 40% and 4%
respectively. Apart from Upper East and Central regions, the estimated initial state vari-
ables of the remaining regions were different compared with the national values. Whilst
the estimated initial susceptible proportions were either 0.55 or 0.5, the exposed and in-
fectious proportions ranged from 0.15 to 0.45 and 0.01 to 0.4 respectively. The national
parameters estimated for the contact rate β, latent rate γ and recovery rate ν for disease
transmission were 0.0480, 0.1254 and 0 respectively. The regional parameters estimated
for the contact rate β and latent rate γ range from 0.0359 to 0.1308 and 0.1234 to 0.7698
respectively whilst the recovery rate ν for all the regions was 0, except Western region
whose recovery rate was 0.0378. The 0 recovery rate indicated that none of the infected
persons was able to clear the disease at the acute stage as characterised by the dynamics
of the disease. Otherwise, the 0 recovery rate could also be a numerical artefact resulting
from with the estimation process.
From an initial state of (s0, e0, i0) = (0.55, 0.40, 0.04), the national disease is predicted to
stabilise at the endemic proportion equilibrium state Q∗ = (0.5741, 0.0706, 0.3553) with
time, where about 57.4% of the population are estimated to be susceptible, 7.1% are
exposed and 35% are infectious. A threshold contact rate of β∗ = 0.0276 was calculated,
where crossover of stability occurs between the endemic and the disease-free equilibrium
states. Furthermore, the national herd immunity threshold value was calculated as H =
0.4067 which indicated that if about 41% of the population was immune hepatitis B
in Ghana would be brought under control. The national value of the epidemiological
threshold parameter was calculated as R0 = 1.6854. Apart from Ashanti, Eastern and
Volta regions whose values of R0 were less than the national value, the remaining seven
regions had values that were greater than the national value. This indicated that the
intensity and burden of hepatitis B in Ashanti, Eastern and Volta regions is below the
national average, whilst it is higher in the case of the remaining seven regions. Greater
Accra and Brong Ahafo regions had an approximate value of R0 = 1.76 which indicated
a similar intensity and burden of hepatitis B in the two regions. The least and greatest
values of R0 = 1.3669 and R0 = 3.7212 were calculated for Volta and Upper East regions
respectively.
118
8.1. Summary of analysis and conclusion
The national and regional values of the epidemiological threshold parameters R0 calculated
were all greater than unity, which indicated that hepatitis B persists in all ten regions of
Ghana. A percentage difference of about 172%, representing a range of 2.3543, between
the least and the greatest regional epidemiological threshold parameters R0 shows signifi-
cant variability in the values, which indicated that there are significant disease differentials
across the regions of Ghana. These disease disparities obviously come with different dis-
ease burdens across the ten regions of the country and certainly require different control
strategies. Interestingly, the calculated regional epidemiological threshold parameters R0
and the corresponding regional herd immunity threshold values H are linearly related.
Thus regions with higher values of R0, which signifies higher transmission and spread of
hepatitis B, require higher proportions H of the population to be immune in order to
control the disease. With the exception of the Central and Western regions, the values
of R0 for the regions show an increasing trend from south to the north across Ghana.
This indicated that the transmission and spread of hepatitis B and its associated burden
increase from south to the north across the regions of the country, although the Central
and Western regions deviate from the trend.
The threshold parameter R0 increases as the vertical transmission α and contact β rates
increase, although α has a larger impact on R0 compared to β. This indicated that vertical
transmission has a larger impact on the disease transmission compared to transmission
through horizontal routes. Reducing transmission of hepatitis B from mother to child
would have much more impact on controlling the disease, although the other routes of
transmission must not be neglected. Variation of R0 with respect to the latent γ and
recovery ν rates is hyperbolic in shape. As γ increases, R0 increases until it peaks above
unity and levels off after γ = 0.4. The latent period is therefore important in modelling
hepatitis B in the population due to its impact on R0. As ν increases however, R0 drops
until after ν = 0.4 when it levels off below unity. This indicated that with an intervention
that adequately increases the recovery rate would reduce the disease transmission and
spread in the population.
The quantum of change in each of the model parameters from the baseline values, needed
to shift stability from the endemic state to the disease-free state, indicated that the contact
rate β requires the least change compared to the birth rate λ, latent rate γ and vertical
transmission rate α. Furthermore, the rate of change of endemic proportion variables
Q∗ = (s∗, e∗, i∗) with respect to the model parameters, indicated that unit increases in
contact β, latent γ and vertical transmission α rates increase the infectious population and
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decrease the susceptible population and tend to shift model stability towards the endemic
state Q∗. A unit increase in α has a larger impact on the shift in equilibrium towards
the endemic state Q∗ compared to β and γ. Unit increases in birth rate λ and recovery
rate ν however increase the susceptible population and decrease the infectious population
and tend to shift stability towards the disease-free state Q0. A higher birth rate is not
desirable due to its socioeconomic and cultural implications on the society. However, a
greater proportion of the population can be immunised to disrupt many chains of infection
and reduce the likelihood of a contact with an infectious individual to keep the disease
from spreading. A policy intervention to control the transmission and spread of hepatitis
B in the population is recommended to aim at reducing the contact, vertical transmission
and the latent rates. A recommended intervention that is considered to be optimal is
vaccination backed by treatment of chronic hepatitis B.
A simple regression analysis performed on the regional values of R0 and H, poverty head-
count and the endemic proportions variables s∗, e∗ and i∗ showed a positive correlation
between poverty and the threshold values R0 and H, a positive correlation between i
∗
and the threshold values R0 and H, and a negative correlation between s
∗ and i∗. This
indicated that regions with high threshold values of R0 and H tend to have high poverty
levels and high proportions of infectious population, and therefore increased transmission
and spread of hepatitis B. This result also indicated that regions with high levels of infec-
tiousness tend to have low susceptible proportions as expected. In relation to the GSS’s
living standard survey report of 2010, which indicated that poverty levels increase from
south to north of Ghana, it can be concluded that transmission and spread of hepatitis
B generally increases from south to north across the regions of Ghana. Interregional and
international hepatitis B prevalence disparities is another phenomenon that potentially
impact the pattern of transmission and spread of the disease, mainly through migration
of people, across the regions of the country.
8.1.4 The vaccination model
In the absence of complete cure, vaccination is the single most effective intervention with
respect to the control of hepatitis B [12, 148, 153, 154]. To examine the impact of this
intervention on the transmission and spread of hepatitis B in Ghana, the original SEIR
model in Equation 3.6 was modified to include a vaccination component that directly
transfers the vaccinated susceptible population into the immune class R of the model at the
rate k ≥ 0. Stability analysis of the model indicated that the disease-free equilibrium state
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is globally asymptotically stable when its epidemiological threshold parameter Rv0 ≤ 1
and unstable when Rv0 > 1, whilst the unique endemic equilibrium state is stable when
Rv0 > 1 and unstable when Rv0 ≤ 1. The model has a threshold value of k∗ such
that if the vaccination rate is equal to k∗, then Rv0 = 1 and there is stability crossover
between the disease-free and the endemic equilibrium states. If k > k∗, then Rv0 < 1
and the disease-free equilibrium state is globally asymptotically stable whilst the endemic
equilibrium state is unstable, and if k < k∗, Rv0 > 1 and the unique endemic equilibrium
Q∗v is asymptotically stable whilst the disease-free equilibrium state Qv0 is unstable.
In the national and all the regional cases, the plots of Rv0 as a function of k showed a
hyperbolic relationship consistent with Equation 7.8. At k = 0 when there is no vaccination
intervention, the model is reduced to the original model in Equation 3.6 and so the value
of Rv0 = R0. As k was increased from 0 to 1, the value of Rv0 dropped from the value of
R0 until it levelled off at a value less than unity when the value of k exceeded the disease
contact rate β. This indicated the disease would be brought under control, if the rate of
vaccination k was increased in excess of the contact rate β.
8.2 Policy recommendation
The discussions and conclusions indicate that hepatitis B persists in Ghana. Vertical
transmission was found to be the major driver of the transmission and spread of the
disease in Ghana, although transmission through horizontal routes cannot be neglected.
The results of the study are indicative of the fact that hepatitis B can be prevented through
vaccination. Other studies have indicated that vaccination, when backed by treatment of
chronic hepatitis, gives the best result [90]. Notwithstanding the competing priorities and
short term focus of policy makers and/or governments, the following recommendations are
made in line with the key findings of this study to inform policy formulation and guidance
for the control and prevention of hepatitis B in Ghana. In all of these considerations, cost
remains a key barrier especially in the acquisition of vaccines and antiviral therapy and
other logistics and resources [156, 157].
The key to achieving significant successes in prevention, treatment and control is to for-
mulate a national action plan, in a framework of a strategic policy, that reflects the
experience and aspirations of the affected people at the community, regional and national
levels [156, 157, 158]. This requires a broad consultative process led by a team of experts
from the healthcare sector and involving relevant governmental agencies and NGOs, and a
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cross-section of the affected people. It also requires identification and collection of quality
data that adequately describe the public health situation, as well as the personal impact
of hepatitis B on the population of Ghana [156, 157]. The goals of the national action
plan must therefore include, but not be limited to, reducing transmission, morbidity and
mortality and minimise the personal and social impact of persons living with hepatitis B
[156, 157, 158, 159].
8.2.1 Prevention of hepatitis B transmission
In the absence of complete cure to hepatitis B, prevention is the most important consider-
ation for the control of the disease [157]. Unlike other viral hepatitis infections, HIV and
sexually transmitted infections (STI) that can be prevented by adopting and maintaining
protective behaviours, the most effective means to prevent the transmission of hepatitis B
is vaccination. Vaccination is particularly important in newborns and children, because of
the risk of vertical transmission and disease progression to the chronic stage with its asso-
ciated complications [10, 35]. Nevertheless, the impact of vaccination on adults who are
at higher risk of infection through other routes of transmission cannot be overemphasised.
Childhood vaccination becomes relevant when it is included in the national immunisation
programme and is universally accessible [156, 157, 160]. In view of the above and on the
basis of the findings of this study, it is recommended that:
1. On the basis of the parameters estimated for the model, given the hepatitis B inci-
dence dataset used in the study
i. Vertical transmission rate has a greater impact on transmission and spread of
hepatitis B in Ghana compared to horizontal transmission (routes other than
vertical transmission). Hence an immunisation intervention targeted at reduc-
ing transmission of hepatitis B from mother to child (vertical transmission)
will have much more impact on controlling the disease compared to horizontal
transmission, although horizontal transmission must not be neglected.
ii. A national vaccination rate exceeding a threshold value of k∗ = 0.0185, with
regional threshold values displayed in Table 7.1, will cause the transmission and
spread of hepatitis B to decline in Ghana.
iii. Achieving a national herd immunity threshold value of H = 0.4067, with the




iv. Any immunisation intervention targeted at reducing the transmission and spread
of hepatitis B in Ghana should aim at reducing the contact rate to below a na-
tional threshold value of β∗ = 0.0276.
2. A comprehensive national vaccination programme is tailored to cover the following
as a matter of priority [156, 157, 160].
i. All women at child bearing age including pregnant women, to prevent mother-
to-child transmission. Screening of pregnant women for hepatitis B is therefore
crucial and those who are diagnosed with the chronic infection must be referred
to clinicians with the requisite expertise to manage the disease condition during
the entire period of gestation.
ii. Infants soon after birth, preferably within 24 hours, to prevent the newborn
from contracting the disease during birthing; Any child born to a mother who
is diagnosed of chronic hepatitis B must have the HBV vaccine in conjunction
with the hepatitis B immune globulin (HBIG), to reduce the likelihood of
contracting the disease at birth. Such infants must be referred immediately to
a paediatric service with expertise in viral hepatitis to be assessed and managed
for chronic hepatitis B.
iii. Unvaccinated adults especially those who are at higher risk of infection, to pre-
vent horizontal transmission of hepatitis B; These include, but are not limited
to:
– Men who have sex with men, sex workers, people who inject drugs, partners
and other household and intimate contacts of people diagnosed with chronic
hepatitis B infection, people in custodial settings and people diagnosed with
HIV and/or hepatitis C infection.
– Healthcare workers and emergency services workers.
– People travelling to and from high prevalence countries and communities.
– Vulnerable populations, including the homeless and people with mental
health issues.
3. Routine mass screening and laboratory diagnosis be made affordable and accessible
through funding from the National Health Insurance Scheme (NHIS) and provision
of well-resourced laboratories at the community, district and regional levels. This
should include provision of opportunistic hepatitis B testing and vaccination [156,
157, 160]:
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i For pregnant women during antenatal care.
ii. For young people who may have missed vaccination at birth.
iii. For adults at their routine health checks.
iv. In association with recruitment activities involving public institutions as part
of medical examination requirements.
v. For health care professionals and emergency services workers.
vi. At the instance of clinicians in primary healthcare at all levels of health delivery.
4. Research, public advocacy and general education on hepatitis B should be promoted
at the community, regional and national levels to [156, 157, 160]:
i. Provide an evidence base for effective public health attention and response to
the disease pandemic.
ii. Increase the understanding of hepatitis B and the support available to persons
who are infected, in order to reduce the burden of the disease and improve
health outcomes.
iii. Increase knowledge among sex workers and people who inject drugs.
iv. Increase public awareness and reduce misconception about the disease that
leads to stigmatisation and discrimination against infected persons.
v. Develop and strengthen effective collaboration between communities and all
levels of government and NGOs, as well as among medical, healthcare, research
and scientific communities at local, regional and national levels.
8.2.2 Treatment of chronic hepatitis B
Essentially, a vaccination programme backed by a treatment regimen for chronic hepatitis
B is highly recommended as the optimal strategy to control transmission and spread of
hepatitis B [90, 156, 157, 158, 159]. Although there is no specific treatment for acute
hepatitis B, there are effective antiviral drugs for treatment of chronic hepatitis B that
keep down viral replications and reduce risk of progression to liver disease and death of
an infected person [157]. Persons who are diagnosed with chronic hepatitis B should be
referred to designated health facilities for clinical management and treatment. A key bar-
rier to treatment for a resource-constrained setting like Ghana, has always been the cost of
medicines, diagnostic and monitoring facilities and staff. The following recommendations
are made based on the admission by the GHS and MOHG in annual reports of 2011 and
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2014 regarding challenges of inadequate provision and supply of standard health facilities,
staff and logistics across the country, especially in the vast rural settings [16, 59]:
1. In view of the high cost of treatment of chronic hepatitis B, it is recommended that
acquisition of antiviral drugs is funded through the NHIS and with support from
NGOs and other developing partners.
2. The complexity of the HBV makes treatment regimens for chronic hepatitis B of-
ten complicated [156, 157]. Thus, the level of awareness and knowledge of general
practitioners and primary care doctors needs consistent improvement and upgrading
regarding management of persons with hepatitis B. All healthcare workers involved
in chronic hepatitis B care must be given a standardised training in administering
the antiviral therapy in addition to regular in-service training and seminars to keep
them abreast with options for treatment of chronic hepatitis B.
3. The government, with support from its developing partners, must provide fund-
ing for adequate provision and resourcing of health facilities at all levels of service
delivery for chronic hepatitis B care and treatment. This must provide increased ac-
cess to adequate clinic infrastructure, healthcare staff, a referral system, laboratory
and diagnostic services, reliable and affordable supply of antiviral medicines to en-
hance disease surveillance and ensure effective ways to collect and compile adequate
database that would facilitate monitoring and follow-ups for treatment and care of
hepatitis B at all levels especially in the poor communities.
8.3 Limitations of study
The study sought to formulate an epidemiological model based on hepatitis B incidence
data, to examine the transmission and spread of hepatitis B pandemic in Ghana. The
study was conducted to achieve a set of targeted objectives listed in Section 1.6 that
served as a guide. Although the set targets were achieved, there were some constraints
that could potentially have had some adverse effect on the outcomes obtained. These
limitations include the following:
1. The hepatitis B incidence data used in the study constitute only cases that had been
reported to the RIUs and CHIMs of the GHS. The GHS’s admission of lack of the
needed tools and personnel to effectively collect and compile data on viral hepatitis
is an indication of underestimation and under-reporting of the true incidence cases
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of hepatitis B in Ghana. In Ghana, the existing health emergency preparedness
and response plan is targeted at communicable diseases like malaria, HIV and more
recently ebola and given high national attention at the expense of equally threatening
diseases like viral hepatitis. A survey on risk communication of health emergency
conducted indicated that most of the information is churned out by media [71].
These are significant gaps in the evidence quantifying the burden of hepatitis B
on individuals, the healthcare system and the community. Although the data were
scaled, this limitation could potentially have affected the conclusions of this work.
2. Hepatitis incidence for cases of persons aged< 5 were assumed to represent vertical
transmission and were used in the computation of the vertical transmission frac-
tion α in the model [23]. The risk of vertical transmission of HBV, especially in
poorly-resourced settings like Ghana, is quite a complicated issue. Although the
standard way of measuring the risk of vertical transmission largely depends on ma-
ternal HBeAg positivity, it is acknowledged that the size of maternal viral load is also
an important determinant [7, 93]. Vertical transmission of HBV most likely occurs
during birth due to the nature of the virus, although it may also occur postpartum
[7, 93]. In the vast rural settings of Sub-Saharan Africa and in particular Ghana,
screening and testing of neonates and mothers for HBV is not a mandatory health
policy due to lack of a requisite health facility and/or the unaffordable cost of service
[102]. HBV infection of these categories of persons most likely would not normally
be detected immediately after birth as routinely done in the developed world [7, 93].
Such cases may be reported and captured in the national database later during early
childhood and categorised based on some medical history as indicated in [102]. This
is noted as a constraint that could potentially have affected the findings of this work.
8.4 Research contribution
Although theoretical analysis of deterministic compartmental modelling and its application
to infectious disease epidemiology has been widely studied, application of this modelling
technique to specific incidence data to study a particular disease epidemiology in a popu-
lation is not common, especially, in the Sub-Saharan Africa and in particular Ghana. A
review of literature indicated a few applications of the SIR deterministic compartmental
modelling to hepatitis B incidence data in Ghana, that neglect the latent period. In this
study, the latent period was found to be important in modelling the dynamics of hepatitis
B in a population and cannot be ignored. Using the SEIR model, the findings indicated
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that an increase in the latent rate, relative to the other parameters of the model, tend
to increase the infected population and a decrease in the susceptible population. The
findings also indicated that the epidemiological threshold parameter R0 is sensitive to the
latent rate. An increase in the latent rate, relative to the other model parameters, tend to
increase R0 until it stabilises above unity, an indication that the disease persists in a pop-
ulation. Apart from the latent period, the commonly used pseudo mass-action incidence
factor βSI was also replaced with the standard proportionate incidence term βSIN which
is more appropriate in dealing with a population that varies in size with time [75, 76].
Vertical transmission of hepatitis B is another important area that has not been ade-
quately studied, particularly with the application of deterministic compartment modelling
to existing infectious disease data in the Sub-Saharan African region and Ghana. Clinical
surveys and systematic reviews of the global burden of hepatitis B have indicated that
vertical transmission is a major route of transmission of hepatitis B in the endemic regions.
In this study, birth fluxes of α(I + E) and λN − α(I + E), where α is the fraction of the
infected population due to vertical transmission, was introduced into the SEIR model to
examine the impact of vertical transmission on the population as applied to a hepatitis
B incidence data. The findings indicated that the model stability and so the disease per-
sistence was most sensitive to the vertical transmission rate, relative to the other model
parameters.
For disease modelling involving deterministic compartment models, estimation of param-
eters is an important process leading to a full determination of the health outcomes. It
is for this reason that an application of a hybrid optimisation process, which combined a
nongradient method (GA) and a gradient method (LM algorithm), is unique and transpar-
ent in the parameter estimation of this study. Whilst the GA provides a global search of
the solution space to identify solutions which are assumed to be close to optimal, the LM
algorithm refines the solution generated by the GA by increasing the likelihood of approx-
imating the optimal solution. Based on the estimated parameters, the findings indicated
that hepatitis B persists in Ghana and the intensity and burden increase from south to
north across the regions of the country. The incidence and spread is higher in poorer
communities compared to the nonpoor due to health sector differentials from south to
north across the regions of Ghana. Prevalence disparities along interregional and interna-
tional boundaries also potentially impacts the hepatitis B epidemiology in the population
of Ghana.
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8.5 Recommendation for future work
The study applied a SEIR deterministic compartmental model with vertical transmis-
sion to existing incidence data, to examine the transmission and spread of hepatitis B in
Ghana. The deterministic model considered the individuals in the population to be more
interdependent and the health outcomes were fully determined by the estimated param-
eter values and the initial conditions without any element of randomness. A stochastic
approach which considers the population as independent units of observation, may be em-
ployed to estimate the probability distribution of potential health outcomes based on the
random variations of the input data with time. The element of randomness and chance
fluctuations in such a process could be modelled using time series or maximum likelihood
estimation processes, to mention but a few.
The global epidemiology of HBV is changing partly because of the impact of migration
between high- and low-prevalence populations. Migration across health and disease differ-
entials significantly influences the epidemiology of hepatitis B globally and in particular the
recipient nations. This study discussed migration impact on hepatitis B in the population
of Ghana on the basis of prevalence differentials between regions and with neighbouring
countries, but did not incorporate migration in the model due to lack of data on hepati-
tis B related to migration. The SEIR model could be modified to include a migration
compartment to examine migration effect of hepatitis B on the Ghanaian population if
adequate data is available.
A modification of the SEIR model could also be made to split the infectious class into
acute and chronic compartments to examine the effects of each of these two stages of hep-
atitis B on the model and also in a population. Age is an important factor in determining
the risk of progression to chronic hepatitis B and that could be studied using a SEIR
model. Another possible area of study would be to examine the impact of HBV coinfec-
tion with other blood borne diseases like HIV/AIDS, HCV and HDV in a population.
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and HT Banks. The estimation of the effective reproductive number from disease
outbreak data. Math Biosci Eng, 6(2):261–282, 2009.
136
Bibliography
[84] Klaus Dietz. The estimation of the basic reproduction number for infectious diseases.
Statistical methods in medical research, 2(1):23–41, 1993.
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Akmatov, Alexander Krämer, and Ralf Reintjes. Changing epidemiology of hepati-
tis B and migration: A comparison of six northern and North-Western European
countries. The European Journal of Public Health, 23(4):642–647, 2012.
[151] Susannah Amiteye. African immigrants at increased risk for hepatitis B: Url
=http://www.hiv.gov/blog/african-immigrants-at-increased-risk-for
-hepatitis-b. Accessed on 3 April 2015.
[152] WHO National Centers for Disease Control& Prevention and Gary Schatz c. Hep-
atitis B global infection rates reviewed 2006: Url=http://www.pkids.org
/files/pdf/phr/02-09globalhbv.pdf, Accessed on 2 february 2015.
[153] WHO. Hepatitis B fact sheet: Url=http:/http://www.who.int/mediacentre/
factsheets/fs204/en/. Accessed on 12 June 2017.
[154] Tanja Karvonen, Kari Auranen, Markku Kuusi, and Tuija Leino. Epidemiology of




[155] C Alina and T Ionela-Rodica. Descartes’ rule of signs. Universitatii Maritime
Constanta. Analele, 12:225, 2011.
[156] Australia Department of Health. National hepatitis B strategy 2014–2017:
url=http://www.health.gov.au/internet/main/publishing.nsf/content/ohp-bbvs-hepb.
2014, Online ISBN: 978-1-74186-165-5, Accessed on 10 January 2018.
[157] WHO. Prevention and control of viral hepatitis infection: A strategy for global
action): url=http://http://www.paho.org/hq/index.php?option=com docman
&task=doc view&gid=18000&Itemid=270&lang=en. Accessed on 10 April 2016.
[158] Cindy M Weinbaum, Ian Williams, Eric E Mast, Susan A Wang, Lyn Finelli, An-
nemarie Wasley, Stephanie M Neitzel, John W Ward, Centers for Disease Control,
Prevention (CDC), et al. Recommendations for identification and public health
management of persons with chronic hepatitis B virus infection. MMWR Recomm
Rep, 57(RR-8):1–20, 2008.
[159] Daniel Lavanchy. Hepatitis B virus epidemiology, disease burden, treatment, and
current and emerging prevention and control measures. Journal of viral hepatitis,
11(2):97–107, 2004.
[160] Stephen Locarnini, Angelos Hatzakis, Ding-Shinn Chen, and Anna Lok. Strategies







% Combined Genetic Algorithm followed by Gradient Approach.






%temp=xlsread('Artificial_Data_I_incidence.xlsx '); % Change
the IC.
time = [0; temp (:,1)]'; % Insert the zeros time.
sick=zeros(1,size(temp ,1) +1);
for i=2: size(temp ,1)+1
time(i)=time(i)/12; % Convert time to units of years.












y0=[0.6 0.35 0.05]; % Initial susceptible , exposed and
infectious fractions
%respectively.
% Also need to consider the range for the parameter exponents
in
% 'gene_to_values.m' and the ga input arguments.
[P, best ,best_val] = ga_SR (100, 300, 0.01, 150 ,0.1); % Note
that second
% argument must be a
multiple of 3.






[t, y] = ode15s('seir ', [0 T_max], y0);
% Need to calculate the incidence h and population size N.
Use the Trapezoid rule and




N(j)=N_current * (1+lambda -mu)^(t(j) -7); % 7 - period of
study in years
end














plot(t, h, time , sick , 'rs')
figure
plot(t, y(:,1), 'b', t, y(:,2), 'r', t, y(:,3), 'g')
% Gradient Method
options = statset('Display ', 'iter ','TolFun ' ,10^( -16));
[values ,r] = nlinfit_nneg_v2(time , sick , 'infection ', [beta
gamma nu], options);




% Set beta and delta to the values found by nlinfit
beta = values (1);
gamma = values (2);
nu = values (3);
% Evaluate the ODE with the new values for beta and delta
[t, y] = ode15s('seir ', [0 T_max], y0);
% Need to calculate the incidence h and population size N.
Use the Trapezoid rule and




N(j)=N_current * (1+lambda -mu)^(t(j) -7);
end













% Display the results
figure
plot(t, h, time , sick , 'r*')
figure
plot(t, y(:,1), 'b', t, y(:,2), 'r', t, y(:,3), 'g')
A.2 Squared error
% squared_error(data_time , data_points , fn_time , fn_points)
% Calculates the squared error between a set of data points
and a
% series of points representing a function output.
% Inputs:
% data_time - A 1D array containing the time points of
the data
% data_points - A 1D array of the data values
% fit_time - A 1D array of the time points for the
function output
% fit_points - A 1D array of the function values
% Output:
% error = the sum of the squared residuals of the data vs.
the function
function error = squared_error(data_time , data_points ,
fn_time , fn_points)
% Intepolate the fit to match the time points of the data
fn_values = interp1(fn_time , fn_points , data_time);
% Square the error values and sum them up
error = sum(( fn_values - data_points).^2);
A.3 SEIR
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% seir.m
% Implements an SEIR infection model
% dS/dt = lambda N - alpha (I + E) - beta SI/N - mu S
% dE/dt = beta SI/N + alpha (I + E) - mu E - gamma E
% dI/dt = gamma E - mu I - nu I
% dR/dt = nu I - mu R, Not needed since S+E+I+R=1
% Inputs:
% t - Time variable: not used here because our equation
% is independent of time , or 'autonomous '.
% x - Independent variable: this contains four
% populations (S, E, I, and R)
% Output:
% dx - First derivative: the rate of change of the
populations
function dx = seir(t, x)
global lambda alpha beta mu gamma nu;
dx = [0; 0; 0];
dx(1) = lambda - alpha * (x(3) + x(2)) -beta * x(1) * x(3)
- mu *x(1) - x(1) * (lambda - mu);
dx(2) = beta * x(1) * x(3) + alpha * (x(3) + x(2)) - mu * x
(2) - gamma * x(2) - x(2) * (lambda - mu);
dx(3) = gamma * x(2) - mu * x(3) - nu * x(3) - x(3) * (
lambda - mu);
A.4 Nonlinear fit
function [beta ,r,J,Sigma ,mse] = nlinfit_nneg_v2(X,y,model ,
beta ,options)
% Version 2 corrects an error in the original nneg
modification.
if nargin < 4
error('stats:nlinfit:TooFewInputs ','NLINFIT requires four
input arguments.');
elseif ~isvector(y)





if nargin < 5
options = statset('nlinfit ');
else
options = statset(statset('nlinfit '), options);
end
% Check sizes of the model function 's outputs while
initializing the fitted




yfit = model(beta ,X);
catch
[errMsg ,errID] = lasterr;
if isa(model , 'inline ')
error('stats:nlinfit:ModelFunctionError ',...
['The inline model function generated the
following ', ...
'error :\n%s'], errMsg);
elseif strcmp('MATLAB:UndefinedFunction ', errID) ...
&& ~isempty(strfind(errMsg , func2str(model)))
error('stats:nlinfit:ModelFunctionNotFound ',...











'MODELFUN should return a vector of fitted values
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the same length as Y.');
end
% Find NaNs in either the responses or in the fitted values
at the starting
% point. Since X is allowed to be anything , we can 't just
check for rows
% with NaNs , so checking yhat is the appropriate thing.
Those positions in
% the fit will be ignored as missing values. NaNs that show
up anywhere
% else during iteration will be treated as bad values.
nans = (isnan(y(:)) | isnan(yfit (:))); % a col vector





funValCheck = strcmp(options.FunValCheck , 'on');
if funValCheck && ~isfinite(sse), checkFunVals(r); end
% Set the level of display
switch options.Display
case 'off', verbose = 0;
case 'notify ', verbose = 1;
case 'final ', verbose = 2;




% display format for non -robust fit
if verbose > 2 % iter
disp(' ');
disp(' Norm of Norm of');






[beta ,J,lsiter ,cause] = LMfit(X,y, model ,beta ,options ,
verbose ,maxiter);
else
% Do a preliminary fit just to get residuals and leverage
from the
% least squares coefficient. We won 't count this against
the iteration
% limit.
[beta_ls ,J] = LMfit(X,y, model ,beta ,options ,0,maxiter);
res = y - model(beta_ls ,X);
res(isnan(res)) = [];
ols_s = norm(res) / sqrt(max(1,length(res)-length(beta)))
;
% display format for robust fit
% Please note there are two loops for robust fit. It
would be very
% confusing if we display all iteration results. Instead ,
only the last
% step of each inner loop (LM fit) will be output.
if verbose > 2 % iter
disp(' ');
disp('Displaying iterations that re-calculate the
robust weights ');
disp(' ');
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warning('stats:nlinfit:IterationLimitExceeded ', ...
'Iteration limit exceeded. Returning results
from final iteration.');
case 'tolx '
if verbose > 1 % 'final ' or 'iter '
disp('Iterations terminated: relative norm of the
current step is less than OPTIONS.TolX ');
end
case 'tolfun '
if verbose > 1 % 'final ' or 'iter '
disp('Iterations terminated: relative change in




'Unable to find a step that will decrease SSE
. Returning results from last iteration.'
);
end
% If the Jacobian is ill -conditioned , then two parameters are
probably
% aliased and the estimates will be highly correlated.
Prediction at new x
% values not in the same column space is dubious. NLPARCI
will have
% trouble computing CIs because the inverse of J'*J is
difficult to get
% accurately. NLPREDCI will have the same difficulty , and in
addition ,
% will in effect end up taking the difference of two very
large , but nearly
% equal , variance and covariance terms , lose precision , and
so the




if n <= p
warning('stats:nlinfit:Overparameterized ', ...
['The model is overparameterized , and model
parameters are not\n' ...
'identifiable. You will not be able to compute
confidence or ' ...
'prediction\nintervals , and you should use
caution in making predictions.']);
elseif condest(R) > 1/( eps(class(beta)))^(1/2)
warning('stats:nlinfit:IllConditionedJacobian ', ...
['The Jacobian at the solution is ill -conditioned
, and some\n' ...
'model parameters may not be estimated well (
they are not ' ...
'identifiable).\nUse caution in making
predictions.']);
end
if nargout > 1
% Return residuals and Jacobian that have missing values
where needed.
yfit = model(beta ,X);
r = y - yfit;
JJ(~nans ,:) = J;
JJ(nans ,:) = NaN;
J = JJ;
end
if nargout > 3
if strcmp(options.Robust ,'off')
% We could estimate the population variance and the
covariance matrix
% for beta here as
mse = sum(abs(r(~nans)).^2)/(n-p);
else
mse = sig .^2;
end
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Rinv = inv(R);
Sigma = Rinv*Rinv '*mse;
end
%-----------------------------------------------------------
function [beta ,J,iter ,cause] = LMfit(X,y, model ,beta ,options
,verbose ,maxiter)
% Levenberg -Marquardt algorithm for nonlinear regression




funValCheck = strcmp(options.FunValCheck , 'on');
% Set initial weight for LM algorithm.
lambda = .01;
% Set the iteration step
sqrteps = sqrt(eps(class(beta)));
p = numel(beta);
% treatment for nans
yfit = model(beta ,X);
r = y(:) - yfit (:);







while iter < maxiter
iter = iter + 1;
betaold = beta;
sseold = sse;
% Compute a finite difference approximation to the
Jacobian
J = getjacobian(beta ,fdiffstep ,model ,X,yfit ,nans);
% Levenberg -Marquardt step: inv(J'*J+lambda*D)*J'*r
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diagJtJ = sum(abs(J).^2, 1);
if funValCheck && ~all(isfinite(diagJtJ)), checkFunVals(J
(:)); end
Jplus = [J; diag(sqrt(lambda*diagJtJ))];
rplus = [r; zerosp ];
step = Jplus \ rplus;
% Check if current beta contains any zero values and step
will force
% the new beta to violate non -negativity. If it does then
we
% modify the step direction to essentially project onto
the boundary by
% making the component in the relevant direction 0.
alpha_b=ones(size(beta ,2) ,1);
for j=1: size(beta ,2)
if beta(j)+step(j)<0
alpha_b(j)=max(beta(j) ,0)/abs(step(j));
if alpha_b(j)<0 || alpha_b(j)>1





% If the point is on the boundary we need to allow
the algorithm to
% move along the boundary.
step_temp=step;
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% If the point is off the boundary then we simply
scale back the
% search direction so that it stops on the boundary.
step1=min(alpha_b)*step;
end
beta (:) = max(beta (:) + step1 , zeros(size(beta ,2),size(
beta ,1)));
%beta (:) = beta (:) + step;
% Evaluate the fitted values at the new coefficients and
% compute the residuals and the SSE.
yfit = model(beta ,X);
r = y(:) - yfit (:);
r(nans) = [];
sse = r'*r;
if funValCheck && ~isfinite(sse), checkFunVals(r); end
% If the LM step decreased the SSE , decrease lambda to
downweight the
% steepest descent direction. Prevent underflowing to
zero after many
% successful steps; smaller than eps is effectively zero
anyway.
if sse < sseold
lambda = max (0.1* lambda ,eps);
% If the LM step increased the SSE , repeatedly increase
lambda to
% upweight the steepest descent direction and decrease
the step size
% until we get a step that does decrease SSE.
else
while sse > sseold
lambda = 10* lambda;






Jplus = [J; diag(sqrt(lambda*sum(J.^2,1)))];
step = Jplus \ rplus;
% Check if current beta contains any zero values
and step will force
% the new beta to violate non -negativity. If it
does then we
% modify the step direction to essentially
project onto the boundary by
% making the component in the relevant direction
0.
alpha_b=ones(size(beta ,2) ,1);
for j=1: size(beta ,2)
if beta(j)+step(j)<0
alpha_b(j)=max(beta(j) ,0)/abs(step(j));
if alpha_b(j)<0 || alpha_b(j)>1





% If the point is on the boundary we need to
allow the algorithm to
% move along the boundary.
step_temp=step;








% If the point is off the boundary then we
simply scale back the
% search direction so that it stops on the
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beta (:) = max(betaold (:) + step1 , zeros(size(beta
,2),size(beta ,1)));
yfit = model(beta ,X);
r = y(:) - yfit (:);
r(nans) = [];
sse = r'*r;




if verbose > 2 % iter
disp(sprintf(' %6d %12g %12g %12g', ...
iter ,sse ,norm (2*r'*J),norm(step)));
end
% Check step size and change in SSE for convergence.
if norm(step) < betatol *( sqrteps+norm(beta))
cause = 'tolx ';
break
elseif abs(sse -sseold) <= rtol*sse
cause = 'tolfun ';
break
elseif breakOut




if (iter >= maxiter)









'MODELFUN has returned Inf or NaN values.');
end
%-------------------------------------------------------
function [beta ,J,sig ,cause ]= nlrobustfit(x,y,beta ,model ,J,
ols_s ,options ,verbose ,maxiter)
% nonlinear robust fit
tune = options.Tune;
WgtFun = options.WgtFun;




yfit = model(beta ,x);




% Adjust residuals using leverage , as advised by DuMouchel &
O'Brien
% Compute leverage based on X, the Jacobian
[Q,ignore ]=qr(J,0);
h = min (.9999 , sum(Q.*Q,2));
% Compute adjustment factor
adjfactor = 1 ./ sqrt(1-h);
radj = r .* adjfactor;
% If we get a perfect or near perfect fit , the whole idea of
finding
% outliers by comparing them to the residual standard
deviation becomes
% difficult. We 'll deal with that by never allowing our
estimate of the
% standard deviation of the error term to get below a value
that is a small
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% fraction of the standard deviation of the raw response
values.




% Main loop of repeated nonlinear fits , adjust weights each
time
totiter = 0;
w = repmat(NaN ,size(y));
while maxiter >0
beta0=beta;
s = madsigma(radj , length(beta)); % robust estimate of
sigma for residual
% Compute robust weights based on current residuals
w(ok) = feval(WgtFun , radj/(max(s,tiny_s)*tune));
% this is the weighted nlinfit
sw = sqrt(w);
yw = y .* sw;
modelw = @(b,x) sqrt(w).* model(b,x);
[beta ,J1 ,lsiter ,cause] = LMfit(x,yw,modelw ,beta0 ,options
,0,maxiter); % 6th arg always silences display
totiter = totiter + lsiter;
maxiter = maxiter - lsiter;
yfit = model(beta ,x);
fullr = y - yfit;
r = fullr(ok);
radj = r .* adjfactor;
% if there is no change in any coeffcienct , the
iterations stop.




if verbose > 2 % iter
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% this is a warning about the non -convergence
if maxiter <=0
cause = 'maxiter ';
end
% We need the Jacobian at the final coefficient estimates ,
but not the J1
% version returned by LMfit because it has robust weights
included
fdiffstep = options.DerivStep;
J = getjacobian(beta ,fdiffstep ,model ,x,yfit ,~ok);




mad_s = madsigma(radj , p);
% Compute a robust scale estimate for the covariance matrix
sig = statrobustsigma(WgtFun ,radj ,p,mad_s ,tune ,h);
% Be conservative by not allowing this to be much bigger than
the ols value
% if the sample size is not large compared to p^2
sig = max(sig , ...
sqrt((ols_s ^2 * p^2 + sig^2 * n) / (p^2 + n)));
%----------------------- Robust estimate of sigma
function s = madsigma(r,p)




s = median(rs(max(1,min(n,p)):end)) / 0.6745;
% ---------------------- Jacobian
function J = getjacobian(beta ,fdiffstep ,model ,X,yfit ,nans)
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p = length(beta);
delta = zeros(size(beta));
for k = 1:p
if (beta(k) == 0)
nb = sqrt(norm(beta));




yplus = model(beta+delta ,X);











% a List of free parameter values
% x List of time points of interest
% Output:
% y A list of expected cummulative incidence of Hep -B for
each time
% point in x .
function y = infection(a, x)
% Define beta , gamm and nu as globals so we can pass the
values into the
% s e i r function. Also pass the fixed model parameters y0,
lambda , mu
% and N_current.






% Solve our model. Run the model until the
% last time point we are concerned about.
% (we are assuming x is ordered).
[t, yy] = ode15s('seir ', [0 x(end)], y0);






I(j) = interp1(t, yy(:,3), x(j));
S(j) = interp1(t, yy(:,1), x(j));
N(j) = N_current *(1+ lambda -mu)^(x(j) -7);
end













function [P,best ,best_val] = ga_SR(pop_size ,chrom_len ,pm,
max_gen ,migration)
% Modified by Steven Richardson
%------------------------------------------------------------
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% Copyright (C) 2009 George Bezerra
% This program is free software: you can redistribute it and/
or modify
% it under the terms of the GNU General Public License as
published by
% the Free Software Foundation , either version 3 of the
License , or
% (at your option) any later version.
% This program is distributed in the hope that it will be
useful ,
% but WITHOUT ANY WARRANTY; without even the implied warranty
of
% MERCHANTABILITY or FITNESS FOR A PARTICULAR PURPOSE. See
the
% GNU General Public License for more details.
% You should have received a copy of the GNU General Public
License




% pop_size => population size
% chrom_len => chromosome length
% pm => probability of mutation
% pc => probability of crossover
% max_gen => maximum number of generations
% Outputs:
% P => population
% best => best individual of the population
% best_val => max fittness value
% suggested run: [P,best] = ga(100 ,100 ,0.01 ,0.5 ,200);
% INITIALIZE POPULATION






while gen <= max_gen
% BREAD SOLUTIONS - CROSSOVER
Pb = two_point_crossover(P,1);
% MUTATION
Pb = point_mutation(Pb ,pm);
% MIGRATION
Pm = initialize(round(migration*pop_size),chrom_len);
% Combine P, Pb and Pm





fitc = [fitv; fitness ([Pb; Pm])];
end
% SELECTION - Pick pop_size solutions from Pc using
roulette selection. Must ensure top solution is
retained.










% plot evolution curve
plot (1: length(max_fit), max_fit ,'b');
hold on;
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ylabel('Fitness ');
legend('Best fitness ','Average fitness ','Location ','SouthEast
');
% output best individual
[m,ind] = max(fitv);
best = P(ind ,:);
best_val=max(fitv); % Modified by Steven Richardson.
function [P] = initialize(pop_size ,chrom_length)
P = round(rand(pop_size ,chrom_length));
function [P_new] = tournament_selection(P,fitv ,tourn_size)
for i=1: size(P,1)
t = ceil(rand(1, tourn_size)*size(P,1));
[max_fit ,winner] = max(fitv(t));
P_new(i,:) = P(t(winner) ,:);
end




pair = mating_list (1:2);
mating_list (1:2) = [];
if rand <pc
crossover_points = ceil(rand (1,2)*(size(P,2)));
point1 = min(crossover_points);
point2 = max(crossover_points);
individual1 = P(pair (1) ,:);
individual2 = P(pair (2) ,:);
individual1(point1:point2) = P(pair (2),point1:point2)
;
individual2(point1:point2) = P(pair (1),point1:point2)
;
P_new = [P_new;individual1;individual2 ];
else
P_new = [P_new;P(pair ,:)];
end
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end






function [] = disp_info(gen ,fitv)




function [P_new ,fit_new] = roulette_selection(P,fitv ,pop_size
)
P_new = zeros(pop_size ,size(P,2));
fit_new = zeros(pop_size ,1);
[fit_max ,index_max] = max(fitv);





fit1 = (fitv - min(fitv)).^2;
fit1 = cumsum(fit1);
fit1 = fit1/max(fit1);
f = find(fit1 >rand);




A.7 Converting gene to value
% gene_to_values(gene)
% Given a binary array chromosome , returns real values for
beta , gamma
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% and nu.
% Inputs:
% gene - A 1D binary array , the first third representing
beta , the




% beta - The value for beta
% gamma - The value for gamma
% nu - The value for nu
%
function [beta , gamma , nu] = gene_to_values(gene)







% The length of a gene within the chromosome is one third the
total length
gene_len = size(gene ,2)/3;
% Use bi2de to convert binary arrays to decimal numbers
beta_decimal = bi2de(gene (1: gene_len));
gamma_decimal = bi2de(gene(gene_len +1:2* gene_len));
nu_decimal = bi2de(gene (2* gene_len +1:3* gene_len));
% Convert the decimal values to real numbers inside the
% ranges established above.
beta_exponent = beta_min_exponent + ...
(( beta_max_exponent -beta_min_exponent) * ...
beta_decimal / 2^ gene_len);
gamma_exponent = gamma_min_exponent + ...




gamma_decimal / 2^ gene_len);
nu_exponent = nu_min_exponent + ...
(( nu_max_exponent -nu_min_exponent) * ...
nu_decimal / 2^ gene_len);
% We are using base 10 exponents
beta = 10^ beta_exponent;
gamma = 10^ gamma_exponent;
nu = 10^ nu_exponent;
A.8 Fitness
% fitness(P)
% Returns a vector with the fitness scores for each member
of the
% population , P
% Inputs:
% P - A 2D array of the population genomes
% Output:
% fit = A 1D array of fitness scores
function fit = fitness(P)
% Use globals so we can send the values into our sir.m
funciton
global beta gamma lambda mu nu time sick T_max y0 N_current
% I like to initialize any arrays I use
fit = zeros(size(P,1), 1);
% Loop through each individual in the population
for i=1: size(P,1)
% Convert the current chromosome to real values. I chose
to interperet
% the chromosome as three binary representations of
numbers. You may
% also want to consider a Grey Code representation (or
others).
[beta , gamma , nu] = gene_to_values(P(i,:));
% Get the model output for the given values of beta gamma
and nu.
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[t, y] = ode15s('seir ', [0 T_max], y0);
% Need to calculate the incidence h and population size N
. Use the Trapezoid rule and





for j=1: size(time ,2)
I(j) = interp1(t, y(:,3), time(j));
S(j) = interp1(t, y(:,1), time(j));
N(j) = N_current *(1+ lambda -mu)^(time(j) -7);
end
% Note - x may not be uniform.
for j=2: size(time ,2)










error = squared_error(time , sick , time , h);
% The GA maximizes values , so we return the inverse of
the error to





Stability of the endemic
equilibrium; Routh-Hurwitz
criterion approach
Although other tools like the Descartes’ rule for polynomials, discussed in Subsection
3.3.4, can be used to analyze the stability of the endemic state of dynamical systems, the
Routh-Hurwitz criterion is the more generally accepted and routinely used approach. For
the benefit of other users of this thesis, the Routh-Hurwitz criterion is reviewed in this
section. This important criterion provides a necessary and sufficient condition for all the
roots of a characteristic polynomial, with real coefficients, to lie in the left half of the
complex plane. The criterion is given in the following theorem.
Theorem 7 (Routh-Hurwitz Criterion) Given the polynomial,
P (x) = p0x
n + p1x
n−1 + ...+ pn−1x+ pn,
where the coefficients pi, i = 1, 2, ..., n are real constants, define the n
th Routh-Hurwitz
array using the coefficients pi of the characteristic polynomial by
p1 p3 p5 p7 . . . 0
p0 p2 p4 p6 . . . 0
0 p1 p3 p5 . . . 0
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 , ... Hn =

p1 p3 p5 p7 . . . 0
p0 p2 p4 p6 . . . 0
0 p1 p3 p5 . . . 0







0 0 0 0 . . . 0

where pj = 0 if j > n. All of the roots of the polynomial P (x) are negative or have negative
real part if and only if the determinants of all Hurwitz matrices are positive:
detHj > 0, j = 1, 2, 3, ..., n.
Applying this criteria to the characteristic polynomial in Equation 3.31 of the Jacobian of
the endemic state of the model where
a2 =
(λ+ ν)(γν + λν + γ2 + 2λ2) + γλ(3λ+ β) + 2γλν + γν(λ− α)
(γ + λ)(λ+ ν)
,
a1 =
λ(αγ2 + αλ2 + βγ2 + αν2 + βγν + αγν + 2αγλ+ 2βγλ+ 2ανλ)
(λ+ ν)(γ + λ)
,
a0 = λ(βγ + αν)− λ(λ+ ν − α)(λ+ γ)
it can be shown that a1 > 0 and a2 > 0, since the natural birth rate always exceeds the
rate newborns present with hepatitis B, λ > α. Note that the subscript convention of the
polynomial P (x) in Theorem 7 is opposite that in Equation 3.31


















The endemic state Q∗ is stable when detH1 = a2 > 0, detH2 = a2a1 − a0 > 0 and
detH3 = a0(a2a1 − a0) > 0 or unstable otherwise. Stability of the endemic state is
therefore achieved if a2a1 − a0 > 0, and so a2a1 > a0 for a0 > 0. The endemic state
Q∗ is unstable if a2a1 − a0 < 0 and so a2a1 < a0 for a0 > 0, or else if a0 < 0 and so
a0(a2a1 − a0) < 0. Thus if a0 > 0, a2a1  a0 which follows that a0(a2a1 − a0) > 0 and so
the endemic state is stable. The endemic state is therefore unstable only if a0 < 0 and so
a0(a2a1 − a0) < 0.
In conclusion, since a1, a2 > 0, detH1 = a2 > 0, detH2 = a2a1 − a0 > 0 and detH3 =
a0(a2a1 − a0) > 0 if a2a1 > a0 for a0 > 0, and so the endemic equilibrium state Q∗ of the
model in Equation 3.6 is stable. If a0 < 0, detH3 = a0(a2a1 − a0) < 0 and so the endemic
equilibrium state Q∗ is unstable. The above conditions that underpins this approach are
usually difficult to verify analytically and make the approach technically difficult to use.
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Stability of the endemic
equilibrium - Spectral properties
of second additive compound
matrix approach
Stability of the endemic equilibrium Q∗ = (s∗, e∗, i∗) was shown by establishing that all
the eigenvalues of the Jacobian matrix 7.12 have negative real parts using the Descartes’
rule of signs of a polynomial instead of the Routh-Hurwitz conditions which is routinely
used. Note that the Routh-Hurwitz criterion for the stability of Q∗ is usually technically
very difficult to use when the coefficients of the resulting characteristic equation of the
Jacobian matrix is hard to come by [116]. Stability of the endemic equilibrium can also
be discussed using another criterion applied in [116] that uses the spectral properties of
the second additive compound matrix A[2] of a matrix A. A matrix A is generally known
to be stable if all its eigenvalues have negative real parts. The following definitions and
proposition are relevant for the purpose of this discussion [116].
Definition 2 The second additive compound matrix A[2] of a 3× 3 matrix A = (aij), i.e.
for m = 3 is defined as
A[2] =

a11 + a22 a23 −a13
a32 a11 + a33 a12
−a31 a21 a22 + a33

Let ρ(A) = {ξj : j = 1, 2, ...,m} be the spectrum of A [116]
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Proposition 2 The spectrum of A[2], ρ(A[2]) = {ξj1 + ξj2 : 1 ≤ j1 < j2 ≤ m}
The spectral properties of the second additive compound matrix is now used to prove the
following result.
Lemma 2 Let A be a m×m matrix with real entries. For A to be stable, it is necessary
and sufficient that
(i) The second compound matrix A[2] is stable.
(ii) (−1)m det(A) > 0.
To prove this Lemma, the definition of the second additive compound matrix of the Jaco-
bian J(Q) in Equation 7.12 at the point Q = (s, e, i), by Definition 2 is
J [2](Q) =

−2λ− βi− γ + α α+ βs α+ βs
γ −2λ− ν − βi −α
0 βi α− 2λ− ν − γ
 (C.1)
Proof. It requires to show that the Jacobian J (Equation 7.12) satisfies conditions (i)
and (ii) of Lemma 2. For Q∗ = (s∗, e∗, i∗) and the diagonal matrix T = diag(i∗, e∗, s∗),
the matrix J [2] is similar to
TJ [2](Q∗)T−1 =












e∗ α− 2λ− ν − γ
 (C.2)
By the similarity property of matrices, the matrix J [2](Q∗) is stable if and only if
TJ [2](Q∗)T−1 is stable since similarity preserves the eigenvalues. The diagonal elements
of the matrix TJ [2](Q∗)T−1 are negative since λ > α. Geršgorin discs shows that
TJ [2](Q∗)T−1 is stable if it is diagonally dominant in rows. To show that TJ [2](Q∗)T−1
is diagonally dominant is to show that ψ = max{u1, u2, u3} < 0 where





















+ α− γ − 2λ− ν (C.3)
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additive compound matrix approach
Rearranging the homogeneous part of Equation 3.6 gives
λ− α(i∗ + e∗)
s∗
= βi∗ + λ
(βs∗ + α)i∗
e∗
= γ + λ− α
γe∗
i∗
= ν + λ (C.4)


















α . This result implies the diagonal dominance
claim and so satisfies the condition (i) of Lemma 2. Furthermore, by Equation C.4 the







i∗ (γ + λ− α)
βi − i∗e∗ (βs
































[γ(α+ βs∗)− γ(α+ βs∗)]− αβγe∗ − βγe∗(λ+ γ − α)
= −αβγe∗ − βγe∗(λ+ γ − α)
= −αβγe∗ + αβγe∗ − βγe∗(λ+ γ)
= −βγe∗(λ+ γ) < 0 (C.6)
which satisfies condition (ii) of Lemma 2 and thus completes the proof.
The following theorem summarizes the parameter restriction R0 > 1 on the stability of
the endemic equilibrium Q∗.
Theorem 8 If R0 > 1, then the system in Equation 3.6 has a unique equilibrium Q
∗ in
Σ̊ and Q∗ is asymptotically stable.
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Verification of the values of a0, a1
and a2 at the crossover value of β
∗
At the crossover value of β∗, the values of a2, a1 and a0 are
a2 =
γ − α+ 3λ+ ν + (λ(γλ− αλ− αν − αγ + γν + λν + λ2)− λ(γ + λ)(λ+ ν)
(γ + λ)(λ+ ν)
+
αλ(γ + λ+ ν))
(γ + λ)(λ+ ν)
= γ − α+ 3λ+ ν
a1 =
2γλ− 2αλ− αν − αγ + γν + 2λν + α(γ + λ+ ν)− (γ + λ)(λ+ ν) + 3λ2
(γ + λ)(λ+ ν)
+
(γ(λ(γλ− αλ− αν − αγ + γν + λν + λ2)− λ(γ + λ)(λ+ ν) + αλ(γ + λ+ ν)))
(γ + λ)(λ+ ν)
+
(2λ(λ(γλ− αλ− αν − αγ + γν + λν + λ2)− λ(γ + λ)(λ+ ν) + αλ(γ + λ+ ν)))
(γ + λ)(λ+ ν)
+
(ν(λ(γλ− αλ− αν − αγ + γν + λν + λ2)− λ(γ + λ)(λ+ ν) + αλ(γ + λ+ ν)))
(γ + λ)(λ+ ν)
= λ(γ − α+ 2λ+ ν)
a0 =
λ(α(γ + λ+ ν)− (γ + λ)(λ+ ν)) + (λ+ ν)((λ+ (λ(γλ− αλ− αν − αγ + γν)
(γ + λ)(λ+ ν)
+
+λν + λ2 − λ(γ + λ)(λ+ ν) + αλ(γ + λ+ ν))
(γ + λ)(λ+ ν))
(γ − α+ λ)
+
(α(λ(γλ− αλ− αν − αγ + γν + λν + λ2)− λ(γ + λ)(λ+ ν) + αλ(γ + λ+ ν)))
(γ + λ)(λ+ ν))
− αγλ = 0. (D.1)
respectively. Hence Equation 3.31 becomes
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∗
ξ3 + (γ − α+ 3λ+ ν)ξ2 + λ(γ − α+ 2λ+ ν)ξ = 0
and so the eigenvalues are
ξ1 = 0
ξ2&3 =
−(γ − α+ 3λ+ ν)±
√
(γ − α+ 3λ+ ν)2 − 4λ(γ − α+ 2λ+ ν)
2
=
α− γ − ν − 3λ±
√
(γ + λ+ ν − α)2
2
=
(α− γ − ν − 3λ)± (γ + λ+ ν − α)
2





= −λ < 0
ξ3 = α− γ − ν − 2λ < 0 (D.2)
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